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Summary 
 
Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous system. 
The disease is thought to be mediated by autoaggressive lymphocytes that attack the nervous 
myelin sheath, leading to the formation of characteristic lesions in the brain tissue. CD8+ T cells 
are thought to play a role in the immunopathogenesis of the disease because of the directed 
infiltration of an immune privileged structure followed by in situ clonal expansion. They are also 
the dominant brain infiltrating T cell population. However, the events that trigger this 
autoimmune attack, as well as the molecular target(s) of the autoaggressive T cells remain 
unknown. The current study is part of a long term strategy to identify the molecular target(s) of 
these autoaggressive CD8+ T cells. To achieve this, potentially autoaggressive T cells were 
isolated by laser microdissection from the brain tissue samples of MS patients. Their antigen 
specific T cell receptors (TCRs) were characterized, reconstructed in vitro in T hybridoma cells 
and applied in investigating antigen specificities.  
 
The α- and β- chains of the MS brain derived TCRs were characterized using a multiplex PCR 
approach. The TCR chain sequences provide insights into their immune function in context of 
multiple sclerosis. Firstly, identical TCR β-chains were found to be coexpressed with more than 
one α-chain in three different instances. This suggests that  antigen driven receptor development 
or the existence of dual TCR molecules may contribute to autoimmunity. Secondly, one TCR 
clone was detected in cells from three tissue blocks of one patient, indicating that the T cell 
infiltration is not anatomically restricted during the autoimmune attack. Thirdly, four out of nine 
T cell receptor molecules, that were characterized together with colleagues, were found to belong 
to an innate T cell population called the mucosal-associated invariant T (MAIT) cells. These 
cells have been previously detectected in MS patients and are thought to regulate anti-microbial 
immunity, possibly providing a link between microbial infection and autoimmunity. The MAIT 
T cell receptors were expressed in T hybridoma cell lines and used to screen candidate MS 
antigens and plasmid encoded peptide libraries. In addition, the MHC class I related molecule 
MR1 that restricts MAIT antigen recognition, was investigated for its anchor residues to shed 
light on the nature of the bound MAIT antigen. In the long run, these studies promise to  
contribute to the understanding of multiple sclerosis in particular and autoimmunity in general. 
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1 Introduction 
1.1 The immune system 
The human  immune system is a combination of two fronts, the fast acting innate immune system 
and the versatile adaptive immune system, that protect an individual from threats such as 
infectious agents and cancer. When a pathogen infiltrates the first defenses of the body, the 
innate immune mechanism is brought into action. It brings together macrophages, natural killer T 
(NKT) cells, mast cells, granulocytes and the complement system to swiftly get rid of the 
pathogenic threat and stem subsequent infection. This system is rapid in action, but limited in the 
sense that it does not recognize all foreign microbes and substances, especially pathogens that 
have mutated and modified themselves over time. Based on its ability to continuously adjust to 
novel antigenic challenges, the second  line of defense is known as the adaptive immune system. 
This system consists of two branches (Figure 1-1), (a) humoral immunity mediated by B 
lymphocytes and antibodies and (b) cellular immunity mediated by CD4+ helper T lymphocytes 
and CD8+ effector T lymphocytes. 
 
Humoral immunity prevents microbial infection by the production of antibodies that neutralize 
their antigens and facilitate the clearing of opsonized particles by phagocytocis. B cells recognize 
their antigen in the native form and also serve as professional antigen presenting cells (APCs). 
Immunological memory also guarantees that in case of another infection with an encountered 
pathogen, the immune response runs more efficiently. Cellular or cell mediated immunity is 
responsible for protection against microbes and tumor cells. CD4+ helper cells are capable of 
recognizing exogenous antigens (bacteria, parasites, and toxins) that are displayed on the major 
histocompatibility complex (MHC) class II molecules. Post activation, the cells may secrete 
interferon-gamma (Th1 response) that induces a cell mediated immune response against 
intracellular pathogens or interleukin-4 (Th2 response) that leads to a B cell mediated humoral 
immune response directed against extracellular pathogens and toxins. CD8+ effector T cells 
Introduction 
 
 
2 
 
recognize antigen in context of the MHC class I molecule. They possess cytotoxic activity and 
can induce the death of infected or dysfunctional cells. This T cell subgroup is dealt with in 
further detail in Section 1-2.  
 
 
Fig. 1-1: The two branches of the adaptive immune system 
(a) Humoral immunity: An infection with a toxin producing extracellular pathogen activates B cells that secrete 
antigen specific neutralizing (blue) and opsonizing or coating (red) antibodies. The invading pathogens are then 
killed by neutralization or complement system mediated lysis or phagocytosed by polymorphonuclear leucocytes 
(PMN) or macrophages. (b) Cellular immunity: The virus infected antigen presenting cell (APC) displays the 
processed antigen to the CD4+ helper T cell via its MHC class II molecule. Upon activation, the helper T cell 
secretes cytokines that induce the proliferation and activation of various effector cells including CD8+ effector T 
cells that mediate killing of the infected cell. (Castillo 2002) 
 
1.2 Autoimmune disease 
The lymphocytes of the adaptive immune system must be capable of distinguishing between the 
individual’s healthy cells (termed as ‘self’) and the invading pathogen or tumor cells (termed as 
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‘non-self’). During development, both B and T lymphocytes are inspected at various checkpoints 
to eliminate potentially autoreactive cells, i.e. lymphocytes that recognize a ‘self’ component 
(Wekerle 1992). However, if ‘self’ recognizing lymphocytes escape these control mechanisms 
and enter the periphery, they are capable of raising an autoimmune attack on the ‘self 
components’ of an individual’s apparently healthy tissues. This attack may be systemic like in 
the case of systemic lupus erythematosus (SLE), where inflammation may occur in various 
organs like the heart, joints, skin, lungs, kidneys and liver. This condition is thought to be 
mediated by anti-DNA antibodies (Diamond et al. 1992). Alternately, the autoimmune attack 
may be localized in an organ specific manner like in the case of psoriasis. In this disease, 
autoreactive CD4+ and CD8+ T cells infiltrate the epidermis and cause a chronic inflammation 
of the skin (Prinz 2003). This also applies in the case of multiple sclerosis (MS), a chronic 
inflammation that is directed at the central nervous system (CNS) (Section 1.5). The effects of 
organ specific autoimmune attacks may extend beyond the target tissue and indirectly affect 
other organs and body systems. The causes for the loss of tolerance leading to the autoimmune 
reaction, and the underlying immune mechanisms are not well understood.  
 
1.3 Multiple Sclerosis (MS) 
Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS) 
characterized by multi-focal inflammatory demyelination, axonal loss, glial cell activation, and 
the infiltration of immune cells (Compston and Coles 2008). With respect to incidence, MS is the 
second most frequent neurological disease affecting young adults after epilepsy. The disease was 
first described by french neurologist Jean-Martin Charcot in the late 20
th
 century. MS is believed 
to be an autoimmune disorder because of the characteristic infiltration of immune cells via a 
disrupted blood brain barrier into the CNS (Sospedra and Martin 2005). 
1.3.1 Pathology 
Sharply demarcated demyelinated plaques within CNS areas such as optic nerves, periventricular 
regions, brainstem, cerebellum and spinal cord are characteristic of chronic MS brain tissue 
(Lassmann et al. 2001). These lesions are infiltrated by oligoclonal T cells (CD4+, CD8+, and 
Introduction 
 
 
4 
 
γδ), occasional B cells, plasma cells and macrophages (Hauser et al. 1983; Traugott et al. 1983). 
The demyelination and axonal loss is not limited to the white matter (WM) and also affects the 
grey matter (GM) or cortex (Hohlfeld and Wekerle 2001). 
 
1.3.2 Etiology 
The etiology of MS is poorly understood but genetic and environmental factors are thought to 
play a role. Disease prevalence increases within family members of MS patients as suggested by 
the fact that the concordance rate in monozygotic twins is higher than that of dizygotic twins 
(Dyment et al. 2004). Genetic linkage studies have suggested that certain human leukocyte 
antigen (HLA) class II alleles such as the HLA-DRB1*1501 and -DQB1*0601 are associated 
with MS (Olerup and Hillert 1991) besides other genes like TCRβ, cytotoxic T-lymphocyte 
associated protein 4 and CD 45 (Dyment et al. 2004). Environmental triggers such as infectious 
agents and lifestyle are also believed to contribute to disease occurrence (Coo and Aronson 
2004). The human herpesvirus, the Epstein-Barr virus (EBV) (Wandinger et al. 2000), is of 
particular interest in this regard. Of late, CD8+ effector T cells that are the dominant infiltrating 
T cell subpopulation (Woodroofe et al. 1986) have garnered interest for their contribution to MS. 
 
1.4 CD8+ effector T cells 
CD8+ effector T cells are responsible for mediating immune responses against invading 
pathogens and tumor cells. They recognize the ‘non-self’ or altered molecules, presented on the 
surface of these cells by MHC class I molecules, via antigen specific T cell receptors (TCRs) and 
eliminate the infected cells by the release of perforin and granzyme containing cytotoxic 
granules (Harty et al. 2000), or by expressing the Fas ligand (Medana et al. 2000).  
 
1.4.1 TCR diversity generation 
T cells are derived from haematopoietic stem cells in the bone marrow, and then develop into 
naïve T cells in the thymus. Every individual’s T cell repertoire is capable of recognizing a broad 
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antigenic spectrum. To fulfill this requirement, T cells undergo ‘somatic recombination’, which 
is a random rearrangement of TCR gene segments resulting in highly variable TCRs. At the end 
of this process, each T cell clone expresses an exclusive TCR. The genetic loci that determine 
TCR diversity are presented in Figure 1-2. 
 
 
Fig. 1-2: Human TCRα and TCRβ genetic loci 
(a) The human TCRα gene locus is composed of a combination of variable (V), joining (J) and constant (C) gene 
segments that are all derived from a genetic locus consisting of 70 to 80 Vα (or AV), 58 Jα or (AJ) and one Cα gene 
segment. (b) The TCRβ locus has a similar composition in addition to the diversity (D) segment between the V and 
J segments. The β-chain locus consists of 54 Vβ (or BV), 2 Dβ, 14Jβ (or BJ) and 2 Cβ segments. (Arden et al. 1995; 
Rowen et al. 1996) (Modified from Murphy et al. 2008) 
 
 
The β-chain of the TCR is rearranged first by random combination of a D and J segment, 
followed by a V segment. During this combination, there occur insertions and deletion of 
palindromic (P) or non-germline (N) nucleotides that further add to the variability. The ultimate 
unison with the C segment occurs by post-transcriptional RNA splicing. The high variability of 
the TCR is accounted for in the three complementarity determining regions (CDR) CDR1, 2 and 
3 (Jores et al. 1990). The CDR1 and CDR2 are coded  mainly by the variable regions for both α- 
and β-chains. The centrally placed CDR3 region, termed as the N region in the α-chain and the 
NDN region in the β-chain, is the region containing the highest variability. It is this region that 
ultimately binds to the MHC-peptide molecule (Section 1.4.3) and is responsible for antigen 
recognition. 
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1.4.2 The αβ T cell receptor complex 
The T cell receptor (TCR) is a heterodimer consisting of a α- and β-chain that are comprised of 
an antigen specific N-terminal variable region, and an immunoglobulin domain like C-terminal 
constant region. The C region is anchored in the cell membrane. The TCR is associated with a 
number of other molecules, forming the TCR complex (Figure 1-3). 
 
 
Fig. 1-3: The αβ TCR complex 
The TCR complex consists of two variable chains 
α (purple) and β (blue) and the invariant dimers 
CD3γε, CDδε and ζζ. Basic residues within the 
membrane region (CM) are denoted as red dots and 
the acidic residues as blue dots. The 
immunoreceptor tyrosine-based activation motifs 
(ITAM) are denoted in orange. The CD8 co-
receptor (red) may be composed of an αα 
homodimer or an αβ heterodimer, as depicted 
above. This molecule is responsible for stabilizing 
the TCR-MHC-peptide interaction and boosting 
the subsequent signal transduction cascade. 
Disulphide bonds that stabilize inter-chain 
interactions are shown in black. (Modified from 
Murphy et al. 2008) 
 
 
An integral component of this complex is the CD3 glycoprotein complex that is responsible for 
downstream signaling post antigen recognition (Clevers et al. 1988). The TCR signaling cascade 
is initiated with the phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAM) 
(Smith-Garvin et al. 2009) that recruit protein kinases to the activated TCR. This is followed by a 
flux of calcium ions and further signaling events that consequently activate a calcium ion-
calmodulin (CaM)-dependent phosphatase called calcineurin. Calcineurin dephosphorylates 
proteins of the nuclear factor of activated cells (NFAT) family that facilitate their nuclear entry. 
Here the NFAT proteins collaborate with different co-activators to drive gene transcription 
(Katzav, 2004). NFAT is a transcription factor that regulates the expression of several genetic 
loci including interleukin-2 (IL-2). NFAT-dependent promoters can be used as molecular tools to 
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regulate reporter genes like β-galactosidase and detect TCR activation (Karttunen and Shastri 
1991). 
1.4.3 Antigen restriction by the MHC class I molecule 
T lymphocytes recognize their specific antigens in context of the major histocompatibility 
complex (MHC) molecule, a phenomenon called MHC restriction. CD8+ T cells are restricted by 
the MHC class I molecule which is a membrane anchored structure consisting of an α-chain in 
association with β2 microglobulin (Figure 1-4).  
 
  
 
 
 
Fig. 1-4: Interaction of the αβ TCR with the MHC-peptide complex 
(a) The crystal structure of the extracellular domains of an MHC class I molecule (MHC I) presenting antigen 
(yellow) to a TCR. The α1 and α2 domains of the MHC molecule contact the antigen, while the α3 domain is 
associated with β2 microglobulin. The C-terminal of the α-chain spans the cellular membrane ending in a short 
cytoplasmic region (Rudolph et al. 2006). The bound octapeptide (P1 to P8) antigen interacts with the 
complementarity determining regions (CDR 1, 2 and 3) of the two TCR chains (depicted in color). These lie in the 
variable region (Vα, Vβ) of the TCR and are followed by a conserved constant region (Cα, Cβ). (b) A simplified 
representation of the contribution of the CDR regions of the TCR to antigen binding and recognition. The α-chain is 
depicted in purple while the β-chain is depicted in blue. The α1 and α2 domains of the MHC class I molecule are 
shown in grey, bound to the antigen (yellow). The CDR3 region of both TCR chains is mostly responsible for 
interacting with the MHC-peptide complex. (Modified from Garcia et al. 1996) 
 
The MHC locus on chromosome 6 is a polygenic consortium of highly polymorphic genes. The 
gene locus codes for three MHC class I molecules that are HLA-A, HLA-B and HLA-C (where 
a. 
b. 
Introduction 
 
 
8 
 
HLA stands for human leukocyte antigen). Globally, there exist 767 HLA-A alleles, 1178 HLA-
B alleles and 439 HLA-C alleles (from the IMGT-HLA database). These three loci are expressed 
in a co-dominant manner such that each cell can express up to six MHC class I molecules on its 
surface. MHC molecules are expressed on almost all nucleated cells. The cells that are capable of 
processing and presenting MHC bound antigen to the TCR complex are known as antigen 
presenting cells.  
 
The presented peptides are sourced from cytoplasmic proteins that are processed by the 
proteasome. These peptides are trafficked to the endoplasmic reticulum (ER) by the antigen 
processing transporter (TAP). Here the peptides are loaded into the binding site of the respective 
MHC class I molecule aided by chaperones. The MHC-peptide complex now leaves the ER 
lumen and translocates via the Golgi apparatus to the cellular surface (Hansen and Bouvier 
2009). In the absence of a binding partner, the MHC molecule is retained within the ER. 
Depending on the MHC molecule, all binding peptides usually carry anchor positions which are 
fixed amino acid residues that make close contact with the MHC molecule. For e.g. For HLA-
A*0101, the nonapeptides mostly carry an asparagine residue at position 3 and a tyrosine residue 
at position 9.  
 
1.4.4 Proposed role of T cells in MS 
Both helper T cells and effector T cells have been associated with MS. CD4+ T cells were 
observed in lesions of MS and experimental autoimmune encephalomyelitis (EAE), the animal 
model of MS (Handel et al. 2011). Moreover linkage studies have indicated that some degree of 
genetic risk may be conferred by the HLA-DR and HLA-DQ molecules. Transgenic mice that 
expressed these MHC molecules were found to be susceptible to EAE (Kawamura et al. 2000) 
while transgenic mice that expressed these MHC molecules in combination with MS patient 
derived myelin basic protein (MBP) specific TCRs could develop spontaneous or induced EAE 
(Madsen et al. 1999). 
Other studies have reported the preponderance of CD8+ effector T cells in MS lesions 
(Woodroofe et al. 1986) and genetic studies (Lincoln et al. 2005; Sawcer et al. 2011) suggest that 
an independent association exists between MHC class I alleles and MS (Fugger et al. 2009).  
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Moreover, CD8+ T cells are detected in numbers exceeding those of CD4+ T cells in acute and 
chronic lesions of MS (Babbe et al. 2000; Junker et al. 2007). Interestingly, the myelin specific 
CD8+ T cell response is seen to increase in MS patients (Zang et al. 2004) and myelin protein 
specific CD8+ T cells can induce EAE in animal models of the disease (Huseby et al. 2001; Sun 
et al. 2001). As depicted in Figure 1-5, it is believed that CD8+ T cells with autoimmune 
specificities can damage oligodendrocytes and neurons by direct cytotoxicity or cytokine 
secretion.  
 
 
Fig. 1-5: The proposed role of CD8 + effector T cells in MS 
The figure depicts how CD8+ T cells leave the periphery and enter the CNS to mediate an autoimmune attack in 
MS. Dendritic cells in the periphery present antigens to CD8+ T cells that in turn (a) get activated. These further (b) 
differentiate into different subsets such as cytotoxic effector T cells and regulatory T cells (not shown here). (c) 
When the integrity of the blood brain barrier (BBB) breaks down, the cytotoxic CD8+ T cells with ‘self’ antigen 
specificity cross the BBB. (d) Within the central nervous system (CNS) they encounter microglia or macrophages 
(MØ) that express MHC class I peptide complexes (pMHC I). By this interaction, the CD8+ cells get (d) reactivated 
and (f) expand clonally. On meeting their target antigen(s) that are presented on MHC class I expressing 
oligodendrocytes and neurons, they cause tissue damage ultimately leading to neurological deficits. (Modified from 
Friese and Fugger 2005) 
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1.5 Mucosal-associated invariant T (MAIT) cells 
Human mucosal-associated T (MAIT) cells are innate CD8+ cells, characterized by the 
expression of an invariant TCR α-chain (AV7.2-AJ33 in humans) and homing to mucosal-
associated lymphoid tissues (Le Bourhis et al. 2011). MAIT cells are detected in large numbers 
in blood (1-8% of all lymphocytes), liver (20-45% of all lymphocytes) and display an effector 
memory phenotype (Le Bourhis et al. 2011). After thymic development, the MAIT cells require 
the presence of B cell, the gut commensal flora and the evolutionary conserved MHC class I 
related molecule MR1 (also known as MHC-related molecule 1 or MHC-related protein 1) for 
peripheral expansion (Martin et al. 2009). The MR1 (Section 1.5.1) molecule is also responsible 
for restricting antigen presentation to the MAIT receptor (Huang et al. 2005). The role of the 
MAIT subset in the immune system is yet to be delineated, although it is associated with various 
diseases (Section 1.5.2) including MS. The antigen(s) recognized by the MAIT TCR (Section 
1.5.5) remains to be characterized. 
 
1.5.1 The antigen presenting MHC class I related molecule MR1 
The MR1 protein is encoded on human chromosome 1 and is highly conserved among mammals 
(Riegert et al. 1998). It displays a high sequence identity to the MHC class I molecules in the 
putative ligand groove (α1 and α2 domains) (Lybarger et al. 2003). Similar to classical MHC 
molecules, MR1 stably associates with β2 microglobulin and MR1 mRNA is ubiquitously 
expressed in humans and mice (Le Bourhis et al. 2011). Besides its indispensable role in MAIT 
cell development, MR1 is also believed to restrict antigen presentation to the MAIT TCR (Huang 
et al. 2005). 
 
1.5.2 The association of MAIT cells in human diseases including MS 
The MAIT subpopulation has been found to infiltrate diseased organs in various illnesses 
suggesting a much broader role in the immune response. This includes bacterial infection, kidney 
and brain tumors (Peterfalvi et al. 2008), as well as MS. The association between MAIT cells 
and MS was first described in a study (Illes et al. 2003) where the authors detected the MAIT 
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invariant α-chain AV7.2-AJ33 in autopsy central nervous system (CNS) lesions from MS 
patients as well as in a peripheral nervous system biopsy from a patient with chronic 
inflammatory demyelinating polyneuropathy. In a more recent study (Miyazaki et al. 2011) the 
same group reported a reduction in MAIT cell numbers in the peripheral blood of MS patients 
during remission and relapse. This number was seen to decrease in patients with active disease, 
and later increase in parallel with clinical recovery. The authors suggest that MAIT cells are 
capable of suppressing Th1 responses in vitro and probably play a regulatory role in MS. 
 
1.5.3 Hypotheses regarding the MAIT antigen 
There exists conflicting evidence in support for the MAIT antigen being a lipid or a peptide. The 
activation of MAIT cells by α-mannosylceramide derivatives (Shimamura et al. 2007) could 
indicate that MAIT cells also respond to a lipid antigen. On the other hand, a delipidated antigen 
preparation of the M. tuberculosis cell wall was found to be highly antigenic for the MAIT TCR 
while proteolytic digestion of this preparation abolished this activity (Gold et al. 2010). In 
addition, molecular modeling of MR1 suggests that the antigen binding groove is most suited to 
binding a hydrophilic compound (Le Bourhis et al.2011). Furthermore, the mechanism of MR1 
antigen presentation is thought to be independent of the known MHC class I and II pathways (Le 
Bourhis et al. 2011). 
 
Introduction 
 
 
12 
 
 
1.6 Characterizing the molecular target(s) of autoaggressive T cells 
1.6.1 TCR characterization 
Characterization of TCRs of unknown specificity, such as those with ‘self’ targets, is important 
for delineating the underlying protective and pathogenic mechanisms. Efforts in this direction 
have been hindered for various reasons such as the short survival of live T cells in vitro (Dooms 
and Abbas 2002), the need to distinguish relevant clones from an oligoclonal background in vivo 
(Moebius et al. 1990; Pantaleo et al. 1997; Goronzy et al. 1998; Hofbauer et al. 2003; Matsumoto 
et al. 2003) and the need for a method that can detect the entire repertoire (~10
15
 ) of all possible 
αβ TCR heterodimers (Davis and Bjorkman, 1988). Early TCR repertoire studies in MS analyzed 
the germline TCR β-chain repertoire by restriction fragment length polymorphism (RFLP) 
(Biddison et al. 1989; Beall et al. 1989) or reverse transcription of whole RNA from frozen MS 
lesions (Wucherpfennig et al. 1992). However these studies were unable to study the 
contribution of single cells to the TCR repertoire.  
 
More recently monoclonal antibodies that recognize limited TCR chains, RT-PCR amplification, 
spectratyping, random cloning and sequencing of β-chain transcripts have been used to 
characterize TCR chains. An experimental approach to investigate these T cells and eventually 
their molecular target(s) (Dornmair et al. 2003) was used in this study (Figure 1-6). A ‘clone 
specific’ approach that involves detecting the clone of interest with antibodies, followed by 
amplification of TCR genes using clone specific β-chain primers and unbiased α-chain primers 
was first applied in studying autoimmune T cells in muscle autoimmune  disorders (Seitz et al. 
2006). Similarly, an unbiased approach that involves unbiased primers covering all functional 
TCR α and β variable region genes was also applied. The two MS patients, a biopsy case (FE) 
(Skulina et al. 2004) and an autopsy case (MS-4) (Junker et al. 2007) were examined for matched 
α- and β-TCR chains of infiltrating CD8+ T cells. Several β-chain oligoclonal expansions were 
detected in these samples indicating an antigen driven immune reaction in the MS brain. 
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Fig. 1-6: Experimental approach to characterize autoaggressive T cells and their target(s) 
CD8+ T cells are isolated from MS brain tissue on the basis of selection criteria that distinguish between 
autoaggressive and bystander cells. From these single cells, the matching α- and β-chains of the TCR may be 
characterized. These may be reconstructed as stably transfected recombinant TCR molecules in mouse cell lines that 
can be directly applied in antigen search. Alternatively, the recombinant TCR molecules may be reconstructed in an 
animal model of MS (EAE) to evaluate its contribution to the disease. Ultimately, all of these efforts would 
contribute to the understanding of the disease and could be relevant to the development of diagnostic tools and 
therapeutic options to combat MS. (Dornmair et al. 2003) 
 
1.6.2 Antigen determination 
T cell receptors of MS brain derived cells may be determined by different approaches. The first 
of these is the screening of candidate MS antigens (Section 1.6.2.1). Although this approach is 
focused and disease specific, it is restricted by the availability of patient matched antigen 
presenting cells. A second alternative would be the screening of patient derived full-length 
cDNA expression libraries as was done for the identification of melanoma associated tumor 
antigens (van der Bruggen et al. 2002) and other TCR antigens (Wong et al. 1999; Smith et al. 
2001; Uenaka et al. 2003). Nevertheless, this method is also limited by the ability of the APC to 
correctly process the antigen. The need for accurate antigen processing may be overcome by the 
screening of peptide libraries. Hence, the third approach employs the screening of synthetic 
combinatorial peptide libraries in positional scanning format (PS-SCL) (Section 1.7). However 
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this method is successful only for polyspecific TCRs as a large number of peptides have to be 
recognized before a signal can be detected. The fourth approach involves the use of plasmid 
encoded combinatorial peptide libraries (Wang et al. 2005, Siewert et al. in press) wherein TCR 
mimotopes that activate the TCR are isolated and can reveal the naturally occurring ligand by 
peptide sequence database analysis (Section 1.6.2.2).   
 
1.6.2.1    Screening of Candidate MS antigens 
Various proteins are implicated in the immune pathogenesis of experimental autoimmune 
encephalitis (EAE), the animal model of MS. For example myelin oligodendrocyte protein 
(MOG) (Schluesener et al. 1987), myelin basic protein (MBP) (Eylar et al. 1970; Lennon et al. 
1970) and neurofascin (Mathey et al. 2007; Hemmer et al. 2002). MS immunopathogenesis is 
also believed to have an association with viral infection, especially with the Epstein-Barr virus 
(EBV) (Sumaya et al. 1980; Bray et al. 1983; Lucas et al. 2011). Almost all MS patients are 
seropositive for EBV in contrast to only 90% of the healthy population. Moreover, EBV infected 
B cells were detected in the meninges of MS patients (Serafini et al. 2007). It is speculated that 
molecular mimicry might play a role in linking EBV to MS. The hypotheses is that after a 
microbial (EBV) infection, immune cells with specificities against the infectious agent might 
cross react with a similar epitope on healthy cells (of the CNS) leading to an autoimmune attack 
(Lucas et al. 2011). Candidate antigen screening is however restricted by the availability of the 
original HLA-matched antigen presenting cells. No other cell line would be capable of 
processing and presenting protein-derived peptides on MHC class I molecules (Ackerman and 
Cresswell 2004). To circumvent the need for patient matched APCs and correct antigen 
processing, one may screen unbiased peptide libraries (Section 1.6.2.2). 
 
1.6.2.2    Unbiased plasmid encoded combinatorial peptide (PECP) libraries 
Plasmid encoded combinatorial peptide (PECP) libraries code for peptides of fixed length that 
circumvent the need for intracellular protein processing. The PECP library contains mimotopes, 
or peptides that mimic the epitope recognized by the TCR. A recent method developed in our 
laboratory (Siewert et al., in press) describes the application of a PECP library in detecting single 
activated T cells in an APC-TCR hybridoma co-culture. The identification of different 
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mimotopes with converging motifs allows for the detection of the parent peptide antigen. The 
experimental approach is presented in Figure 1-7. The APCs (COS-7 cell line) that have been 
co-transfected with a plasmid encoded combinatorial peptide (PECP) library and MHC class I 
complementary DNA express the MHC-peptide complex on the cell surface. The TCR 
hybridoma coexpresses the TCR, CD8αβ and synthetic green fluorescent protein (sGFP) (Heim 
et al. 1995) under the regulation of NFAT. The sGFP protein is a modified version of GFP 
isolated from the jellyfish Aequorea Victoria where the serine residue at position 65 in the wild 
type is replaced with threonine. sGFP is observed to have a brighter fluorescence level than GFP 
(Heim et al. 1995). During co-culture, the TCR hybridoma cells that make contact with an APC 
presenting the correct antigen get activated, and turn bright green. The APC underlying the green 
TCR hybridoma is then isolated by a microcapillary pipette under a fluorescence microscope, 
and the plasmids coding for the antigenic peptide that it expresses can be isolated. 
 
 
Fig. 1-7: Experimental strategy for antigen search using PECP libraries 
First the TCR hybridoma cells (grey) are transfected with plasmids coding for TCR α-(blue) and β-(purple) chains 
(derived from T cell lines or clones), followed by the transfection of plasmids coding for  the human CD8 α- and β- 
chains (pink, red) and sGFP (Heim et al. 1995) whose expression is regulated by a NFAT enhancer element (green). 
The antigen presenting cells (APCs) are COS-7 cells (blue). APCs are co-transfected with the suitable MHC 
molecule (brown) and a PECP library (peptide library). On presentation of the correct antigenic peptide (yellow), the 
TCR hybridoma expresses sGFP as a result of TCR activation, and is easily detected. (Based on Siewert et al., in 
press)  
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The application of PECP libraries in an unbiased screening of T cell antigens provides many 
advantages. First, it circumvents the need for intracellular APC specific protein processing. 
Second the antigen recognition mimics TCR recognition of a MHC-peptide complex. Third, low 
affinity TCR interactions can still be detected as the cells remain in close physical contact due to 
gravity. Most importantly, T cell activation can be detected at the level of single cells. 
 
1.7 Anchor position determination 
The anchor positions of a MHC molecule determine the peptides that it can efficiently bind to 
and present to the compatible TCR. The peptide ligands bound to the antigen presenting MHC 
molecules can be extracted and analyzed to reveal these anchor positions as done for endogenous 
ligands that are expressed by healthy cells (Falk et al. 1991; Rudensky et al. 1991), ‘non self’ 
ligands on infected cells (Rötzschke et al. 1990) or tumor cells (Schirle et al. 2000). The MHC 
molecules carrying bound peptides are purified from cellular lysates by immunoprecipitation, 
after which they undergo a mild acid treatment for peptide release. The released peptides can 
then be examined by Edman degradation (Edman 1950) or mass spectrometry. Edman 
degradation involves a sequential derivatization and removal of amino acids from the amino 
terminus, which are then identified by chromatography. Mass spectrometry can identify a peptide 
sample by determining the mass ratio of the ionized peptides. The detected ions are separated 
according to their mass-to-charge ratio, detected and processed into mass spectra. For MHC 
molecules where the anchor positions are not known, this would be a useful T cell independent 
approach. 
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1.8 Objectives 
 
It has long been believed that CD8+ T cells play an important role in the immune mechanisms of 
the autoimmune disease MS. They are seen to infiltrate the brain in large numbers, and 
proliferate there giving rise to clonally expanded subpopulations. However, the processes that 
prompt this infiltration and the molecular target(s) of the autoaggressive T cells remain 
unknown. 
 
In order to characterize potentially autoaggressive brain infiltrating CD8+ T cells from MS 
patients, this study had four objectives: 
 
 The first objective was to identify the matching α- and β- TCR chains from brain 
infiltrating CD8+ effector T cells. This would include oligoclonal expansions as well as T 
cell clones that were activated in situ and provide a MS patient specific TCR repertoire 
from single, putatively autoaggressive T cells.  
 
 The second objective was to reconstruct and recombinantly express these putatively 
autoagressive TCR molecules in mouse T hybridoma cell lines in order to employ them 
in cell based assays.  
 
 The third objective was to search for the ligands of these TCR molecules using methods 
such as the screening of (i) candidate MS antigens, and (ii) unbiased plasmid encoded 
peptide libraries.  
 
 The fourth objective was a TCR independent approach  to characterize the anchor 
positions of antigen presenting molecules  by screening a positional scanning 
combinatorial peptide library using recombinantly generated antigen presenting 
molecules. 
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2 Materials and Methods 
 
2.1 Material 
 
2.1.1 Chemicals and consumables 
Chemicals were, unless mentioned otherwise, procured from the companies Merck (Darmstadt) 
and Sigma-Aldrich (Taufkirchen). Consumables such as pipette tips, reaction tubes and 
centrifuge tubes were obtained from Biozym (Hess, Oldendorf), Eppendorf (Hamburg) and 
Becton Dickinson (Heidelberg). Special tips and polypropylene tubes were ordered from the 
companies Biozym and Eppendorf. Cell culture dishes were from companies BD Falcon 
(Heidelberg), Corning (Wiesbaden) and Nunc (Langenselbold). 
 
2.1.2 Oligonucleotides  
All oligonucleotides were synthesized by the company Metabion (Martinsried) with the 
exception of the M13 primers (Invitrogen, Karlsruhe). All primers were obtained at a stock 
concentration of 100 µM. When primers had to be stored long prior to use, lyophilized primers 
were ordered and re-constituted in sterile buffer prior to use. The sequences and sources of all 
primers used in this study are listed in Appendix I. 
 
2.1.3 Expression vectors 
The expression vectors used are described in the relevant section. Vector maps are presented in 
Appendix II. 
Materials and Methods 
 
 
20 
 
2.1.4 Antibodies 
Specificity Conjugated 
Fluorophore 
Clone Species/ 
Isotype 
Concentration Source 
Mouse CD3e - 145-2C11 Hamster/
IgG 
0.5 mg/ml eBioscience (Frankfurt)  
Human CD8α - LT8 Mouse/ 
IgG1 
1.0 mg/ml AbD Serotec 
Human CD8α FITC DK2F Mouse/ 
IgG1k 
2.0 mg/ml DAKO (Glostrup, 
Denmark) 
Human CD8β - 2ST8.5H7 Mouse/ 
IgG2a 
1.0 mg/ml Beckman Coulter 
(Marseille, France) 
Human CD134 FITC ACT35 Mouse/ 
IgG1 
50 µg/ml BD Pharmingen 
Human TCR Vβ 1 FITC BL37.2 Rat/ 
IgG1 
2.5 mg/ml Beckman Coulter  
Human β2 
microglobulin 
- polyclonal Mouse/ 
IgG 
n.k Abnova (Eching) 
Human HLA-ABC FITC/PE W6/32 Mouse/ 
IgG2a 
2.5 mg/ml Beckman Coulter 
c-myc - 9E10.3 Mouse/ 
IgG1k 
200 µg/ml Millipore (USA) 
6x His - HIS.H8 Mouse/ 
IgG2b 
 
1.0 mg/ml Abcam (Cambridge, 
UK) 
Secondary antibodies 
Fluorescein Alexa Fluor 
488 
polyclonal Goat/ IgG 1 mg/ml Molecular Probes 
(Leiden, The 
Netherlands) 
Mouse FITC polyclonal  
 
Goat/ 
F(ab’)2 
n.k DAKO 
Mouse Peroxidase polyclonal Goat/ IgG 
+ IgM 
(H+L) 
n.k. Dieter Jenne (MPI of 
Neurobiology) 
Isotype Controls (IC) 
IC Mouse/ IgG1 - X40 Mouse/ 
IgG1 
50 µg/ml Becton Dickinson 
IC Mouse/ IgG2a FITC X39 Mouse/ 
IgG2a 
50 µg/ml Becton Dickinson 
n.k: not known 
MPI: Max Planck Institute 
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2.1.5 Patients and tissue samples 
All specimens were characterized by genomic HLA typing at the Institute for Immunogenetics, 
Ludwig-Maximilians-Universität München (LMU). The HLA composition of the two patients 
analyzed in this study has been presented in Table 2-1. 
 
Patient ID HLA- 
 A* B* C* DRB1* DQB1* 
FE 0101 0801 0701 0301 05 
      
MS – 4 0201 0702 0702 04 0302 
 0301 5101 1502 15 0602 
 
Tab. 2-1: HLA composition of the MS patients 
Column 1 displays the identification code (Patient ID) of the MS patients. This is followed by the HLA alleles 
determined by genomic HLA typing. Patient FE is seemingly homozygous for the haplotype as only one allele was 
detected for each of the loci analyzed. Patient MS-4 is heterozygous for all loci. (Skulina et al. 2004; Junker et al. 
2007) 
 
2.1.5.1    Biopsy case: Patient FE 
2.1.5.1.1 Diagnosis 
Patient FE, a male patient, was diagnosed at the age of 49 (1996) with a malignant glioma in the 
right temporooccipital lobe of the brain. The affected region was surgically removed and a 
detailed pathological examination resulted in the diagnosis of MS (Skulina et al. 2004). The 
tissue sample hails from a relatively early phase of the disease and data gathered might provide 
hints into the early events of pathogenesis. The patient is apparently homozygous for the MHC 
class I alleles (Skulina et al. 2004), meaning that the antigen must be researched in context of 
only three (instead of six) MHC class I molecules. 
 
2.1.5.1.2 Samples 
A part of the biopsy that was stored in liquid nitrogen was used in this analysis. In the course of 
this study, three tissue blocks (designated #9, #10 and #11) originating from the same lesion 
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were investigated. These blocks contained cortex or grey matter (GM), white matter (WM) and 
meninges.  
 
2.1.5.1.3 TCR repertoire 
Since biopsy acquisition in 1996, the TCR repertoire of this patient was studied in great detail in 
our laboratory (Skulina et al. 2004; Babbe et al. 2000). This is summarized in Table 2-2. 
 
Single cell PCR (Babbe et al. 2000) CDR3-Spectratyping (Skulina et al. 2004) 
Brain  
1996 
TCR BV CDR3 Sequence Brain 
1996 
CSF 
2001 
PBL 
2001 
PBL 
2003* 
Frequency of        
Par. 
CD8+ 
T cells 
Per. 
CD8+ 
T cells 
    
 
CD4 
 
 
CD8 
 
 
CD138 
 
 
CD8 
 
1/24  
 
1/46  
 
BV1-CAS-TPERDPS-NEQ-BJ2.1 
 
+ 
 
- 
 
- 
 
- 
 
- 
 
- 
1/24  2/46  BV1-CASS-ISRKD-TQY-BJ2.3 + (+) - + + + 
4/24  2/46  BV4-CS-VWEV-SGA-BJ2.6 + + - + - - 
2/24  -  BV13.1-CASS-LGA-DTQ-BJ2.3 + - - - - - 
2/24  1/46  BV13.2-CAS-RALVAT-YNE-BJ2.1 + - - - - - 
-  2/46  BV13.2-CASS-YP-GEL-BJ2.2 + - - - - - 
1/24  3/46  BV13.3-CASS-PGDRAQ-BJ2.1 + + - (+) - - 
1/24  1/46  BV14-CASS-PLWEGGIG-NTE-BJ1-1 + + - + - - 
3/24  -  BV22-CASS-EGAGEH-NEQ-BJ2.1 + (+) - - - - 
Tab. 2-2: Repertoire of clonally expanded β-chains in patient FE 
+: readable sequence, (+): sequence of clonal expansion determined on an oligoclonal background,           - : clone 
not identified by CDR3 spectratyping or direct sequencing, TCR: T cell receptor, BV: Variable region of the β-
chain, BJ: Joining region of the β-chain, CSF: cerebrospinal fluid, PBL: peripheral blood lymphocytes, par.: 
parenchymal, per.: perivascular, CD4: helper T cell marker, CD8: effector T cell marker, CD138: cell proliferation 
and migration marker. (Babbe et al. 2000; Skulina et al. 2004). *Unpublished data from Klaus Dornmair and 
Joachim Malotka, MPI of Neurobiology. 
 
The BV1-BJ2.3 expansion that was detected over a period of seven years in the patient could be 
expected to contribute to the disease. An analysis of the patient’s peripheral blood lymphocytes 
yielded the sequence of a pairing AV7.2-AJ16 α-chain in six T cells (personal communication 
from Joachim Malotka and Klaus Dornmair, MPI of Neurobiology). In collaboration with David 
Laplaud and Katherina Siewert (MPI of Neurobiology), efforts were then made to confirm 
whether this TCR could also be detected in the brain tissue (Section 3.1). 
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2.1.5.2    Autopsy case: Patient MS-4 
2.1.5.2.1 Diagnosis 
The male patient was diagnosed at age 38 with primary progressive MS. The patient was affected 
with the disease for 4 years, and the cause of death was unknown. For this study, tissue blocks 
from the periventricular region (block #6: slowly expanding chronic lesion) and temporal white 
matter (block ‘9: inactive demyelinated lesion) were analyzed (Junker et al. 2007). 
 
2.1.5.2.2 Samples 
Tissue regions that included either visible lesions or normal appearing CNS tissue were dissected 
by the pathologist, snap frozen and stored at -80°C.  
 
2.1.5.2.3 TCR repertoire 
The analysis of the TCR repertoire in the four tissue blocks of patient MS-4 (Junker et al. 2007) 
revealed the presence of some clonal expansions, such as the BV1-BJ1.1 β-chain that was found 
in more than one tisuue block (blocks 6, 7 and 9) and may be termed as ‘pervasive’. The 
repertoire of clonally expanded TCR β-chains is shown in Table 2-3. Such clonal expansions 
were equally interesting for further characterization of the pairing α-chain. 
 
CDR3-Spectratyping 
Lesion number NAWM TCR BV CDR3 Sequence 
5 6 7 9 12  
      
- + + + - BV1-CASS-VGDVRQM-NTEAFF-BJ1.1 
* + + + (+) BV4-CS-VGTGGVGSAG-TNEKLF-BJ1.4 
- + + + * BV4-CS-ATGDRG-SNQPQHF-BJ1.5 
+ + + + + BV4-CS-TQTGT-GANVLTF-BJ2.6 
- + + + - BV6-CASS-LGTGM-NTEAFF-BJ1.1 
(+) + (+) + + BV15-CATS-PGGQI-YGYTF-BJ1.2 
Tab. 2-3: Repertoire of clonally expanded TCR β-chains in patient MS-4 
TCR: T cell receptor, BV: Variable region of the β-chain, BJ: Joining region of the β-chain, NAWM: Normal 
appearing white matter, +: monoclonal expansion found at two or more anatomical site, (+): Oligo- or polyclonal 
expansion, *: NDN-sequence different from the pervasive clone, - : absence of PCR product in spectratyping 
reaction, Modified from Fig. 4, Junker et al. 2007 
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2.1.6 Laboratory Equipment 
 
Autoclave  Varioklav Type 500 (liquids) H+P Labortechnik 
(Oberschleißheim, Germany) 
Autoclave  Webeco Type A5 
(consumables) 
Webeco (Selmsdorf, Germany) 
Balance  L2200P Sartorius (Göttingen, Germany) 
Balance 2001 MP2 Sartorius  
Centrifuge  5417 C Eppendorf (Hamburg, Germany) 
Centrifuge 5417 R Eppendorf 
Centrifuge  Heraeus® Megafuge 1.0R Thermo Fisher Scientific (Schwerte, 
Germany) 
Centrifuge  Sorvall RC-5C PLUS Thermo Fisher Scientific  
Cryotome CM3050 Leica (Wetzlar, Germany) 
DNA gel imager Gel DocTM XR Bio-Rad (München, Germany) 
Incubator  Thermomixer 5436 (reaction 
tubes) 
Eppendorf 
Incubator  BBD 6220 (eukaryotic cell 
culture) 
Heraeus (Hanau, Germany) 
Incubator  Jouan EB 53 (bacterial cultures) Thermo Fisher Scientific  
Microinjector CellTramVario Eppendorf 
Micromanipulator LN25 Mini Luigs und Neumann (Ratingen, 
Germany) 
Microscope AxioVert 200M Zeiss (Munich, Germany) 
Microscope  AxioVert 25 Zeiss  
Microscope  Microbeam-Z Zeiss  
Microscope  Axio Observer  
Water preparation Milli-Q Advantage Millipore (Schwalbach, Germany) 
ELISA-Reader  MR 4000 Dynatech (Rückersdorf, Germany) 
Flow cytometer  FACS Calibur Becton Dickinson (Heidelberg, 
Germany) 
Flow cell sorter  FACS Sorter FACS Vantage SE Becton Dickinson  
Freezing box  Nalgene (Roskilde, Denmark) 
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Gel electrophoresis 
chambers 
 MPI of Neurobiology workshop 
Gel electrophoresis 
power supply 
 GE Healthcare (Munich, Germany) 
Electroporation device Genepulser Bio-Rad 
Electroporation device Micropulser Bio-Rad 
Electroporation device Multiporator Eppendorf 
Cell counting chamber Neubauer Roth (Karlsruhe, Germany) 
PCR cycler  GeneAmp PCR system 9600 Perkin Elmer (Rodgau, Germany) 
pH-meter  pH521 WTW (Weilheim, Germany) 
Pipettes  Gilson or Eppendorf 
Photometer  Gene Quant II Pharmacia Biotech 
UV-Vis 
spectrophotometer  
Nanodrop 1000 Thermo Fisher Scientific 
 
Equipment or devices that were utilized exclusively for specific experiments are mentioned in 
the relevant section. 
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2.2 Microbiological methods 
 
2.2.1 Preparation of electrocompetent E. coli 
Electrocompetent E. coli are a prerequisite for the transformation of bacteria by electroporation. 
First, a pre-culture was prepared by inoculating 'MAX Efficiency® DH5αF'IQ
TM
' E. coli in 
10 ml LB-medium supplemented with 50 µg/ml Kanamycin and grown overnight at 37 °C in the 
shaker incubator. Then, 6 ml of this was further inoculated into a half liter volume of the same 
media and incubated until an optical density of 0.5 was measured. The growth curve was 
monitored at 600 nm. After this, the bacteria were concentrated to a 1 ml volume by a four 
course centrifugation (rotor SLA-1500: 4.000 rpm, 5 min, 4 °C) followed by resuspension of the 
sediment in sterile 10 % Glycerol pH 7.0 (Carl Roth, Karlsruhe) in a stepwise manner. Finally, 
the competent cells were distributed as 50 µl aliquots and stored at -80 °C. The transformation 
efficiency of each charge was tested by transforming 10 pg of pUC DNA per 50 µl cells as 
explained in Section 2.2.2. This is defined as the number of visible colonies per microgram of 
transformed DNA and was measured within a range of 10
8
 und 10
9
. 
 
 MAX Efficiency® DH5αF'IQTM competent cells (Invitrogen) 
 
 LB medium (Luria-Bertani) 
1 % (w/v) Bacto tryptone (Becton Dickinson), 0.5 % (w/v) yeast extract (Becton Dickinson), 0.5 % (w/v) 
NaCl, autoclaved 
 
2.2.2 Bacterial transformation by electroporation 
Electrocompetent DH5α-bacteria from Section 2.2.1 were transformed with plasmid DNA via 
electroporation. During this process, the applied electric field leads to a short term 
permeabilisation of the bacterial cell membrane, allowing for the entry of plasmid DNA into the 
cell. In a typical experiment, 1.8 µl of the ligation reaction was added to 50 µl of the 
electrocompetent cells in a pre-cooled electroporation cuvette (Bio-Rad, 0.2 cm). Care was taken 
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to avoid the formation of air bubbles. After the electric shock using the ‘Gene Pulser II’ 
(machine settings: 2,5 kV, 25 µFD, 200 Ω) the cells were allowed to recover in 1 ml LB medium 
for 1 hour in the shaker incubator at 37°C. The bacteria were then plated on ampicillin (Amp) 
supplemented LB agar for the selection of positive clones, and grown overnight at 37°C. pUC 
DNA was used as a positive control, and the empty (lacking insert) linearized vector was used as 
a negative control.  
 
The plasmid encoded peptide (PECP) libraries were maintained in electrocompetent ElectroMax 
DH10B™T1R E. coli. This electroporation procedure was optimized in the laboratory for best 
results. 50 µl of the bacteria were mixed with the purified ligation product (Section 2.4.3.6) and 
transferred, without bubble formation, to a pre-cooled cuvette (Bio-Rad, 0.1 cm). The 
electroporation was carried out at 2.5 kV as before. The bacteria were immediately re-suspended 
in 1 ml of pre-warmed SOC media and allowed to recover for 60 minutes at 37°C in the shaker 
incubator. Post recovery, the bacteria were expanded overnight in a 1000-fold greater volume, 
i.e. 50 ml for 50 µl, of LB agar (+Amp) media. This is of vital importance as the ElectroMax 
DH10B™T1R cells are provided at a very high density of 2.8 x 10
11
/ml, as determined in the 
laboratory (by OD600 nm measurements and plating), which demands a  starting OD600 nm ≤ 0.2 
(OD = optical density) that would ensure that each individual clone was well represented in the 
final population. The number of individual clones present in the library were determined by 
plating aliquots (1/1000 and 1/500,000) of the transformation mixture on to LB agar (+Amp) 
plates (explained in Section 2.2.4). The empty linearized vector was used as a negative control. 
 
 ElectroMax DH10B™T1R E. coli (Invitrogen) 
 
 LB agar (+Amp) 
LB medium with 1.5 % (w/v) bacto agar (Becton Dickinson); autoclaved; (+ 100 µg/ml ampicillin) 
 
2.2.3 Bacterial transformation by heat shock 
The chemically competent 'One Shot® TOP10' E. coli strain was routinely used in TOPO-TA 
cloning. Once the bacterial aliquot was thawed on ice, 2 µl DNA was added and this mix was 
further incubated for 30 minutes on ice to allow the DNA to attach itself to the bacterial cell 
membrane. This was followed by a 30 second heat shock in a water bath that permeabilises the 
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cell membrane for a short duration and allows for cellular entry of DNA. Following 20 minute 
incubation on ice, the transformed bacteria were inoculated into pre-warmed S.O.C medium and 
grown in the shaker incubator at 37 °C for 1 hour. The pCR®2.1-TOPO vector renders the 
bacterial clones resistant to ampicillin. In addition, one may carry out a ‘blue-white colony’ 
selection by supplementing the LB (+Amp) agar plate with 40 µl X-Gal stock solution. The 
enzyme ß-galactosidase, coded by the lac-Z gene catabolizes the X-Gal (5-bromo-4-chloro-3-
indoxyl-β-D-galactopranoside) into galactose and indoxyl. Indoxyl gets oxidized to an indigo 
blue product that renders color to the cellular cytoplasm. The insertion of a PCR product into the 
pCR®2.1-TOPO vector interrupts the lacZ gene. As a result, the positive colonies are white in 
color. 
 
 One Shot® TOP 10 E. coli (Invitrogen) 
 
 pCR®2.1-TOPO 
3.1 kb, Kan
R
, Amp
R
, for vector map refer to Appendix II 
 
 X-Gal stock solution (40 mg/ml): 
400 mg X-Gal in 10 ml dimethylformamide (DMF); sterile filtered and stored at -20 °C 
 
2.2.4 Determination of bacterial cell numbers 
Bacterial cell numbers were determined in parallel by OD600 nm measurements and plating the 
bacteria on LB agar plates. The OD600nm measurements were recorded on the UV-VISIBLE 
Recording spectrophotometer. A value of 1.0 corresponds to a bacterial population of 1x 109 cells /ml 
and the apparatus is most accurate for values ranging from 0.1 to 0.5. Based on these observations, 
the bacteria were diluted to achieve desired concentrations. This was further verified by plating 
defined bacterial aliquots on LB-agar (+Amp) plates, growing overnight at 37°C and then counting 
the number of appearing clones. 
 
2.2.5 Long term storage of bacterial cultures: glycerol stocks 
Bacterial cultures were mixed homogenously with sterile glycerol in a 1:1 proportion, distributed 
in cryotubes and stored at -80°C. 
Materials and Methods 
 
 
29 
 
2.3 Cell-culture based methods 
 
2.3.1 Cultivation of cell lines 
2.3.1.1    Cell line COS-7 
The COS-7 cells were used as antigen presenting cells in antigen search experiments. They were 
stably transfected with human MR1 (pHSE3’ expression vector) and transiently transfected with 
plasmid encoding peptide libraries (pcDNA6/-His A expression vector). COS-7 is an adherent, 
fibroblast-like, african green monkey kidney cell line that has been immortalized by 
transformation with the simian vacuolating virus 40 (SV40) that is able to produce the large T 
antigen. Consequently, when a vector such as the pcDNA plasmid bearing the SV40 promoter is 
introduced into the COS-7 cell, it can be replicated to a great extent. The cells were cultivated in 
RPMI complete media at 37°C under 5% CO2 in different appropriate tissue culture vessels. 
During routine cell culture, the cells were detached from the vessel surface using trypsin 
preceded by a 1X phosphate buffered saline (PBS) wash. 
 Cell line ‘COS-7’  
ATCC number: CRL-1651 (Gluzman, 1981) 
 
 pHSE3’-MR1 
10.2 kb, Amp
R
, Neo
R
, for vector map refer to Appendix II. Provided by Wakiro Sato, MPI of Neurobiology 
(Pircher et al. 1989) 
 
 pcDNA6/V5-HisA (Invitrogen) 
5.1 kb, Amp
R
, Blasticidin
R
, for vector map refer to Appendix II 
 
 RPMI complete medium 
RPMI 1640, 10 % FCS (Sigma, Deisenhofen, Germany), 100 U/ml penicillin, 100 µg/ml streptomycin, 1 mM 
sodium pyruvate, 1X non-essential amino acids,  (Invitrogen, Karlsruhe, Germany) 
 
 1X PBS 
150 mM NaCl, 8.4 mM Na2HPO4, 2 mM NaH2PO4 
 
 Trypsin :  
Trypsin/EDTA 1X (Invitrogen) 
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2.3.1.2    Cell line 58-/- 
58
-/-
 is a TCR deficient, mouse T hybridoma cell line derived from the BW5147 thymoma cell 
line that lacks inherent functional TCR chains. Hence, it is a suitable recipient cell line for the 
expression of human TCRs. The cell line is cultivated in suspension in the RPMI complete 
medium. In addition to the two TCR chains cloned into pRSV vectors, this cell line was also 
used for the simultaneous expression of the human CD8 molecule (pLPC-hCD8α-IRES2-hCD8β 
expression vector ) and sGFP under NFAT regulation (pcDNA-NFAT-sGFP expression vector). 
Each construct was selected for and maintained within the cells under antibiotic selection as 
summarized in Table 2-4. 
 
Expression vector* 
 
Antibiotic selection Stock conc. 
(mg/ml) 
Selection conc. 
(µg/ml) 
Maintenance 
conc. (µg/ml) 
TRAV pRSVhygro Hygromycin (Invitrogen) 50 500-1000 300 
TRBV pRSV5.neo Geneticin (Invitrogen) 100 2000-3000 1500 
pLPC-hCD8α-IRES2-hCD8β Puromycin (Biomol) 1 2-4 1 
pcDNA-NFAT-sGFP Blasticidin (Invitrogen) 10 2-4 3 
Tab. 2-4: Antibiotics used for selection in eukaryotic cell culture 
The 58-/- cells transfected with the expression vectors mentioned in the first column were cultured in a 
cocktail of four antibiotics to maintain the stable expression (Section 2.3.3). TRAV: TCR α-chain, TRBV: 
TCR β-chain, Stock conc.: the conc. at which the antibiotics are stored for long term; Selection conc.: 
antibiotic conc. at which clones are selected post transfection; Maintenance conc.: antibiotic conc. at which 
the selected clones are propagated for routine experiments; conc.: concentration. *Vector maps presented in 
Appendix II 
 
 Cell line ‘58 -/-’ 
Provided by Klaus Dornmair, MPI of Neurobiology, (Letourneur and Malissen, 1989) 
 
 pRSVhygro  
5.9 kb, Hygro
R
, Amp
R
, for vector map refer to Appendix II, provided by Joachim Malotka, MPI of 
Neurobiology 
 
 pRSV.neo  
6.1 kb, Neo
R
, Amp
R
, for vector map refer to Appendix II, provided by Joachim Malotka, MPI of 
Neurobiology 
 
 pLPC-hCD8α-IRES2-hCD8β  
PuroR, provided by Klaus Dornmair, MPI of Neurobiology 
 
 pcDNA-NFAT-sGFP  
5.8 kb, Amp
R
, Blasticidin
R
, generated by Michael Ackman and Daniela Hackl, provided by Klaus Dornmair, 
MPI of Neurobiology 
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2.3.1.3    Cell line HEK293E 
The HEK293E cell line was used for the expression of recombinant human MR1 and β2 
microglobulin. It is a modified human embryonic kidney cell line that grows in suspension in 
serum free media. The cells are stably transfected with a plasmid coding for the nuclear EBV-
antigen 1 (EBNA-1). EBNA-1 is required for the episomal replication of plasmids that carry the 
EBV specific replication of origin ‘oriP’(Hennessey et al. 1983). The plasmid also carries a 
geneticin (G-418) resistance marker for maintenance of the plasmid within the cells. The pTT5-
vector employed in the experiments carries not only the ‘oriP’, but also a promoter of the human 
cytomegalovirus (CMV). This genetic combination, in addition to the constitutive expression of 
the adenoviral protein E1a that transactivates the CMV promoter (Gorman et al. 1989), facilitates 
high expression rates. These factors make this cell line an ideal high protein expression system. 
All steps that involved cell line handling were carried out aseptically in the ‘LaminAir®’cell 
culture hood. 
 
 Cell line ‘HEK293E Large Scale Transient Expression System’ 
 
 pTT5 (NRC Biotechnology Research Institute) 
4401 bp, Amp
R
, for vector map refer to Appendix II, patented by Yves Durocher, NRC Biotechnology 
Research Institute, Ottawa, Ontario, CA, provided by Dieter Jenne (License holder), MPI of Neurobiology 
 
 Cell culture medium  
GIBCO® FreeStyle
TM
 293 expression medium with 0.1 % (v/v) Pluronic® F-68 (Invitrogen) and 25 µg/ml 
G-418 sulfate (PAA laboratories, Cölbe, Germany) 
 
2.3.2 Determination of cell count and viability 
The viable cell count was determined by mixing the cell suspension and trypan blue solution in a 
1:1 ratio and placing this mixture within a ‘improved Neubauer’ cell counting chamber. The 
perforated membranes of dead cells allow the trypan blue to enter these cells, rendering them 
blue while live cells exclude the dye. Live cells in the four large quadrants are counted under a 
compound microscope; the average of this value is multiplied by the dilution factor and then 
adjusted by the cell counting chamber constant 10
4
. The resulting value describes the cells/ml in 
the suspension. 
 Trypan blue solution (0.1 %) 
0.4 % Trypan blue solution 1:4 in 1X PBS pH 7.4; sterile filtered 
Materials and Methods 
 
 
32 
 
2.3.3 Transfection of eukaryotic cells: stable protein expression 
The 58
-/- 
cell lines were transfected for the stable expression of TCR molecules. Electroporation 
or Fugene HD reagent was used as a means of transfection. The plasmid DNA was linearized 
prior to transfection to facilitate chromosomal integration, and eventually, stable transfectants. 
The rare cutter restriction enzymes Xmn1 and Nde1 were used to linearize the TCR chains cloned 
into the pRSV vector. The linearized DNA was precipitated in ethanol at -80°C and then re-
suspended in sterile water.  
 
For electroporation, cells were harvested during the logarithmic growth phase and washed twice 
in non-supplemented RPMI. When using the GenePulser the cells were resuspended in non-
supplemented RPMI, while in case of the multiporator the provided hypoosmolar buffer was 
used. To 0.8-8 x 10
6
 cells, 16 µg of plasmid DNA (in 10 mM Tris-HCl, pH 8.5) was added and 
this suspension was pipetted into 0.4 cm electroporation cuvettes suited to the device. An electric 
pulse was applied at 280V, 960 µF for the GenePulser and 1200 V, 40 ms for the multiporator at 
room temperature. Following the pulse, the cells were immediately re-suspended in pre-warmed 
RPMI complete media, seeded to the desired density and grown under regular cell culture 
conditions. 
 
Transfection by Fugene HD was done following the manufacturer’s recommendations. To 2 µg 
of DNA in 100 µl of RPMI, 7 µl of Fugene HD was added. The transfection complex was mixed 
shortly, incubated for 15 minutes at room temperature and then 25 µl of it was added to one well 
of a 24-well plate that had been previously seeded with cells (100,000 cells / well). These 
parameters were followed for the up- and down scaling of similar experiments. Antibiotic 
selection was applied 2 days post transfection. The minimum amount of antibiotic used for this 
purpose was determined by varying antibiotic concentrations and plotting a ‘killing curve’. 
These values are presented in Table 2-4. The stably transfected cell lines employed in this study 
are listed in Table 2-5. 
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Cell line Transfected molecules Application of cell line 
 
Human TCRs transfected in the 58-/- T hybridoma cell line 
58-Fe-BV1-AV7.2-AJ16 TCRα-chain: AV7.2-AJ16 
TCRβ-chain: BV1-BJ2.3 
Human CD8αβ, NFAT-sGFP 
TCR expression for antigen determination 
58-Fe-BV1-AV7.2-AJ24.2 TCRα-chain:AV7.2-AJ24.2 
 TCRβ-chain: BV1-BJ2.3 
Human CD8αβ, NFAT-sGFP 
TCR expression for antigen determination 
58-Fe-BV1-AV7.2-AJ33 TCRα-chain:AV7.2-AJ33  
TCRβ-chain: BV1-BJ2.3 
Human CD8αβ, NFAT-sGFP 
TCR expression for antigen determination 
58-Fe-BV1-AV7.2-AJ54 TCRα-chain:AV7.2-AJ54 
TCRβ-chain: BV1-BJ2.3 
Human CD8αβ, NFAT-sGFP 
TCR expression for antigen determination 
58-Fe-BV8.1-AV30.1 TCRα-chain: AV30.1-AJ18 
TCRβ-chain:BV8.1-BJ1.1 
Human CD8αβ 
 
TCR expression for antigen determination 
Human MR1 transfected in the COS-7 cell line* 
COS-7-hMR1* Human MR1 Antigen presenting cell in antigen determination 
experiments 
 
Tab. 2-5: Cell lines generated by stable transfection 
TCR: T cell receptor, BV: TCR β-chain variable region, BJ: TCRβ-chain joining region; AV: TCR α-chain variable 
region, AJ: TCRα-chain joining region; hMR1: human MHC-related protein 1, *this cell line was provided by 
Wakiro Sato, MPI of Neurobiology 
 
2.3.4 Transfection of eukaryotic cells: transient protein expression 
The HEK293E cells were transfected  for the transient expression (Durocher et al. 2002) of β2 
microglobulin associated human MR1 (hMR1). The cells were diluted in pre-warmed media to a 
concentration of 10
6
 cells / ml an hour prior to transfection. 1 µg plasmid DNA (precipitated in 
ethanol and re-suspended in sterile water) was transfected per ml of this cell suspension, i.e. 
100x10
6
 cells were transfected with a combination of 50 µg of the hMR1-pTT5 expression 
vector and 50 µg of the β2 microglobulin-pTT5 expression vector (for vector maps see 
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Appendix II). The transfection reagent polyethylenimine (PEI) was used at a final concentration 
of 2 µg/ml (Boussif  et al. 1995). The positively charged PEI binds to the negatively charged 
phosphate backbone of plasmid DNA, and this complex is then endocytosed into the cell 
(Godbey et al. 1999). First, 1 ml PEI was diluted in 4 ml OptiPro
TM
 SFM. At the same time, the 
plasmid DNA was diluted in OptiPro
TM
 SFM to a final volume of 5 ml. The PEI was then added 
to the DNA and this mixture was incubated for 30 minutes at room temperature (RT). Finally, 
this transfection complex was added in a drop wise manner to the cells. 0.5 % (w/v) Tryptone 
was added to the cells 24 hours after transfection. This protein hydrolysate is broken down to 
free amino acids by proteases and can be directly taken up by the cells for protein biosynthesis 
(Heidemann et al. 2000). In addition, it can also be removed easily from the cellular supernatant 
during protein purification (Pham et al. 2003). The supernatant was harvested 110 hours post 
transfection by centrifugation for 5 minutes, 1500 rpm at 4°C. Further protein purification steps 
are elaborated in Section 2.5.2. The plasmid encoded peptide libraries were transiently expressed 
in COS-7 cells using electroporation and FugeneHD as outlined in Section 2.3.4. 
 
 PEI stock solution (1 mg/ml) 
500 mg 25 kDa linear PEI (Polysciences Inc. Warrington, Eppelheim) dissolved in H2O at pH 2, adjusted to 
pH 7 with NaOH; diluted to 500 ml with H2O, sterile filtered 
 
 Tryptone stock solution (5 %) 
50 g Bacto TC lactalbumin (Becton Dickinson) in 1 L H2O, sterile filtered 
 
 
2.3.5 T hybridoma cell activation assay 
2.3.5.1    T hybridoma activation by CD3 cross-linking 
The CD3e antibody (clone 145-2C11) was used to determine the functionality of the 
recombinant TCR in vitro. TCR activation and subsequent downstream signaling (Call et al. 
2002) leads to the nuclear transport and accumulation of nuclear factor of activated T cells 
(NFAT) that further results in interleukin 2 (IL-2) secretion. The activation status can be 
determined by assaying secreted IL-2 or by a NFAT driven GFP production that renders the 
activated cell fluorescent. The TCR antigen would display a similar effect. The CD3e antibody 
(1 µg/ml in PBS) or antigens to be tested were coated onto a 96 well cell culture plate by 
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incubation at 37°C for 3 hours. The plate was rinsed with 200 µl PBS and 40,000 hybridoma 
cells were added per well. After 16 hour incubation at 37°C, the samples were assayed for 
activation by IL-2 detection in cellular supernatant or fluorescence microscopy for the presence 
of GFP+ cells as explained in following Section 2.3.5.2 and Section 2.3.5.3. 
 
 
2.3.5.2    T hybridoma activation by antigenic stimulus 
MS patient derived TCRs may be tested for their reactivity to brain tissue sections (2.3.5.2.1) and 
extracts (2.3.5.2.2). Similarly, candidate antigens that are observed to cause the MS equivalent 
(experimental autoimmune encephalitis or EAE) in animal models may be tested. These include 
autologous and Epstein-Barr virus (EBV) antigens (2.3.5.2.3), as well as myelin derived proteins 
(2.3.5.2.4).  
 
The MAIT TCR derived from patient FE was tested as described above using antigen presenting 
cells isolated from a HLA-matched donor. Even though the antigen-restriction element of the 
MAIT TCR is thought to be MR1, APCs that specifically expressed MR1 were not used. This is 
because this series of experiments was performed at an early stage when it was not known that 
the AV7.2-AJ33 was the invariant MAIT α-chain. 
 
 
2.3.5.2.1 Human brain tissue 
To test whether the putatively autoaggressive TCRs recognized an antigen that was specific to 
the patient, or even to MS, the TCR expressing hybridoma cells were co-incubated with brain 
tissue and the resulting activation was measured. For this, tissue derived from the same MS 
patient, an unrelated MS patient and a meningitis patient was tested. 10 µm sections of each 
sample were placed on UV-illuminated glass cover slips that had been coated with poly-L-lysine 
(50-100 µl/slide). The slide was air dried for 10 minutes and then placed into a 3.5 cm culture 
dish containing RPMI complete medium to which 1.5 x 10
6 
hybridoma cells were added. The set 
up was incubated for 16 hours at 37°C, and the number of activated cells was counted manually 
under a fluorescence microscope. In an additional experiment, a pan-MHC class I antibody, 
(clone W6/32) (1:50 dilution) was used to block MHC class I mediated antigen presentation and 
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eventual hybridoma activation. This was done to verify whether the activated cells were indeed a 
function of MHC-peptide complex recognition. The antibody was added to the culture media and 
incubated on wet ice for 30 minutes prior to the addition of hybridoma cells.  
 
 
2.3.5.2.2 Human brain extracts 
The activation of TCR hybridoma cells was tested in the context of grey matter (GM) and white 
matter (WM) homogenates as well as their respective glycoprotein fractions. These brain extracts 
were provided by Prof Meinl (MPI of Neurobiology). A fraction of peripheral blood 
lymphocytes containing dendritic cells and macrophages from a HLA-matched donor were used 
as antigen presenting cells (APCs). These were isolated from blood as follows. 40 ml of freshly 
drawn blood was diluted with 20 ml PBS and applied onto 15 ml of a ‘PANCOLL human’ 
separating agent solution. This mixture was centrifuged (500 g, 25 minutes, RT) for the 
separation of the PBMC fraction. The PBMCs were carefully removed, and the residual fraction 
containing the dendritic cells was washed with PBS. The cells were counted and seeded at a 
density of 100,000 cells per well on a 96-well plate. After an overnight incubation at 37°C, the 
immature dendritic cells remained adherent to the cell culture plates, and the supernatant was 
removed. The brain extracts were added and incubated for 6 hours, during which the APCs were 
given sufficient time to take up the extracts by endocytosis, process the antigens and present 
them appropriately. This was followed by a wash and addition of hybridoma cells. 16 hours after 
co-culture, the cellular supernatant was assayed for IL-2 as explained in Section 2.3.5.3.1. 
 PANCOLL human separating agent solution 
PAN Biotech GmBh, Aidenbach, Germany 
 
 
2.3.5.2.3 Autologous and Epstein-Barr Virus (EBV) antigens 
To test whether the TCR hybridoma recognize ‘self’ antigens or antigens derived from the 
Epstein-Barr Virus, they were co-cultured with autologous EBV-transformed B cells of patient 
FE. 100,000 EBV transformed B cells were seeded per well of a 96-well plate in RPMI medium. 
The lytic cycle of replication was induced by transfecting the cells with the PZLF1 and BRLF1 
plasmids (provided by Prof. Miller, Yale University). The T hybridoma cells were added 48 
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hours post transfection. 16 hours after co-culture, the cellular supernatant was assayed for IL-2 as 
outlined in Section 2.3.5.3.1. 
 
 
2.3.5.2.4 Myelin derived antigens 
The reactivity of the MS derived TCR to myelin proteins such as myelin oligodendrocyte protein 
(MOG) (Schluesener et al. 1987), myelin basic protein (MBP) (Eylar et al. 1970; Lennon et al. 
1970) and neurofascin (Mathey et al. 2007) was examined. These proteins were provided by 
Judy Ng and Prof Meinl (MPI of Neurobiology). HLA-matched antigen presenting cells from a 
healthy donor were used as explained in Section 2.3.5.2.2.  To these cells 5 mg of each protein 
was added and incubated for 6 hours. Then the T hybridoma cells were co-cultured for 16 hours, 
after which the cellular supernatant was assayed for secreted IL-2 as described in Section 
2.3.5.3.1. 
 
 
2.3.5.3    Readouts for T hybridoma activation assay 
2.3.5.3.1 IL-2 ELISA 
IL-2 is a leukocytotrophic signaling molecule that plays a role in the development of the 
immunologic memory of cytotoxic T cells. Physiologically, it is secreted during T cell response 
to antigenic challenges such as a microbial infection. This secreted IL-2 could be assayed in the 
cellular supernatants by the IL-2 enzyme linked immunosorbent assay (ELISA) kit. The 
manufacturer’s instructions were followed while performing the assay. For each ELISA a 
standard curve with IL-2 was performed with concentrations ranging from 5-1,000 pg/ml. The 
detection limit of the kit was 5 pg/ml or 0.25 pg/ well. 
 
 IL-2 ELISA kit 
Mouse IL-2 ELISA Ready-SET-Go, eBioscience 
50 µl of cellular supernatant was assayed for each sample 
 
2.3.5.3.2 Fluorescence microscopy 
On antigenic encounter, also simulated by CD3 cross-linking, the TCR expressing hybridoma 
cells express green fluorescent protein (GFP) that was best observed after 16 hours incubation at 
Materials and Methods 
 
 
38 
 
37°C. GFP (238 amino acids, 26.9 KDa) displays green fluorescence when excited with blue 
light (emission at 498/516 nm). This fluorescence can be clearly detected on a fluorescence 
microscope, and even measured by flow cytometry (Section 2.6.1) by using a GFP filter. The 
details of the microscope set up are listed below. 
 
 Microscope 
Axiovert 200M, Zeiss 
 
 CCD camera 
CoolSNAP-HQ, Roper Scientific  
 
 Fluorescence lamp 
HXP 120, Visitron 
 
 Objectives 
5x, NA 0.15; ∞/0, Epiplan-NEOFLUAR 
10x, NA 0.45 Plan apochromat 
20x, NA 0.4; ∞/0-1.5 Achroplan, condenser Ph2 
 
 Fluorescence filters 
Cy3 filter - excitation/emission: 545(25)/605(70) nm, Zeiss 
GFP filter - excitation/emission at 472(30)/520(35) nm, Semrock, BrightLine 
 
 Automated scan system 
BioPresision2, Visitron 
 
 Image acquisition and analysis software 
MetaMorph-Software, V7.7 
 
 
2.3.6 Long term storage of eukaryotic cell lines 
Eukaryotic cell lines were frozen at -80°C and then transferred to liquid nitrogen for long term 
storage. The cells were counted and then centrifuged for 6 minutes, 1200 rpm at 4°C. 
Dimethylsulfoxide (DMSO) used in the freezing media functions as a protective agent that 
hinders ice crystal formation and eventual cell destruction. The freezing media and cell number 
vary depending on the cell line being handled. This has been clarified in Table 2-6 for the cell 
lines employed in this study. The cells were revived by thawing at 37°C in a water bath, 
followed by centrifugation for the removal of DMSO, and a wash with serum free media before 
re-suspension in the suitable growth media. 
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Cell line Freezing media Cells frozen /ml of freezing media 
COS-7 Fetal calf serum with 10 % (v/v) DMSO (Sigma)  0.5 to 5 x 10
6
 
58
 -/-
 FCS with 10 % (v/v) DMSO  1 to 5 x 10
6
 
HEK293E GIBCO® FreeStyle
TM
 293 expression medium with 10 
% (v/v) DMSO 
1 x 10
7
 
Tab. 2-6: Specifications for freezing of eukaryotic cell lines 
FCS is routinely used as a freezing medium, but has to be excluded in the case of HEK293E cells which are 
cultivated under serum free conditions. 
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2.4 Molecular biology based methods 
 
2.4.1 RNA isolation 
The RNA isolated from live TCR expressing hybridoma cells was used as a template to verify 
the expression of the transfected TCR α-chain as antibodies specific to the TCR were 
commercially unavailable. For this purpose, the TRIzol® reagent was used and the 
manufacturer’s instructions were followed at each step. To 1 x 10
7 
hybridoma cells, 0.75 ml of 
the reagent was added, and this led to a yield of 5 µg/µl total RNA. The reverse transcription 
(RT) reaction is outlined in Section 2.4.3.1. 
 TRIzol® reagent 
Ambion, Austin, USA 
 
2.4.2 DNA isolation 
2.4.2.1    Isolation of plasmid DNA from E. coli 
Plasmid DNA was isolated from E. coli cultures using commercially available kits and the 
manufacturer’s instructions were followed. The method is based on the alkaline lysis of the 
bacteria. Details are presented in Table 2-7. 
 
Vol. of starting culture  Plasmid isolation kit Vol. of isolated plasmids 
1-3 ml Spin miniprep kit 30 µl 
250-500 ml Plasmid maxi kit 200-300 µl 
Tab. 2-7: Plasmid isolation kits 
The bacteria were grown overnight in LB (+Amp). After precipitation, the 
plasmids were re-suspended in EB buffer (10 mM Tris, pH 7.5-8, 5, Qiagen). 
This volume has been mentioned in the last column. 
 
2.4.2.2    Agarose gel electrophoresis 
In the presence of an electric field, DNA migrates towards the anode due to its negatively 
charged phosphate groups. This property allows for the separation of DNA fragments on the 
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basis of size in a gel matrix. The agarose gel is prepared in TBE buffer with 0.5 µg/ml ethidium 
bromide (EtBr). The EtBr intercalates between the double helices of the DNA and being 
fluorescent under UV (λ = 254 to 366 nm) it is used to visualize the DNA. The size of the 
migrating DNA can be determined by direct comparison to DNA markers of varied sizes such as 
50 bp, 100 bp and 1 kb The samples were mixed in loading buffer and then run at 180 V for gels 
of 250 ml and at 90 V for 45 ml gels.  
 
 DNA loading buffer (6x) 
50 % (v/v) glycerol, 0.02 % (w/v) bromphenol blue (Serva, Heidelberg) 
0.02 % (w/v) xylenecyanol (Bio-Rad), 10 mM Tris, pH 7.5 
 
 TBE buffer (10x): 
0.89 M Tris, 0.89 M boric acid, 0.02 M EDTA (Bio-Rad), pH 8.0 
 
 Ethidium bromide stock solution (1 mg/ml) 
1 % ethidium bromide solution (Carl Roth) 1:10 in H2O 
 
 DNA markers  
50 bp (Peqlab, Erlangen), 100 bp or 1 kb (New England BioLabs, Frankfurt) 
 
 
2.4.2.3    DNA extraction from agarose gels 
DNA fragments were visualized under a UV transilluminator and excised with a scalpel. They 
were extracted using commercially available kits in accordance with the manufacturer’s 
instructions. 
 
 Easypure® DNA Purification Kit( Biozym) 
10 µl elution volume 
 
 QIAquick Gel Extraction Kit (Qiagen)  
30 µl elution volume 
 
 
2.4.2.4    DNA precipitation 
To increase the concentration of the sample, or exchange buffer, DNA samples were routinely 
precipitated in ethanol. Smaller samples (1 µg and below) were precipitated using the ‘Pellet 
Paint
®
 Co-precipitant’ reagent in accordance with the manufacturer’s instructions. This reagent 
allows for the visualization of the precipitated sample. Larger samples were precipitated using 
ethanol.  At first the sample was mixed with 1/10 volume sodium acetate (3 M) and then with 2.5 
Materials and Methods 
 
 
42 
 
volumes of 100 % ethanol. This was followed by 30 minute incubation at -80°C. The 
precipitated sample was centrifuged followed by the removal of the supernatant under sterile 
conditions. After air drying the sample for 5 minutes, it was re-constituted in ‘ultra-pure’ water. 
This sterile DNA was further used for transfection of eukaryotic cells. 
 
 Pellet Paint® Co-precipitant’ (Novagen) 
 
 
2.4.2.5    Other methods of DNA sample preparation 
PCR products or short DNA fragments were purified from the reaction mix by using the   
‘MinElute PCR Purification Kit’. Following the manufacturer’s instructions, the samples were 
bound to a column, washed and eluted in 10 µl buffer. In addition, the ‘QiaQuick Nucleotide 
Removal Kit’ was used to get rid of residual nucleotides in the reaction mix. The sample was run 
on a column, and then eluted in 30 µl buffer. 
 
 
2.4.2.6    Determination of DNA concentration 
DNA has an absorption maximum at 260 nm, and can be measured photometrically at this 
wavelength. The photometer ‘GeneQuantII’ and ‘NanoDrop 1000’ were utilized for this purpose. 
When the DNA sample was not sufficiently pure, the amount could be estimated directly on the 
agarose gel by direct comparison to a known standard run in a parallel lane.  
 
 
2.4.3 Enzymatic treatment of DNA 
2.4.3.1    Reverse transcription (RT) 
During the process of reverse transcription, single stranded RNA is used as a template to 
synthesize a complementary cDNA strand that can be further amplified by PCR (Section 
2.4.3.2). The total RNA extracted from TCR hybridoma cells (Section 2.4.3.1) was reverse 
transcribed to cDNA for the verification of correct TCR expression. In addition, the african green 
monkey MHC related I (MR1) gene was reverse transcribed from COS-7 cells (Wakiro Sato, 
MPI of Neurobiology). The reaction was catalyzed by the SuperScript™III reverse transcriptase, 
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an engineered version of the moloney murine leukemia virus reverse transcriptase, and the 
manufacturer’s instructions were followed.  First, the 5 µg of RNA was mixed with 1µl oligo 
(dT) and 1 µl dNTP (10 mM) and incubated at 65°C for 5 minutes followed by incubation on ice 
for 1 minute. The reaction tube was centrifuged; 4 µl of the first strand buffer (5x), 1 µl DTT 
(0.1 M) and 1 µl enzyme were added. This reverse transcription reaction was carried out at 45 °C 
for 60 minutes. The cDNA synthesized was further amplified using Vα-chain specific primers 
for TCR and MR1 specific primers listed in Appendix I. 
 
 SuperScript™III reverse transcriptase 
200 U/µl; 10,000 units (Invitrogen) 
 
 
2.4.3.2    Polymerase Chain Reaction (PCR) 
PCR is a method that allows for the amplification of a single or few copies of DNA to multiple 
copies by cycles of annealing, amplification and denaturation. Oligonucleotides flanking a 
specific DNA sequence (forward and reverse primers) are used by the Taq DNA polymerase as 
anchors to synthesize the sequence by the additions of nucleotides. The variations of the PCR 
that were used in this study are explained in detail below. In every case positive (known 
template) and negative (water instead of template) controls were included. The reactions were 
carried out in the ‘GeneAmp PCR System 9600 Thermocycler’ or in the ‘T personal 
Thermocycler’. The results were analyzed by gel electrophoresis (Section 2.4.2.2). 
 
2.4.3.2.1 Colony PCR 
The colony PCR was used to determine the successful ligation of a DNA fragment into the 
desired vector. Single bacterial clones were picked with a pipette tip and transferred directly into 
the PCR mix. The primer pairs used for the amplification flank the site of insertion on the vector. 
These are listed in Table 2-8. The additions for the PCR reaction and the subsequent PCR 
program are listed below. 
 
 PCR reaction  (20 µl) 
1x PCR buffer (10X) (Roche), 200 µM dNTP (10 mM), 0.5 µM forward primer (100 µM) ,0.5 µM reverse 
primer (100 µM), 1 u Taq polymerase (5 u/µl) (Roche) 
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 PCR program 
 
3 min  94 °C  Denaturation 
   1 min  94 °C  Denaturation 
   1 min  53 °C  Hybridization  25 cycles 
   1 min  72 °C  Elongation 
   10 min  72 °C  Elongation 
 
 
Vector Forward primer Reverse primer 
pCR®2.1-TOPO M13 forward (-20) M13 reverse 
pTT5 pTT5-for seq pTT5-rev seq 
Tab. 2-8: Primer pairs employed in colony PCR 
The listed primers were either provided by manufacturer or ordered from Metabion (desalted). Primer sequences are 
provided in Appendix I. 
 
 
2.4.3.2.2 Single cell multiplex PCR for TCR chains 
RT PCR was performed on single CD8+ T cells, isolated from MS patient brain tissue, for the 
characterization of putatively autoaggressive TCRs. In this technique the first template is RNA 
which is transcribed by the enzyme reverse transcriptase into its complementary DNA (cDNA) 
strand. Subsequent steps use this DNA as template for amplification as in a traditional PCR. The 
T cells to be analyzed were first isolated from the brain tissue via laser microdissection. Cells 
that were double positive for either T cell markers or only CD8+ were marked electronically 
using the PalmRobo software (Zeiss). After 1-propanol evaporation, the cells were cut and laser 
pressure catapulted into the mineral oil coated lids of single reaction 200 µl PCR tubes. The 
tubes were transferred to dry ice until addition of the PCR reagents.  
 
Double positive (CD8+, TCRVβ+) cells were processed as described earlier (Seitz et al. 2006). 
The method employs clone specific, nested TCR β-chain primers and a pool of unbiased TCR α-
chain primers. CD8 single positive were processed using an unbiased protocol (developed in 
collaboration with Jörg Prinz, LMU). These two approaches are depicted in Figure 2-1. The 
PCR mix was pipetted into the cap of the PCR tube, and the tube was centrifuged at 14,000 rpm 
for 3 minutes at 4°C. A touch-down PCR, beginning with a high annealing temperature that 
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gradually reduces in each subsequent step, was applied to minimize unspecific primer binding 
and amplification. Between reactions, samples were stored on ice to maintain sample integrity. In 
every experiment, a negative control was included where water was added instead of the 
template. After PCR 3 and 4, the products were analyzed by gel electrophoresis (Section 2.4.2.2) 
before proceeding to the next step, and eventually sequenced. The TCR chains were named 
according to Arden et al. 1995. The reagent additions as well as PCR programs for each 
approach are mentioned in full detail below. To avoid contaminations due to carryovers, the TCR 
specific primers were aliquoted in sterile reaction tubes, stored at -20°C and thawed fresh for 
each experiment. All primer sequences are listed in Appendix I. 
 
 
Clone specific PCR 
 
 RT reaction (20 µl) 
QIAGEN OneStep RT-PCR enzyme Mix (Sensiscript and Omniscript reverse transcriptases and HotStarTaq 
DNA polymerase) (1 µl), 5x QIAGEN OneStep RT-PCR buffer (2µl), dNTP mix (0.5 µl, 10 mM), RT 
primers (0.625 µm each), RNase-free water  
 
PCR program: 30 min, 50°C 
 
 
 
 PCR 1 (5 µl) 
Template: product from RT PCR (20 µl), QIAGEN OneStep RT-PCR enzyme mix (0.2 µl), 5x QIAGEN 
OneStep RT-PCR buffer (1 µl), dNTP mix (0.2 µl, 8 mM), Cα-rev-out primer (0.15 µl,  0.6 µm), Vα-i-for-out 
primer pool (0.45 µl , 0.062 µm each), BV-JBx-for-out (0.6 µM , 0.15 µl), BV-JBx-rev-out (0.6 µM , 0.15 µl) 
, RNase-free water  
 
PCR program: 
15 min  95 °C   
   1 min  94 °C  Denaturation 
   1 min  61 °C  Hybridization  4 cycles 
   1 min  72 °C  Elongation 
   1 min  94 °C  Denaturation 
   1 min  58 °C  Hybridization  4 cycles 
   1 min  72 °C  Elongation 
   1 min  94 °C  Denaturation 
   1 min  56 °C  Hybridization  4 cycles 
   1 min  72 °C  Elongation 
   1 min  94 °C  Denaturation 
   1 min  53 °C  Hybridization  30 cycles 
   1 min  72 °C  Elongation 
   10 min  72 °C  Elongation 
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 PCR 2 (20 µl) 
Template: product from PCR 1 (1 µl), Taq DNA Polymerase (5 U/l, Roche Diagnostics) (1.5 U), 10x PCR 
buffer (Roche Diagnostics) (2 l), dNTP Mix (0.2 µl, 10 mM), BV-JBx-for-nest (10 µM, 0.1 µl), BV-JBx-
rev-rest (10 µM, 0.1 µl), RNase-free water  
 
PCR program: 
2 min  94 °C   
   1 min  94 °C  Denaturation 
   1 min  53 °C  Hybridization  40 cycles 
   1 min  72 °C  Elongation 
 
 
 PCR 3 
Additions and PCR program same as for PCR 3. Primers: BV-JBx-for-in (10 µM, 0.1 µl), BV-JBx-rev-in (10 
µM, 0.1 µl) 
 
 
 PCR 4 
Template: product from PCR 1 (1 µl), Taq DNA polymerase (1 U), 10x PCR buffer (2 l), dNTP Mix (0.4 µl, 
4 mM), Vα-j-for-in primer pool (2 µl, 0.5 µM each), Cα-rev-in (2 µl, 0.5 µM), RNase-free water  
 
PCR program: 
2 min  94 °C   
   30 sec  94 °C  Denaturation 
   1 min  61 °C  Hybridization  4 cycles 
   1 min  68 °C  Elongation 
   30 sec  94 °C  Denaturation 
   1 min  58 °C  Hybridization  4 cycles 
   1 min  68 °C  Elongation 
   30 sec  94 °C  Denaturation 
   1 min  56 °C  Hybridization  4 cycles 
   1 min  68 °C  Elongation 
   30 sec  94 °C  Denaturation 
   1 min  53 °C  Hybridization  40 cycles 
   1 min  68 °C  Elongation 
   10 min  68 °C  Elongation 
 
 
 PCR 5 
The template from PCR 1 is re-amplified by clone-specific primers from the positive pool. Additions of 
reagents and PCR program in keeping with PCR4.  
 
 
Unbiased PCR 
 
 RT Reaction (12.5 µl) 
QIAGEN OneStep RT-PCR enzyme mix (0.5 µl), 5x QIAGEN OneStep RT-PCR buffer (1.3 µl), dNTP Mix 
(0.75 µl, 10 mM each), C/C RT primers: Cα-out and C-out, (10 M each), RNase-free water  
PCR program: 30 min 50°C 
 
 
 PCR 1 (12.5 µl) 
QIAGEN OneStep RT-PCR enzyme mix (0.5 µl), 5x QIAGEN OneStep RT-PCR buffer (2.5 µl), dNTP mix 
(0.5 µl, 10 mM each), V and V primer pools (0.6 l, 3 M each), RNase-free water 
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PCR program: 
15 min  95 °C   
   30 sec  94 °C  Denaturation 
   1.5 min  60 °C  Hybridization  10 cycles 
   1 min  68 °C  Elongation 
   30 sec  94 °C  Denaturation 
   1 min  53 °C  Hybridization  30 cycles 
   1 min  68 °C  Elongation 
   15 min  68 °C  Elongation 
 
 
 
 PCR 2 (20 µl) 
Taq DNA polymerase (0.10 l), 10x PCR buffer (2 l), dNTP mix (0.4 µl, 10 mM each), Vp1-UP to Vp-9-
UP primers (0.2 µl, 11.1 M each), RNase-free water  
 
PCR program: 
 
   5 min  94 °C  Denaturation 
   2.5 min  53 °C  Hybridization 10 cycles 
   15 min  68 °C  Elongation 
 
 
 
 PCR 3 (20 µl) 
Taq DNA polymerase (0.20 l), 10x PCR buffer (2 l), dNTP Mix (0.4µl, 10 mM each), UP and C-in 
primer (2 µl, 2.5 µM each), RNase-free water  
 
PCR program: 
 
2 min  94 °C  
   30 sec  94 °C  Denaturation 
   1 min  58 °C  Hybridization  50 cycles 
   1 min  68 °C  Elongation 
   15 min  68 °C  Elongation 
 
 
 
 PCR 4 and 5 (same as for the clone specific PCR) 
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Fig. 2-1 Relative positions of primers in the clone specific and unbiased PCR approaches for amplification of TCR α- and β- chains 
The TCR chains are shown with the variable (V), hypervariable (NDN), joining (J) and constant (C) regions (not drawn to scale). Both PCR approaches consist of 5 different PCR 
reactions. In the clone specific approach, β-chain specific primers were designed based on CDR3 spectratyping results while the unbiased approach uses universal primer pools. 
After reverse transcription, the cDNA is used for the pre-amplification of the α- and β- chains. This PCR product serves as a template for further β- chain amplification. The last 
two nested PCR reactions (4 and 5) for the α-chain are common in both approaches. The outer primers bear the suffix ‘-out’, followed by the suffix ‘-nest’ and ‘-in’ for nested 
primers. The suffix ‘for’ indicates that the primer anneals in the 5’ to 3’ direction, and the opposite is true for the suffix ‘rev’. The primers ‘Cα-RT-imp, Cα-out, Cα-in’ 
corresponds to the constant region of the TCR α-chain (order: outer to inner). The Vα-i-for-out pool consists of 24 primers that lie in the variable region of the α-chain and the 
nested Vα-j-for-in pool comprises 36 primers divided into 5 different pools. The Vα-spec-for and α-rev-spec primers are designed to specifically amplify the CDR3 region of a 
particular clone. Similarly, the Cβ-RT-2, Cβ-out and Cβ-in primers correspond to the TCR β-chain constant region. In the clone specific PCR, ‘BVx-Jbx’ indicates the clonal 
expansion of interest, for e.g. BV1-BJ2.3 in Patient FE. The Vp pool consists of 9 primers that lie in the β-chain variable region. The Vp-UP pool is nested to the Vp primers, and 
adds a 22 nucleotide sequence designated as ‘UP’ (denoted in light blue) to the amplified product from the previous PCR reaction. This addition makes it possible to further 
amplify all amplicons in a nested reaction using a universal UP primer that is complementary to the added region. Modified in part from Seitz et al. 2006.
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2.4.3.2.3 Single cell PCR for amplification of library plasmids 
Single APCs were isolated with the aid of a microcapillary and immediately placed into a PCR 
tube containing ammonia solution for DNAse inactivation. In some cases, the PCR tubes were 
additionally incubated at 80°C for 5 minutes to inactivate the DNAse. After this, the PCR tubes 
were placed under a sterile hood for up to 60 minutes to allow for complete evaporation of 
ammonia. Following the first PCR reaction, a second nested PCR was carried out using the 1:100 
dilution of the first PCR product as a template. Both PCR products were run on a gel (Section 
2.4.2.2) for estimation of DNA concentration.  
 
 
 First (outer) PCR reaction mix (50 -100 µl) 
1X PCR buffer (10X) (Roche), 0.2 mM dNTP (10 mM) (Qiagen), 0.5 μM pcDNA-for-1 primer, 0.5 μM 
pcDNA-rev-1 primer, 0.05 U/µl Taq polymerase (Roche) 
 
PCR program: 
3 min  94 °C   
    1 min  95 °C  Denaturation 
    1 min  53 °C  Hybridization                 40 cycles 
    1 min  72 °C  Elongation 
    10 min  72 °C  Elongation 
 
 Second (nested) PCR reaction mix (50 µl) for cloning by restriction digestion 
Additions same as for first PCR except primers, 0.5 μM pcDNA-2
nd
-for primer, 0.5 μM pcDNA-rev-10 
primer 
 
 Second (nested) PCR reaction mix (50 µl) for directional TOPO cloning 
1X iProof HF Master mix (iProof™ High-Fidelity PCR Kit, Bio-Rad), 0.5 μM pcDNA-for-2-TOPO or 
pcDNA-2
nd
-for primer, 0.5 μM pcDNA-rev-3 or pcDNA-rev-2 primer 
 
PCR program: 
3 min  98 °C  
    20 sec  98 °C  Denaturation 
    20 sec  56 °C  Hybridization                 40 cycles 
    30 sec  72 °C  Elongation 
    10 min  72 °C  Elongation 
 
 
 
 
 
Materials and Methods 
 
 
50 
 
2.4.3.3    TOPO TA cloning 
‘TOPO-TA Cloning®’ (Invitrogen) is based on the fact that the Taq polymerase enzyme adds a 
desoxyadenosine to the 3’end of the PCR product due to its transferase activity. The linearized 
pCR®2.1-TOPO®-vector carries complementary 3’-desoxythymidine overhangs. The PCR 
product was ligated into the vector via 5 minute incubation at RT by following the 
manufacturer’s instructions. The ligated product was then transformed into chemically 
competent ‘One Shot® TOP10’ E. coli bacteria as explained in Section 2.2.3. 
 
 pCR®2.1-TOPO® vector (Invitrogen) 
3.9 kb, Amp
R
, KanR, for vector map refer to Appendix II 
 
 
2.4.3.4    Directional TOPO TA cloning 
Directional TOPO TA cloning was performed for the cloning of library plasmids that were 
isolated from antigen presenting hMR1-COS-7 cells (Section 2.4.3.4). The peptide coding 
inserts on the library plasmid were amplified (Section 2.4.3.9.2) and the resulting blunt ended 
PCR products carried 5’CACC ends. This facilitated the ligation into the topoisomerase activated 
pcDNATM3.1D/V5-His-TOPO vector that carries a complementary sequence. All steps were 
carried out according to the manufacturer’s instructions. The only exception was the use of 0.5 µl 
vectors, instead of the recommended 1µl, and the extension of the incubation at 16°C to 
overnight. The resulting ligated plasmids were precipitated in ethanol (Section 2.4.2.4) and 
further used to transform the ElectroMax DH10B bacteria (Section 2.2.2). 
 
 pcDNATM3.1D/V5-His-TOPO vector (Invitrogen) 
5.5 kb, Amp
R
, Neo
R
, for vector map refer to Appendix II 
 
 
2.4.3.5    Restriction digestion of DNA 
Restriction enzymes are endonucleases that are capable of recognizing specific sequences in 
double stranded DNA and then cutting the phosphodiester bonds at a related position. This 
property can be exploited to create DNA fragments with complimentary overhangs that can 
eventually be ligated. One unit of a restriction enzyme is defined as that quantity which can 
digest a fixed amount of substrate DNA, for e.g. 1 µg of λ DNA (48.5 kb), within one hour under 
optimal conditions of buffer and temperature. The amount of enzyme units required per reaction 
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is determined by calculating for the size, amount and number of restriction sites present in the 
sample DNA sequence. All restriction enzymes used in this study were purchased from New 
England Biolabs (Frankfurt, Germany) and used in accordance with the manufacturer’s 
instructions. The reactions were set up in volumes between 20 to 200 µl for 1 to 16 hours at 
37°C. Double digests could be performed when the two restriction sites were separated by more 
than 100 bp and compatible buffers were available. In case of sequential digests in compatible 
buffers, the first enzyme was heat inactivated prior to addition of second enzyme. For buffer 
change, the restriction product was first ethanol precipitated (Section 2.4.2.4) and the 
reconstituted as required. The rare cutting AscI and NotI were employed sequentially with an 
intermediate ethanol precipitation step for the generation of plasmid encoded combinatorial 
peptide libraries (Section 2.4.3.8) and the recovery of antigen coding plasmids from APCs 
(Section 2.4.3.9). For the latter, the 9 and 10 bp flanking fragments were removed by the 
application of the ‘Qiaquick nucleotide removal kit’ (Qiagen). The vector maps are presented in 
Appendix II. 
 
 
2.4.3.6    Ligation of DNA 
The T4 DNA Ligase enzyme (Invitrogen) catalyses the formation of a phosphodiester linkage 
between the free 3’ hydroxyl group of one DNA fragment and the free 5’ phosphate group of the 
second fragment. The ATP required for this reaction is provided in the ligase buffer (5X, 
Invitrogen) and used at a final concentration of 1 mM. To prevent the self-ligation of the vector, 
the DNA fragment to be inserted is added at a four times higher molar concentration than the 
vector. Self-ligation may be tested by setting up a negative control in parallel that lacks the 
insert. The ligation reaction is incubated overnight at 16°C. The incubation time for the ligation 
of library plasmids to the pcDNArc-spacer backbone (Section 2.4.3.8.2) was extended to ≥ 48hrs 
to ensure high yields. The ligated products were precipitated in ethanol (Section 2.4.2.4) and 
stored at -80°C before transformation into E. coli cells (Section 2.2.2 and 2.2.3). 
 
 Ligation mix (20 µl reaction) 
1 u T4 DNA ligase, 100 ng vector, 4x molar concentration of insert, in 1x T4 ligase buffer 
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2.4.3.7    Cloning of TCRs 
The TCR chains detected in the patient tissue were cloned into the pRSV vector for generating 
transgenic TCR cell lines for antigen studies. Based on the single cell PCR product, part of the- 
and β- chains were chemically synthesized (Section 2.4.3.11). These fragments started with a 5’ 
SalI restriction site, covered the leader, variable, N (D) N-J and joining region and ended in a 
unique site in the conserved constant region. The pBRDel vector was used as a subcloning vector 
for the β-chain. The V-NDN-J region was cloned using the SalI and BglIII sites. The constant 
region lies between the BglIII and BamHI sites. Hence the entire TCR β-chain could be cut out 
via a SalI-BamHI restriction. The TCR chains were incorporated into the expression plasmids 
pRSVhygro (α-chain) and pRSVneo (β-chain) between the SalI and BamHI restriction sites. These 
were then co-transfected via electroporation (Section 2.3.3) into the T hybridoma cell line 58
α-/β-
 
for stable TCR expression. The vector maps are presented in Appendix II. 
 
 
2.4.3.8    Cloning of human MR1 and β2 microglobulin 
Human MR1 and β2 microglobulin were cloned into pTT5 vectors with leader sequences from 
Fab fragments (that had been successfully expressed in the HEK293E cell line). The pTT5 
vectors were obtained from Birgit Obermeier, MPI of Neurobiology. In the MR1-pTT5 vector, 
the MR1 coding region followed by a myc tag, polyhistidine (His(6)) tag, BirA (for biotin tagged 
purification) was inserted into the vector after the leader sequence of the heavy chain via a SacI 
and BamHI restriction. In the β2 microglobulin vector, the β2 microglobulin coding region was 
inserted after the leader sequence of the light chain via BssII and BamHI restriction sites. These 
were then co-transfected into the HEK293E cell line for protein expression. The leader 
sequences of the heavy and light chains were used as it was known that the signal peptidase 
efficiently cleaves these sequences (Klaus Dornmair and Birgit Obermeier, MPI of 
Neurobiology, personal communication). The vector maps are presented in Appendix II.  
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2.4.3.9    Generation of plasmid encoded combinatorial peptide (PECP) libraries 
The PECP libraries were a pre-requisite for the unbiased determination of peptide antigens of 
TCRs. They were constructed by ligating peptide coding library inserts into the pcDNArc-spacer 
expression plasmid. 
 
2.4.3.9.1 Preparation of peptide coding library inserts 
In the course of this study the unbiased N library was used to screen for MR1 antigens. This 
library was provided by Katherina Siewert, MPI of Neurobiology. In addition, two libraries with 
anchor residues matched to patient FE HLA class I molecules A*0101 and B*0801 were 
synthesized. For this purpose, high-performance liquid chromatography (HPLC) purified single 
stranded oligonucleotides were custom designed and procured from Metabion. A fill-in reaction 
was then carried out to generate a complementary strand yielding a double stranded product. 
This was followed by a denaturation step of 100°C for 5 minutes. The reaction mix was 
gradually cooled to RT over the period of 60 minutes and to it an equal volume of the PCR mix 
was added. The following reaction was carried out according to the cycling conditions mentioned 
below to amplify the double stranded products. These products were sequentially digested with 
AscI and NotI and purified as explained in Section 2.4.3.5.  
 
 Strand fill-in reaction mix (100 µl) 
1X PCR buffer (10X) (Roche), 20 μM oligonucleotide (N27-all-lib-ASc-for / N27-A1-39-lib-Asc-for / N27-
B8-359-lib-Asc-for), 20 μM N27-Not-rev primer (Metabion) (Primer sequences in Appendix I) 
 
 PCR mix (100 µl) 
1X PCR buffer 200 μM dNTP (10 mM) (Qiagen), 5 U Taq polymerase (Roche) 
PCR program: 60°C  5 min, 63°C  4 min, 65°C 60 min 
 
 
 
2.4.3.9.2 The ‘pcDNArc-spacer’ backbone for ligation of the library inserts 
The ‘pcDNArc-spacer’, where ‘rc’ stands for ‘rare cutter’ was used as the vector backbone for 
the PECP libraries. This expression plasmid was provided by Katherina Siewert, MPI of 
Neurobiology. Prior to ligation of the library inserts, the backbone was digested with AscI/NotI 
(Section 2.4.3.5), and purified with agarose gel electrophoresis (Section 2.4.2.2) and the 
‘QIAquick gel extraction kit’ (Qiagen). After determination of DNA concentration (Section 
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2.4.2.6), the backbone was dephosphorylated with the ‘Rapid DNA Dephos and Ligation’ kit 
(Roche) according to the manufacturer’s instructions (Section 2.4.3.10) before ligation (Section 
2.4.3.6) with the library inserts. 
 
 pcDNArc-spacer 
7.6 kb, Amp
R
, Neo
R
 
Provided by Katherina Siewert, MPI of Neurobiology 
 
 
 
2.4.3.10   Recovery of antigen coding plasmids from antigen presenting cells 
The live antigen presenting cells were isolated by micromanipulation (Section 2.4.3.9.1) and 
their contained antigen coding plasmids were amplified by a nested PCR reaction (Section 
2.4.3.2.3). These amplified inserts were cloned into expression plasmids (Section 2.4.3.9.2) and 
expanded in E. coli before repeating the transfection into COS-7 cells to evaluate enrichment of 
the activation signal.  
 
 
2.4.3.10.1   Isolation of positive APCs by micromanipulation 
The TCR hybridoma cells were co-cultured for 16 hours with APCs expressing the PECP 
libraries. The co-culture was screened under a fluorescence microscope for activated, GFP+ TCR 
hybridoma cells. The APCs of interest were those that were in stable contact with these, 
activated TCR hybridoma cells. These were isolated by the use of custom designed glass 
capillaries (custom-tips, Ø 15-30 µm, beveled edge, Eppendorf) attached to a microinjector (Cell 
Tram Vario) that allowed one to dislodge the cell from the cell culture dish with minimal 
amounts of cell culture medium (1-3 µl). This entire method is depicted in Figure 2-2 using the 
MAIT TCR as an example. The isolation was closely followed on the computer monitor. The 
isolated cell was directly transferred into a PCR tube and the antigen coding plasmids were 
amplified as outlined in Section 2.4.3.2.3. 
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Fig. 2-2: Recovery of antigen coding plasmids from APCs 
(1) The N library was transfected into MR1 expressing COS-7 cells (8 µg library plasmids/4 x 10
6
 cells). (2) 32-60 
hours post transfection the MAIT TCR hybridoma cells (1.6 x 10
6
 cells/ 3ml culture medium) were added and 
incubated for 16 hours. (3a) The co-culture was monitored under a fluorescence microscope for the detection of 
activated, GFP+ hybridoma cells that were in contact with the underlying APC (that contained the antigen that had 
caused activation). (3b) The underlying APC was isolated and (4) the intracellular antigen encoding plasmids were 
amplified. (5) The recovered plasmids were cloned into the expression plasmid and (6) expanded in bacteria.  (7) 
The plasmids were further enriched by another round of APC transfection followed by the aforementioned steps. 
 
 
2.4.3.10.2  Cloning of PCR products into expression plasmid 
The PCR products were inserted into the pcDNArc-spacer backbone by restriction digestion and 
ligation (Section 2.4.3.6) or directional TOPO TA cloning (Section 2.4.3.4). The PCR products 
were purified on a column (Section 2.4.2.5) and then ligated to the pcDNA backbone (Section 
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2.4.3.6). The plasmids were then precipitated in ethanol and transformed into electrocompetent 
ElectroMax DH10B™T1R E. coli (Invitrogen) by electroporation (Section 2.2.2). To ensure that 
all clones were represented in the pool, the bacterial were inoculated in higher volumes of LB 
media, such as 500-750 ml prior to DNA isolation (Section 2.4.2.1). The isolated plasmids were 
transfected into COS-7-MR1 cells as outlined in Section 2.3.4. These were tested for T 
hybridoma activation, and the obtained signal was compared to that from the first round to see if 
an increase had been caused due to enrichment. 
 
2.4.3.11   Dephosphorylation of DNA 
Dephosphorylation of digested vector DNA prior to ligation reduces the background caused due 
to vector self-ligation. The alkaline phosphatase enzyme catalyzes the removal of 5’ phosphate 
groups from nucleic acids and prevents self-ligation of vector via phosphodiester linkage. The 
pcDNArc-spacer backbone (Section 2.4.3.8.2) of the peptide encoding library was 
dephosphorylated prior to insertion of library encoding fragment. The reaction was carried out as 
recommended by the manufacturer. 
 Rapid DNA Dephos and ligation kit (Roche) 
 
 
2.4.3.12  Gene synthesis and DNA sequencing 
The TCR α- and β- fragments (variable region to beginning of constant region) were synthesized 
at Geneart (Regensburg, Germany).The samples were sequenced at the service centers of the 
MPI of Biochemistry and the Biocenter of the LMU. 
2.4.4 Analysis of DNA sequences 
The obtained sequences were analyzed with the software ‘Chromas’ (Version 1.45, Griffith 
University, Australia). The detailed analysis of sequences from TCRs was carried out with the 
NCBI Blast software (Version 2.2.25), and the IMGT database provided at ‘http: 
//www.imgt.org/’. The sequences were aligned using the clustwal software (Version W2) 
(Thompson et al. 1994).  Nucleotide sequences could be translated into the amino acid sequence 
using the ‘Translate Tool’ provided at ‘http: //www.expasy.ch/tools/dna.html’ (Swiss Institute of 
Bioinformatics).
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2.5 Protein analysis 
 
2.5.1 Determination of protein concentration 
The concentration of proteins in solution can be determined by measuring the absorbance at 280 
nm. The aromatic ring groups present in amino acids such as tryptophan, and to a lesser extent 
tyrosine and phenylalanine, are responsible for this effect. An absorption peak at 190-230 nm 
may be attributed to peptide bonds. All measurements were carried out at the spectrophotometer 
‘NanoDrop 100’. 
2.5.2 Protein purification 
2.5.2.1    Protein G affinity chromatography 
Protein G affinity chromatography using Dynabeads
®
 was applied for the purification of myc 
tagged hMR1 using a myc tag recognizing antibody (clone 9E10.3). The expression of hMR1 in 
HEK293E cells is explained in Section 2.3.4. To 100 ml of cell supernatant (containing 
approximately 25 µg MR1), 80 µg of commercially available human β2 microglobulin and the 
myc tag recognizing antibody (clone 9E10.3) were added. After incubation for 60 minutes at RT, 
100 µl of Protein G Dynabeads
®
 were added. The recombinant protein G, coupled to the 
magnetic bead matrix, binds to the Fc region of an IgG antibody hence purifying it from the 
solution. The magnetic beads can be easily collected by applying a Dynal
®
 magnet to the exterior 
wall of the reaction tube. Before use, the beads were washed thrice in the wash buffer to get rid 
of residual ethanol. Post incubation, the beads were washed to get rid of all unbound protein. The 
supernatant was then removed and the beads were re-suspended in the chemically synthesized 
positional scanning nonapeptide library to screen peptides in order to determine the anchor 
positions of human MR1 (Section 2.5.4).  
 Dynabeads® Protein G, Invitrogen 
 
Dynabeads® wash buffer: 1 M sodium acetate, 150 mM NaCl, pH 5.0 
 
 Human β2 microglobulin, Sigma 
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2.5.2.2    Ni-NTA-Affinity chromatography 
The recombinant protein expressed by the HEK293E cells carries a His (6) peptide tag that allows 
it to bind with high affinity to the Ni-NTA matrix as a function of the aromatic imidazole group. 
The stationary phase is a composed of nitriloaceticacid (NTA) and Ni
2+
 ions coupled onto an 
agarose matrix. The bound proteins are later eluted in excess of imidazole that in turn displaces 
the His (6) peptide from the matrix. The entire purification procedure was carried out in columns. 
A 5 ml bed volume of the Ni-NTA-agarose was washed with 10 column volumes water for the 
removal of residual ethanol. The matrix was then equilibrated with 10 mM imidazole in 1X PBS 
(pH 8.0). The cellular supernatant was cleared of cell debris by a centrifugation step (Rotor SLA-
1500, 12,500 rpm, 30 min, 4 °C) followed by sterile filtration (0.2 µm filter) to get rid of residual 
micro debris. The pH of the supernatant was adjusted to pH 7.5 using 1 M Tris (pH 8.6) and then 
equilibrated to 1X PBS with a final concentration of 10 mM imidazole. This low imidazole 
concentration is thought to reduce unspecific binding of the protein to the matrix. Furthermore, a 
protease inhibitor phenylmethanesulfonylfluoride (PMSF) was added to a final concentration of 
100 µM. 200 ml supernatant was loaded onto the column at a flow rate of 1.5 ml per minute. 
Post binding, the column was washed with 20 ml PBS/20 mM imidazole, pH8.0 for the removal 
of the nonspecifically bound protein fraction. The elution was carried out with 20 ml PBS/200 
mM imidazole, pH8.0 at the FPLC apparatus (Section 2.5.2.3). All buffers were sterile filtered 
(0.2 µm filter) and degassed prior to use. 
 
 Ni-NTA agarose, Qiagen 
 
 1.5 x 10 cm Luer-lock columns , flow through, Sigma 
 
 0.2 µm filter, Milipore 
 
 
2.5.2.3    Fast protein liquid chromatography (FPLC) 
The proteins, purified on the Ni-NTA matrix (Section 2.5.2.2), were eluted using an FPLC 
system from Amersham Pharmacia Biotech. This elution can be followed by monitoring the 
absorbance value of the component aromatic amino acids at λ = 277 nm on the in-built UV 
detector (Uvicord SD). The FPLC apparatus is composed of two pumps, one of which is filled 
with 1X PBS while the second with PBS/200 mM imidazole. The in-built control system (LCC-
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501 Plus) is used to determine the proportion to which the two buffers are mixed before running 
through the column. The washing step at PBS/20 mM imidazole was carried out until all 
nonspecifically bound proteins had been eluted. The imidazole concentration was then raised to 
200 mM, and as the absorption value rose, the eluate was collected. This was followed by 
dialysis (Section 2.5.2.4) against PBS for the removal of imidazole and concentration 
determination. The purified proteins were stored at 4°C in PBS, 0.07 % sodium azide and 100 
µM PMSF. 
 
2.5.2.4    Dialysis 
Dialysis is a technique employed to get rid of certain buffer components form the sample, or for 
the complete buffer exchange. The technique is based on the creation of a concentration gradient 
across a semi-permeable membrane, whereby small molecules are able to cross the membrane 
whereas larger molecules are retained. Depending on the size of the said molecules, dialysis 
membranes of different molecular weight cut offs (MWCO) can be used. The ‚D-tube
 TM
 
Dialyzer Mini‘- tube was used for volumes up to 200 µl  while for larger volumes up to 3 ml, the 
‘D-Tube™ Dialyzer Maxi’ tube were used (Novagen, Darmstadt). Both of these have a MWCO 
between 12 to 14 kDa. The dialysis for the reduction in imidazole was carried out against PBS in 
the cold room. The buffer was constantly stirred during this time. 
 
2.5.3 Gel electrophoresis 
Gel electrophoresis is based on the migration of charged molecules in the presence of an electric 
field. Smaller molecules are able to migrate faster than larger ones, in a porous gel matrix, and 
are hence separated from each other. In contrast to DNA, where the phosphate groups are 
negatively charged, proteins exhibit a wide spectrum of net charge and this property is exploited 
during this charge based separation procedure. 
 
2.5.3.1    SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins may be separated on the basis of their size by concealing their inherent charges. This is 
achieved by mixing the protein sample with an excess of the anionic detergent sodium dodecyl 
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sulphate (SDS). The SDS also leads to the unfolding of secondary structure. Hence the 
separation is truly size based and independent of both charge and protein folding. Depending on 
the complexity of the protein mixture to be separated, SDS-PAGE Novex® Tris-Glycine mini 
gels (8 cm x 8 cm x 1 mm, Invitrogen) were used. The ‘Wide Range SigmaMarker™’ was taken 
as the molecular weight standard. Prior to loading, the samples were mixed either with the 
reducing or non-reducing loading buffers. The reducing buffer contains β-mercaptoethanol 
which breaks the proteins down to their sub units by the breakage of disulfide bonds. The 
complete reduction and denaturation of the sample was achieved a 95°C. Electrophoresis was 
carried out in the ‘MightySmall’ apparatus (Hoefer) with the SDS running buffer with a constant 
voltage of 130 V for 90 minutes. 
 
 SDS running buffer  (10X) 
1 % (w/v) SDS, 0.24 M Tris, 1.92 M glycine 
 
 Loading buffer ,non- reducing (5X) 
0.2 M Tris-HCl pH 6.8, 7.5 % (w/v) SDS, 20 % (v/v) glycerol, 0.02 % (w/v) bromphenol blue 
 
 Loading buffer ,reducing (3X) 
0.15 M Tris-HCl pH 6.8, 15 % (w/v) SDS, 45 % (v/v) glycerol, 0.01 % (w/v) bromphenol blue, 6% (v/v) ß-
mercaptoethanol  
 
 
2.5.3.2    Staining of protein gels 
2.5.3.2.1 Coomasie Brilliant Blue staining 
The Coomassie
®
 Brilliant Blue dye can be used when the sample contains at least 500 ng of 
protein. This dye does not interfere with downstream mass spectrometry analysis. The Novex
®
 
mini gels were incubated for 30 minutes with the dye on a swinging surface. The acetic acid in 
the solution precipitates the proteins, thereby fixing them to the gel. Nonspecific background 
staining was reduced by washing the stained gel in the destaining solution. 
 
 Coomassie® dye solution 
0.1 % (w/v) Coomassie® Brilliant-Blue R-250, 40 % methanol, 10 % acetic acid 
 
 Destaining solution 
50 % methanol, 7 % acetic acid 
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2.5.3.2.2 Silver staining (Heukeshoven protocol) 
Silver staining is more sensitive in comparison to Coomassie
®
 Brilliant blue dye and can detect 
protein levels of 5 ng or less. Following the Heukeshoven protocol , the proteins were first fixed 
on the gel for 30 minutes and then sensitized for 60 minutes. The cross linking effect of 
glutaraldehyde does not allow later analysis by mass spectroscopy. After washing three times 
with water, the gels were stained for 45 minutes during which Ag
+
 ions bind to the proteins. The 
gel development is carried out in an alkaline solution that reduces the ions to metallic silver. The 
protein bands are stained brown to black depending on protein concentration. Once the desired 
stain was achieved, the reaction was stopped. 
 
 H-fixation solution  
40 % ethanol, 10 % acetic acid 
 
 H-sensitization solution 
0.2 % (w/v) sodium thiosulfate, 0.5 M sodium acetate 0.5 % (v/v) glutaraldehyde, 30 % ethanol 
 
 H-staining solution 
0.1 % (w/v) silver nitrate, 0.02 % (v/v) formaldehyde 
 
 H-development solution 
0.01 % (v/v) formaldehyde, 2.5 % (w/v) sodium carbonate 
 
 H-stop solution 
1.5 % (w/v) EDTA 
 
2.5.3.2.3 Silver staining (Shevchenko protocol) 
The silver staining protocol from Shevchenko, based on (Rabilloud et al. 1988), does not include 
cross-linking by glutaraldehyde, hence making the sample compatible with mass spectroscopy 
analysis. The detection limit is approximately 5 ng. The protein gel was fixed for 20 minutes and 
then rinsed in 50% methanol for 10 minutes. Following a 1 minute sensitization it was washed 
three times in water. During the 20 minute staining that followed, the nonspecifically bound 
silver ions were trapped in soluble complexes due to the sodium thiosulfate pre-treatment and 
these were removed by a two time water wash. During development the solution was refreshed 
when a yellow discoloration was observed. The reaction was stopped by lowering the pH of the 
solution. 
 
 S-fixation solution 
50 % methanol, 5 % acetic acid 
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 S-sensitization solution 
0.02 % (w/v) sodium thiosulfate 
 
 S-staining solution 
0.1 % (w/v) silver nitrate; pre-cooled 
 
 S-development solution 
0.04 % (v/v) formaldehyde, 2 % (w/v) sodium carbonate 
 
 S-stop solution 
5 % acetic acid 
 
 
2.5.3.3    Electro-blotting 
During electro-blotting, an electric field is employed to transfer proteins separated on the 
polyacrylamide gel onto a membrane surface. For this purpose, a ‘semi-dry-system’ apparatus 
was used. Three Whatman-filter papers (GE Healthcare) were soaked in the anode buffer and 
placed onto the lower anode plate. A polyvinylidene fluoride (PVDF) membrane was shortly 
activated in methanol, washed in water and dipped in the anode buffer, before placing onto the 
filter papers. The polyacrylamide gel was placed on top of the membrane and further covered by 
three Whatman filter papers that had been soaked in the cathode buffer. The blot ‘sandwich’ was 
completed by the placing of the upper cathode plate. The transfer was carried out at 35 mA for 3 
hours. 
 Anode buffer 
50 mM boric acid, 20 % ethanol, pH 9.0 
 
 Cathode buffer 
50 mM boric acid, 5 % ethanol, pH 9.0 
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2.5.4 Peptide screening for anchor position determination 
2.5.4.1    Synthetic combinatorial peptide library in positional scanning format (PS-SCL) 
Synthetic combinatorial peptide libraries in positional scanning format (PS-SCL) are composed 
of peptide pools. Within a given pool, each peptide contains fixed amino acids at one position 
and randomized amino acids at all other positions (Gundlach et al. 1996; Sospedra et al. 2003; 
Nino-Vasquez et al. 2004). For instance, a PS-SCL nonapeptide library would contain 180 
peptide pools for the 20 amino acids that can be arranged in 9 positions. Such libraries have so 
far been applied for TCR based antigen searches (Rubio-Godoy et al. 2002). In this study, 
recombinant MHC molecules (MR1) were incubated with a PS-SCL in order to isolate their 
nonapeptide binding partners. The experimental design for determining the anchor positions of a 
MHC molecule (using HLA-A*0101 as an example) by this approach is shown in Figure 2-3. 
 
 
Fig. 2-3: Experimental design for anchor position determination of a HLA molecule (HLA-A*0101) 
(a) Recombinant β2 microglobulin associated human HLA-A*0101 is produced and purified via a terminal tag such 
as His (6). (b) The HLA molecule may now be used to screen a synthetic combinatorial peptide library in positional 
scanning format (PS-SCL). This is shown as a nonapeptide library where a given amino acid (here aspartic acid) is 
fixed from position 1 to 9 while every other position is randomized (denoted by ‘X’). (c) The peptides that bind to 
the HLA molecule can be eluted by acid treatment, and sequenced. The sequences shown here are examples for a 
hypothetical, successful experiment where the anchor positions of the MHC molecule HLA-A*0101 were revealed. 
(d) The sequence of the eluted peptides will reflect the anchor positions of the MR1 molecule. For HLA-A*0101 
these are aspartic acid (D) at position 3 and tyrosine (Y) at position 9. The amino acids in (b), (c) and (d) have been 
denoted according to standard one letter nomenclature.  
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The recombinant human MR1 (approximately 25 µg) purified via the myc tag and protein G 
affinity chromatography and was immobilized on magnetic beads (Section 2.5.2.1). The MR1 
immobilized on magnetic beads was added to 450 µl of a chemically synthesized nonapeptide 
PS-SCL (gift from Clemencia Pinilla, Torrey Pines Institute for Molecular Studies). Individual 
peptides have a concentration of about 1x 10
-15
 M in this library. 25 µg of commercially 
available β2 microglobulin was also added to the mixture. This MR1-peptide- β2 microglobulin 
mixture was incubated for 48 hours to allow sufficient time for binding of the peptides to MR1 
after which the peptides were eluted by acid treatment (Section 2.5.4.2). 
 
2.5.4.2    Elution of bound peptides 
After the incubation, with the PS-SCL nonapeptide library, the MR1 (and binding partners) were 
separated by magnetic purification and washed three times with 1X PBS to remove unbound 
peptides and once shortly with water to remove residual salt.  250 µl of 0.2 % trifluoroacetic acid 
was added for elution of bound peptides from MR1. The eluate was diluted to 0.1 % 
trifluoroacetic acid and sequenced by Edman degradation (Reinhard Mentele, MPI of 
Biochemistry) and mass spectrometry (Ignasi Forné, LMU). 
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2.6 Immunological methods 
 
2.6.1 Flow cytometry  
Flow cytometry enables multiparametric cellular analysis such as the detection of multiple 
cellular markers, both intracellular and those expressed on the surface. The cells to be analyzed 
are suspended in solution and stained for markers of interest by using fluorophore tagged 
antibodies. A beam of (laser) light is applied on a hydrodynamically focused single cell 
suspension. Cells passing through this beam scatter the light, as well as emit light from the 
excited fluorophores. This scatter and emission is analyzed by detectors positioned in front of 
and perpendicular to the beam. Information based on the forward scatter (FSC) and side scatter 
(SSC) produced by the cell, correlating to cellular volume and inherent granularity respectively, 
allows one to characterize the cells. 
 
Flow cytometry was employed for analyzing the surface expression of transfected molecules as 
well as intracellular sGFP expression. A FACS Calibur (Becton Dickinson) with excitation lasers 
for 488 nm and 633 nm was used 1x10
4 
- 1x10
6
 cells were taken per well of a 96 well conical 
bottomed plated, washed twice with 200 µl FACs buffer, re-suspended in 50 µl of primary 
antibody solution and incubated on ice, in the dark for 30 minutes. The cells were then re-washed 
and suspended either in a secondary antibody solution or in the dead cell counterstain solution. 
The antibodies used for staining are tabulated in Section 2.1.2. 10,000 cells were acquired per 
sample and analyzed with the software Cell Quest (Becton Dickinson, V3.3) or FlowJo (Tree 
Star, V7.6).  
 
 FACS buffer 
10 % FCS in 1X PBS 
 
 Antibody solution 
Primary-1:50 diluted in FACS buffer,  
Secondary-1:200 diluted in FACS buffer 
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 Dead cell counter stain solution 
TOPRO-3 (Invitrogen), stock solution: 1 mM in DMSO, final conc. 1:4000 
 
2.6.1.1    Fluorescence-activated cell sorting (FACs) 
Fluorescence-activated cell sorting was used to sort human peripheral blood lymphocytes (PBLs) 
directly into PCR tubes (Wolfgang Klinkert, MPI of Neurobiology) as a positive control to 
validate the unbiased β-chain primers. Details of the PCR protocol are presented in Section 
2.4.3.2.2. FACS allows for the separation of single cells from a heterogeneous suspension based 
on their light scattering and fluorescence characteristics. The cell suspension is 
hydrodynamically focused so that droplets, each containing single cell, are formed. The droplets 
are charged and then analyzed for fluorescence, after which they are electrostatically deflected 
based on their charge. The charge returns to neutral when the droplet has broken off from the 
stream. 
 
15 ml of human blood was collected in EDTA and diluted 1:1 in PBS. 15 ml of Lymphoprep was 
added to this mixture and then centrifuged for 20 minutes at 500 g. The cellular phase was 
collected in a separate tube, washed with PBS and centrifuged at 500 g for 15 minutes. The cells 
were incubated on ice for 30 minutes with FITC labeled CD3 antibody that was diluted 1:50 in 
PBS containing 2 % fetal calf serum (FCS). The cells were washed twice with PBS and re-
suspended in PBS containing 1:4000 TOPRO 3 dye (for identification of dead cells). Prior to cell 
sorting, the cell suspension was passed through a cell strainer to ensure a homogenous single cell 
suspension. CD3+ and TOPRO 3- cells (live T cells) were gated and single cells were sorted 
directly into pre-cooled PCR tubes containing 5.5 µl of the RT PCR Buffer. The tubes were 
immediately stored at -80°C until the RT reaction. 
 
 Cell strainer 
BD Falcon tube with cell strainer cap 
 
 RT PCR buffer 
QIAGEN OneStep RT-PCR kit 
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2.6.2 Staining of brain tissue 
2.6.2.1 Staining for laser microdissection  
Brain tissue sections of patient FE and MS-4 were stained with antibodies specific for CD8 
(effector T cell marker) and CD134 (T cell activation marker) to identify T cells that had 
infiltrated the MS lesion.  Polyethylene tretraphtalate (PET) membrane slides (P.A.L.M 
Microlaser) were baked at 180°C for 4 hours, followed by UV irradiation and coating with poly-
L-lysine hydrobromide. 10 µm thick cryostat sections from frozen tissue specimens were 
mounted onto these slides and stored at – 80°C. All aqueous staining solutions were treated with 
RNase inhibitor and DEPC for ribonuclease (RNase) inactivation.   
 
Prior to staining, the slides were thawed to ambient temperature, fixed briefly in 100% acetone 
and then rehydrated in PBS for 10 seconds. Blocking was performed for 3 minutes in PBS 
containing 2 % BSA. Next, the sections were co-incubated for 5 minutes with 1:100 diluted Cy3 
labeled anti-CD8 beta chain antibody (clone 2ST8.547) and 1:20 diluted FITC labeled anti CD 
134 antibody (clone ACT35) or 1:25 diluted FITC labeled anti BV1 antibody (clone BL37.2) . 
The sections were then rinsed with 1ml of PBS and incubated for 3 minutes with a 1:00 diluted 
Alexa-488 labeled anti-FITC antibody (polyclonal) in order to enhance the fluorescence signal. 
All incubation steps were carried out in a humidified staining chamber. After a second PBS 
rinse, the sections were covered with isopropanol to retard RNase activity as well as specimen 
drying, and immediately analyzed under the P.A.L.M Microbeam-Z microscope. Laser 
microdissection and the RT PCR that followed are elaborated in Section 2.4.3.2.2. 
 
The entire staining and cell isolation was carried out within a room meant specifically for this 
purpose. All surfaces within the room are cleaned with alcohol followed by an RNase removal 
agent (RNaseZAP™, Sigma) and the room is illuminated with UV light for 3 hours before and 
after use. To prevent RNase transfer from body surface, the user is dressed in lab coat, gloves, 
face mask, head and shoe covers.  
 
 Poly-L-lysine hydrobromide (Sigma) 
 
 Protector RNase inhibitor, 1U/ml, (Roche) 
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 Bovine serum albumin (BSA), (Sigma) 
 
 Cy3-mAb labeling Kit, (GE Healthcare) 
 
2.6.2.2    Staining for localization of T cells in white and grey matter 
Sequential 10 µm sections from frozen tissue (block # 9, 10, 11) patient FE were stained with 
luxol fast blue (LFB) for differentiation of white and grey matter, and with CD8 for detection of 
effector T cells to see visualize the infiltration in each region. The LFB stained sections were 
additionally stained with a haematoxylin nuclear stain to visualize all cells. The staining reagents 
were a gift from Edgar Meinl, MPI of Neurobiology. 
 
2.6.2.2.1 Luxol fast blue and haematoxylin staining 
The luxol fast blue (LFB) stain, also known as the modified Klüver’s stain is used to stain the 
myelin sheath in white matter blue, hence differentiating it from the grey matter. LFB is an 
alcohol soluble sulfonated copper phthalocyanine dye that works via an acid-base reaction 
wherein the myelin lipoprotein base is replaced with the base of the dye. The haematoxylin 
nuclear staining involves the application of haemalum, a complex of aluminium ions and 
oxidized haematoxylin. This occurs due to the binding of the dye-metal complex to arginine-rich, 
basic nucleoproteins such as histones. Prior to staining, the section was first placed at room 
temperature for 15 minutes followed by fixing in 4 % paraformaldehyde for 30 minutes at 4°C. 
Following a 4X wash in PBS, the sections were placed in 0.1 % Luxol fast blue solution 
overnight at 55°C. The section was then washed in 96 % ethanol, followed by deionised water, 
and differentiated in 0.1 % Lithium carbonate solution and 70 % ethanol. The reaction was 
stopped by washing with deionized water. The LFB stained section was then dipped for 5 
seconds in the haematoxylin solution followed by a water wash to remove excess dye. The 
stained slides were dehydrated by dipping in a series of increasing ethanol concentration (70% - 
90 % - 96 %), followed by 100 % isopropanol and xylene. A drop of the mounting medium 
Eukitt was then applied before placing a cover glass. The slides may now be observed under the 
microscope. 
 
 Paraformaldehyde (Sigma) 
 
 Luxol fast blue solution (Sigma) 
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 Haematoxylin solution (Merck) 
 
 Mounting medium ‘Eukitt’ (Gröppel) 
 
 
2.6.2.2.2 CD8 staining  
The brain infiltrating CD8 T cells were detected using the Cy3 labeled anti-CD8 beta chain 
antibody mentioned in Section 2.6.2.1. Incubation times were longer as RNA did not have to be 
isolated from the tissue. After fixing the sections as done in Section 2.6.2.2.1, blocking was 
performed for 30 minutes in PBS containing 2 % BSA. The section was then incubated with the 
antibody for one hour at room temperature. Both blocking and antibody incubation was carried 
out in a humidified chamber. After antibody incubation, the sections were washed 3 times in 
PBS. A drop of fluorescence mounting medium (Dako) was placed on the section and covered 
with cover glass before analysis at the fluorescence microscope. 
 
2.6.3 Western Blot 
The recombinant hMR1 and β2 microglobulin, purified from HEK293E cells, were detected 
using western blot. First, the proteins that had been differentiated according to molecular weight 
on a gradient gel (4-20%) (Section 2.5.3) were immobilized onto a PVDF membrane. Next, all 
unspecific binding sites on the membrane were blocked by incubation in the blocking buffer for 
2 hours. The membrane was then incubated overnight at 4°C with the primary detection antibody 
(anti c-myc for myc tagged MR1 and anti-β2 microglobulin) diluted in the wash buffer. This was 
followed by a 45 minute 5 step washing procedure for the removal of unbound antibody. Then 
the secondary antibody diluted in wash buffer was added for 1 hour and followed by the 45 
minute wash. The enhanced chemiluminescence (ECL-system) of detection was used. The 
secondary antibody is coupled to the enzyme horse radish peroxidase (HRP) that oxidizes the 
luminol present in the ECL-A solution in the presence of hydrogen peroxide (H2O2), thereby 
driving it into an excited state. It decays to the ground state by emitting light. This emission 
darkens the corresponding part of the X-ray film, marking the location of the protein of interest. 
The ECL-B solution contains p-hydrocoumarin acid for enhancement of this light signal. For 
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each membrane, a mixture of 10 ml ECL-A solution, 3.1 µl of 30 % H2O2 and 100 µl ECL-B 
solutions was used. The membrane was incubated in this mix for 1 minute and then immediately 
placed into a film cassette and overlaid with an X-ray film which was developed in the dark 
room. 
 
 Wash buffer (PBS-T) 
PBS with 0.05 % (v/v) tween-20 
 
 Blocking buffer 
5% (w/v) skimmed milk, blotting grade (Bio-Rad) in PBS-T  
 
 Primary antibody (1:1000) 
For MR1: anti-c-myc, clone 9E10.3 (Millipore) 
For β2 microglobulin: polyclonal (Abnova)  
 
 Secondary antibody (1:2500) 
Goat anti-mouse IgG + IgM (H+L), peroxidase conjugated 
From Dieter Jenne, MPI of Neurobiology 
 
 ECL-A solution 
0.25 % (w/v) luminol in 1M Tris/HCl  
 
 ECL-B solution 
0.11 % (w/v) para-hydroxycoumarin acid in DMSO 
 
 X-ray film  
Amersham Hyperfilm ECL, (GE Healthcare) 
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3 Results 
 
3.1 Identification of TCR α- and β-chains from single T cells infiltrating 
the MS brain 
 
Multiple sclerosis (MS) is an autoimmune demyelinating condition characterized by axonal loss, 
glial cell activation and the infiltration of immune cells into the CNS. CD8+ T cells are the 
predominant lesion infiltrating subset in MS and represent the effector population that can direct 
the ‘autoimmune attack’ on the nervous tissue (Friese and Fugger 2009). To date, the molecular 
target of the T cell receptor (TCR) of these autoaggressive T cells remains unknown. The 
identity of the autoaggressive TCR, therefore, would provide important information about the 
antigen(s) that it recognizes. To shed some light on the identity of the MS antigen(s), the 
putatively autoaggressive T cells, that had infiltrated the brain tissue in MS patients, were 
characterized. In order to differentiate between autoaggressive and bystander cells, certain 
criteria were followed while isolating cells from MS tissue cryosections. First, the cellular 
appearance had to be in keeping with T cell morphology (diameter: 7 -21 µm). Second, the cell 
of interest should express cytotoxic T cell surface makers such as CD8 besides activation 
markers such as CD134. Clonally expanded T cell populations could be identified by CDR3 
spectratyping and such cells were analyzed (i) when TCR-specific antibodies were available, and 
(ii) with clone-specific primers. When TCR-specific antibodies were not available, the CD8+ T 
cells were additionally stained for an activation marker (such as CD134). Cells fulfilling the 
above criteria were isolated from the frozen tissue sections by laser microdissection (LMD) as 
depicted in Figure 3-1. To characterize their TCRs, a clone specific PCR approach (Seitz et al. 
2006) (Section 3.1.1) and an unbiased PCR approach developed for live T cells (Section 3.1.2) 
was applied for the first time to frozen brain tissue originating from two MS patients (patient FE, 
biopsy; patient MS-4, autopsy).  
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Fig. 3-1: CD8+ T cells infiltrating MS brain and their isolation by laser microdissection  
Cryosections from patient FE brain sample stained for effector T cell marker CD8 (red) and T cell activation marker 
CD134 (green) (a) CD8+ T cells infiltrating brain tissue, (b-d) immunolocalization of activated effector T cells that 
are double positive (white arrows) for (b) CD8+ and (c) CD134+ as well as non activated CD8+ T cells (yellow 
arrow), (e-h) representative micrographs of the cryosections on membrane-covered polyethylene tretraphtalate 
(PET) slides used for laser microdisscetion (LMD). Activated single T cells are co-stained for CD8 (e) and a TCR 
chain or T cell activation marker CD134 (f). They are then dissected and catapulted out of the tissue directly into the 
cap of a PCR tube for subsequent amplification of the expressed TCR. Panels (g) and (h) represent the bright-light 
image of the tissue before (g) and after (h) LMD. The numbers in the yellow field refers to apparatus parameters (a-
d). The image quality is affected as the tissue is not covered with a cover slip during cell isolation. The scale bars 
correspond to 20 µm.  
 
 
3.1.1 Application of the clone specific PCR approach 
It was possible to delineate the clonally expanded TCR populations within the different tissue 
blocks of the two MS patients FE (Skulina et al. 2004) and MS-4 (Junker et al. 2007) by CDR3 
spectratyping. Clonal expansions belonging to TCRs (i) that had persisted in the patient for a 
long time and (ii) for which antibodies were commercially available were analyzed with this 
approach. The methodology was developed in the context of muscle infiltrating T cells (Seitz et 
al. 2006) and applied for the first time to MS patient derived frozen brain tissue.   
 
Overlay 
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3.1.1.1    TCR α- and β-chains derived from Patient FE 
The BV1-BJ2.3 expansion that had persisted in the patient for seven years (1996-2003) was 
studied (Skulina et al. 2004; Babbe et al. 2000). An earlier analysis of peripheral blood cells of 
the patient had revealed the coexpression of an AV7.2-AJ16 α-chain (Malotka and Dornmair, 
unpublished). During this study, the expression of this α-chain in the brain was investigated in 
collaboration with Katherina Siewert and David Laplaud. Vβ1+ CD8+ single T cells were 
isolated from the brain and a TCR specific RT PCR was carried out. The peptide sequences of 
the recovered TCR chains are presented in Table 3-1. 
 
 a. β-chain sequence 
 
Variable 
region 
Peptide sequence 
Variable-CDR3-Joining 
Joining 
region 
Frequency 
 
Detected 
in 
1 CASS-ISGRKD-TQYFGPG 2.3 36 Blood, Brain 
    (Skulina et al. 2004) 
(Babbe et al. 2000) 
b. α-chain sequence 
 
Variable 
region 
Peptide sequence 
Variable-CDR3-Joining 
Joining 
region 
Frequency 
(Total: 15) 
Detected 
In 
7.2 CAV-RDNLE-LLFARG 16 6 Blood (#) 
7.2 CAV-RDQA-TDSWGKLQFGAG 24.2 1 Brain 
7.2 CAV-RDS-NYQLIWGAG 33 7 Brain 
7.2 CAV-QEP-SGSLTFGEG 58 1 Brain 
 
Tab. 3-1: TCR sequences derived from patient FE using the clone specific approach 
(a) The BV1-BJ2.3 β-chain that persisted in patient FE for 7 years (Skulina et al. 2004; Babbe et al. 2000). (b) The 
four AV7.2 α-chains that are coexpressed with this β-chain. This work was done in collaboration with colleagues at 
the MPI of Neurobiology. (#) Klaus Dornmair and Joachim Malotka detected the AV7.2-AJ16 α-chain in blood. The 
following three α-chain sequences were found together with David Laplaud and Katherina Siewert. The variable 
regions of the TCRs are named in accordance with the Arden nomenclature (Arden et al., 1995). The CDR3 region 
is represented as flanked by the terminal amino acid (AA) residues of the variable region up till the underlined 
‘FGXG’ consensus sequence of the joining region. These are separated by dashes. ‘Frequency’ relates to the number 
of cells where a particular TCR sequence was detected. 
 
Of the 490 cells isolated, 36 carried the β-chain of interest and these were further analyzed using 
a pool of unbiased α-chain primers. The α-chain sequences could be recovered from 15 cells. 
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Within these 15 cells, some sequences appeared more than once, and these added to a total of 4 
TCR pairs. Within these TCR pairs, the four different α-chains were coexpressed with the 
identical β-chain (Vβ1-Jβ2.3). Further analysis revealed that these α-chains were homologous at 
the peptide level and belonged to the mucosal- associated invariant T cell (MAIT) subset, with 
the AV7.2-AJ33 expansion being the classical MAITα-chain. These observations are discussed 
in Section 4.2. 
 
3.1.1.2 TCR α- and β-chains derived from MS-4 
All experiments carried out on material from Patient MS-4 were done in collaboration with 
Gintare Kemezyte (MPI of Neurobiology). The BV1-BJ1.1 expansion that had been earlier 
detected in both tissue blocks numbered 6 and 9 was studied (Junker et al. 2007). Of the 375 
cells analyzed with clone specific primers, the sequence was recovered from one cell. This is 
presented in Table 3-2. The pairing alpha chain sequence could not be recovered. 
 
Variable 
region 
Peptide sequence 
Variable-CDR3-Joining 
Joining 
region 
Frequency 
(Total: 1) 
1 CASS-VGDVRQM-NTEAFFGQG 1.1 1 
 
Tab. 3-2: TCRβ-chain sequence derived from Patient MS-4 using the clone specific approach 
The variable regions of the TCRs are named in accordance with the Arden nomenclature (Arden et al. 1995). The 
CDR3 region is represented as flanked by the terminal amino acid (AA) residues of the variable region up till the 
underlined ‘FGXG’ consensus sequence of the joining region. These are separated by dashes. ‘Frequency’ relates to 
the number of cells positive for the TCR sequence. This work was done in collaboration with Gintare Kemezyte, 
MPI of Neurobiology.  
 
 
3.1.2 Application of the unbiased PCR approach 
The clone specific PCR approach, although successful, allows one to only study TCRs for which 
antibodies were commercially available. To overcome this limitation, an unbiased β-chain primer 
pool was developed in collaboration with Song-Min Kim and Jörg Prinz (LMU) that, in 
combination with the pre-established universal α-chain primer pool (Seitz et al. 2006), allows for 
the detection of all TCR chains in a manner that is independent of CDR3 spectratyping. With this 
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approach all lesion infiltrating CD8+ T cells, including those that were also positive for the 
CD134 activation marker, could be analyzed. The protocol was developed for analyzing live T 
cells isolated directly from skin tissue. The RNA derived from live cells would be of better 
quality and of larger quantity, than that of T cells isolated from frozen tissue. Hence, it was 
essential to modify the protocol to suit the needs of this study. This was first tested on live TCR 
expressing cell lines (Section 3.1.2.1), followed by human peripheral blood lymphocytes 
(Section 3.1.2.2) and then ultimately applied to frozen brain tissue (Section 3.1.2.3). 
 
 
3.1.2.1    Validation of protocol on human TCR transfected cell lines 
The universal β-chain primer pool was first tested on live, recombinant human TCR expressing 
mouse hybridoma cell lines (Table 3-3). Since these cell lines express the TCR under the 
influence of a strong CMV promoter, it would be the appropriate gold standard for checking the 
accuracy of the protocol. The 58
-/- 
cell line that does not express human TCRs (58
 -/- 
(untransfected)) and a 58
-/- 
cell line expressing the γ/δ TCR (58 
-/- γ/δ
) were used as negative 
controls (Table 3-3). 
 
TCR hybridoma cell line Result Yield 
58 
-/- 
BV1 correct sequence 6/16    
58 
-/- 
BV9 correct 15/16  
58 
-/- 
BV17 correct 2/16   
58 
-/- 
 (untransfected) no product 
BV1 (contamination) 
13/16  
3/16    
58 
-/- γ/δ
 no product 
BV17 (contamination) 
12/16  
4/16    
 
Tab. 3-3: TCR sequences recovered from TCR expressing hybridoma cell lines 
The universal β chain-primer pool was tested on live, human TCR expressing, mouse hybridoma cell lines (58 
-/-
). 
The cell line has been designated with the TCR β-chain that it expresses. For each cell line, 16 single cells were 
tested. The obtained PCR products were sequenced to ascertain correct identity. The ‘yield’ relates to positive 
sequences for a particular cell line. A fraction of the negative controls gave a PCR product (contamination) resulting 
from a carryover from the test samples. The TCRs are named according to Arden nomenclature.  
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For the three test samples (BV1, BV9, BV17), correct sequences were recovered. However, PCR 
products were not observed for all processed samples. This might indicate that within the primer 
pool, some primers are more efficient than others.  β-chain TCR sequences were recovered from 
some negative control samples as well. Since the experiments were not carried out in a clean 
room, the carryover of samples may have occurred. However, these results also point to the 
sensitivity of the technique, which is an essential prerequisite to single cell experiments. The 
47.91 % yield indicates that the technique was successful in amplifying human TCRs from 
strongly expressing live cells. 
 
 
3.1.2.2    Validation of protocol on human peripheral blood lymphocytes 
Next, the protocol was tested on FACs sorted single T cells that were isolated from the 
peripheral blood lymphocytes of a healthy donor. The T cells were frozen at -80°C immediately 
after isolation to replicate actual experimental conditions. The RT-PCR was carried out directly 
on the thawed cells. Of the 40 single cells analyzed, PCR products were recovered from 20 cells 
with a yield of 50%. On further analysis, four α-chains were recovered. The results are presented 
in Table 3-4. 
 
a.  β-chain sequences 
 CDR3 Sequence Frequency 
β-chain  Vβ N(D)N Jβ (Total: 20) 
1 1 CASS VGG LQFFGPG 2.1 1 
2 2.1 CSA SLCQQLSP NEQFFGPG 2.1 1 
3 3 CAS RPAPKGWGDTES EAFFGQG 1.1 1 
4 3 CAS THGRGD TEAFFGQG 1.1 1 
5 3 CASS DRT EKLFFGSG 1.4 1 
6 5.2 CASS ISDG TQYFGPG 2.3 1 
7 6.2 CASS SLPSP TYTFGSG 1.2 1 
8 6.4 CASSL VPY TDTQYFGPG 2.3 1 
9 7.1 CASS HAGTGNP NEKLFFGSG 1.4 1 
10 7.2 CAS RVPT LTFGAG 2.6 1 
11 8.1 CAS PLAWR EQFFGPG 2.1 1 
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12 9 CASS HGTRLLARR NYGYTFGSG 1.2 1 
13 12.4 CAISE STLSKP FFGQG 1.1 1 
14 13.5 CASS GRQ NEQFFGPG 2.1 1 
15 19.1 CAS FLIQYYN QFFGPG 2.1 1 
16 20 CAW PRSLCLR FFGSG 1.4 1 
17 21.3 CASSL DAPL EAFFGQG 1.1 1 
18 25.1 CASS EQGV TIYFGEG 1.3 1 
19 27.1 CTS GTQ LFFGEG 2.2 1 
20 32.1 CGS QQSLDQG QFFGPG 2.1 1 
 
b. α-chain sequences 
Coexpression 
with β-chain 
CDR3 Sequence Frequency 
Vα N(D)N Jβ (Total: 4) 
6 2.1 CAV VNYT FKTIFGAG 9 1 
15 19.1 CAV CQSS SGSRLTFGEG 58 1 
18 1.3 CAV CDLLT NVLHCGSG 35 1 
19 20.1 CLVG GPRPI SARQLTFGSG 22 1 
 
Tab. 3-4: TCR sequences from human peripheral blood lymphocytes (unbiased PCR approach) 
(a) β-chain sequences from 20 single peripheral blood lymphocytes (PBLs). These are arranged according to the 
increasing order of the variable region number, followed by the TCR chain peptide sequence.      (b) Matching α-
chain sequences from 4 PBLs. These are arranged according to the β-chain sequence that was coexpressed in the 
same cell. A total of 4 TCR pairs were recovered by applying the unbiased PCR to 40 single PBLs. The sequence 
begins at the conserved terminal cysteine residue of the variable region and ends in the underlined ‘FGXG’ 
consensus sequence of the joining region. Frequency corresponds to the number of times a particular sequence was 
recovered. Vβ: variable region of β-chain (Arden nomenclature), Jβ: joining region of β-chain; N (D) N: 
hypervariable region; Vα: variable region of α-chain, Jα: joining region of α-chain 
 
 
3.1.2.3 Unbiased identification of TCR chains from frozen brain tissue 
Once the protocol had been validated, it was applied to T cells isolated from frozen tissue. As the 
sample tissue had been in -80°C storage for a prolonged time period, and was repeatedly thawn 
and frozen for making tissue sections, the quality of the RNA, and hence the efficiency of the 
RT-PCR would be expected to be greatly reduced. To make up for this, a larger sample size was 
considered, and all reactions were carried out in quick short steps. In certain PCR steps, the 
reaction volume was modified. Ultimately, TCR sequences were successfully recovered from 
frozen brain tissue by the application of the unbiased PCR approach. 
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3.1.2.3.1 Patient FE 
Three tissue blocks (#9, #10, and #11), originating from the same lesion of the patient, were 
analyzed during this study. Tissue infiltrating T cells were stained for the marker of cytotoxic 
cells (CD8) as well as the T cell activation marker (CD134). Of the 643 laser-microdissected 
single CD8+ T cells isolated, TCR β-chain sequences were amplified from 68 samples. Some β-
chains were recovered more than once, and 13 distinct chains were detected in total. On further 
analysis of these samples, 5 different α-chains were detected from 13 cells. Interestingly, in two 
cases, the identical β-chain paired with 2 different α-chains. Both of these β-chains belonged to 
dominant expansions that were detected in 46 and 8 cells. Previously, we have reported a similar 
observation in the context of inflammatory muscle diseases (Seitz et al. 2006). The fifth TCR 
pair was found in just one cell, but was known to be expanded from previous studies (Babbe et 
al. 2000). These results are presented in Table 3-5. 
 
a. β-chain sequences 
 CDR3 Sequence Frequency in 
different tissue  blocks 
β-chain Vβ N(D)N Jβ # 9 # 10 # 11 Total 
1 6.2 CASS PYPH TEAFFGQG 1.1 0 0 1 1 
2 6.2 CASS SRDRG GYTFGSG 1.2 0 0 1 1 
3 6.2 CASSL RPN GELFFGEG 2.2 1 0 0 1 
4 6.2 CASS PTSL TDTQYFGPG 2.3 1 0 0 1 
5 6.3 CASSL AFTGES EQYFGPG 2.7 1 0 0 1 
6
#†
 6.5 CASSL APN GELFFGEG 2.2 5 3 0 8 
7 8.1 CAS THRGHG NTEAFFGQG 1.1 1 0 0 1 
8
#†
 8.1 CAS TQGWGD TEAFFGQG 1.1 23 13 10 46 
9 13.1 CASS TSPGGARG GNTIYFGEG 1.3 1 0 0 1 
10
¤†
 13.1 CASS LGA DTQYFGPG 2.3 1 2 0 3 
11
¤
 13.2 CAS RALVAT YNEQFFGPG 2.1 0 0 1 1 
12
†
 17.1 CASS SRS SYEQYFGPG 2.7 1 1 0 2 
13 21.3 CASS LAY GELFFGEG 2.2 1 0 0 1 
b. α-chain sequences 
 CDR3 Sequence Frequency in 
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Coexpression 
with β-chain 
different tissue blocks 
Vα N(D)N Jα 1 2 3 Total 
6a
†
 20.1 CLVGD SRKG DDKIIFGKG 30 1 1  2 
6b
†
 20.1 CLVG AT GNTGKLIFGQG 37 1 1  2 
8a 1.5 CAV SA TDKLIFGTG 34 1   1 
8b
†
 30.1 CAV PF DRGSTLGRLYFGRG 18 5 1 1 7 
11 21.1 CAAS G GSNYKLTFGKG 53   1 1 
Tab. 3-5: TCR sequences recovered from patient FE using the unbiased PCR approach 
A total of 5 TCR pairs were recovered from 68 single cells. All the β-chains and α-chains are arranged according to 
the increasing order of the variable region number. This is followed by the TCR chain peptide sequence beginning 
with the conserved terminal cysteine residue of the variable region and ending in the ‘FGXG’ consensus sequence of 
the joining region. The term ‘frequency’ corresponds to the number of times a particular sequence was recovered, 
and this has been distributed amongst the three blocks analyzed in the study. (a) β-chain sequences from 13 cells. 
(b) α-chain sequences that were found to be coexpressed with a particular β-chain. The designation of ‘a’ or ‘b’ 
following the TCR chain number corresponds to the two different alpha chains that pair with the identical beta 
chain. Vβ: variable region of β-chain (Arden nomenclature), Jβ: joining region of β-chain, N (D) N: hypervariable 
region Vα: variable region of α-chain, Jα: joining region of α-chain; †: detected in more than one tissue block; #: β-
chain found in coexpression with two different Vα rearrangements; ¤: also detected in earlier studies (Babbe et al. 
2000) 
 
A study in our laboratory (Junker et al. 2007) demonstrated that T cell clonal expansions are 
found in different physical regions of the MS brain. Having found the β-chains of T cell clones 6, 
8, 10, 12 in more than one tissue block from patient FE, we could confirm that these clonal 
expansions were not localized in one part of the brain, but were present as ‘pervasive clones’ in 
other parts as well.  
 
3.1.2.3.1.1 Effector T cell distribution in white and grey matter 
The demyelinating inflammation in MS has been mainly thought to be a white matter (WM) 
disorder of the brain and the involvement of grey matter (GM) in the disease was noted early, but 
came to the forefront only recently (Geurts and Barkhof, 2008; Geurts et al. 2009). By staining 
sequential sections for infiltrating CD8+ effector cells, and luxol fast blue (white matter/ grey 
matter differentiation), we were able to visualize the infiltration in these two regions. 
Representative images for block # 9 and # 11 from patient FE are depicted in Figure 3-2. 
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 a. CD8 β staning for 
effector T cells 
b. LFB staining for 
WM/GM differentiation 
 
 
 
Block # 9 
 
 
 
 
 
 
Block # 11 
  
Fig. 3-2: CD8+ T cell infiltration in grey matter (GM) and white matter (WM) of patient FE 
Sequential cryosections from block #9 and #11 of patient FE brain sample stained for (a) infiltrating CD8+ effector 
T cells (red) using a Cy3 labeled CD8β antibody. The cells are seen in both white matter (WM) and grey matter 
(GM). (b) The WM/GM differentiation by luxol fast blue (LFB) that stains the myelin in the white matter blue. The 
boundaries between WM and GM are depicted in all images as dotted grey lines. The sections were additionally 
stained with the haematoxylin nuclear stain that stains the nuclei of all cells purple. The staining reagents were a gift 
from Edgar Meinl, MPI of Neurobiology. The scale bars correspond to 50 µm 
 
 
CD8+ T cells were observed to infiltrate white matter, grey matter and the meninges (data not 
shown here). The T cells isolated from patient FE (Section 3.1.2.3.1) were isolated bonafide 
from both grey and white matter. Since it was not technically possible to perform a stain for 
effector T cells and differentitate between white and grey matter on the sections used for laser 
microdissection, it is not possible to determine the exact localization of these cells. 
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3.1.2.3.2 Patient MS-4 
All experiments carried out on material from patient MS-4 were done in collaboration with 
Gintare Kemezyte (MPI of Neurobiology, Martinsried). The unbiased PCR primer approach was 
applied to a total of 969 single CD8+ cells and from these 6 β-chain sequences could be 
recovered. Of these 6, one TCR chain was found twice. The low yield may be due to the 
mediocre RNA quality of the frozen sample as discussed in Section 4.1.4. These sequences are 
presented in Table 3-6. 
 
β-chain sequences 
 
β-chain  
CDR3 Sequence Frequency 
Vβ N(D)N Jβ (Total: 6) 
1 6.2 CQQ RTEGGRRG DTIYFGEG 1.3 1 
2 6.3 CASS LIGSV TDTQYFGPG 2.3 2 
3 6.5 CASS FTQF   NQPQHFGDG 1.5 1 
4 6.5 CASS RIGG SYNEQFFGPG 2.1 1 
5 8.1 CASS RDRG IQYFGAG 2.4 1 
 
Tab. 3-6: TCR sequences derived from patient MS-4 using the unbiased PCR approach 
A total of 5 β-chain re-arrangements were recovered from 969 single cells. These are arranged according to the 
increasing order of the variable region number. This is followed by the TCR chain peptide sequence beginning with 
the conserved terminal cysteine residue of the variable region and ending in the underlined ‘FGXG’ consensus 
sequence of the joining region. Frequency corresponds to the number of times a particular sequence was recovered. 
Vβ: variable region of β-chain (Arden nomenclature), Jβ: joining region of β-chain; N (D) N: hypervariable region 
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3.2 In vitro expression of recombinant TCRs 
The four MAIT TCRs (BV1-BJ2.3 β-chain coexpressed with four α-chains AV7.2-AJ16, AV7.2-
AJ33, AV7.2-AJ24.2 and AV7.2-AJ58) and BV8.1-AV30.1 TCR (BV8.1-BJ1.1 coexpressed 
with AV30.1-AJ18) derived from patient FE were reconstructed during the course of this study. 
The variable and NDN region of the BV1-BJ2.3 and AV7.2-AJ33 were cloned from patient FE 
cDNA by David Laplaud, MPI of Neurobiology. For the other five chains, the recombinant TCR 
was put together by ligating a chemically synthesized ‘leader-variable-joining region’ fragment 
into a pRSV vector containing the relevant TCR constant region. The 58
-/-
 mouse hybridoma cell 
line was chosen as an expression system as it lacks the inherent expression of functional TCR 
chains. The 58
-/-
 cells were first co-transfected with the expression vectors for the two chains of 
the TCR heterodimer (Section 3.2.1). Following antibody selection, positive clones were 
subjected to a CD8 super-transfection (Section 3.2.2) and an ultimate NFAT-GFP transfection 
(Section 3.2.3). This scheme is illustrated in the Figure 3-3. 
 
 
Fig. 3-3: Pictorial representation of the expression of recombinant TCR molecules 
The α- (hygromycin selection) and β- (geniticin selection) TCR chains cloned into pRSV vectors were first co-
transfected into the murine 58
-/-
 cell line, followed by super transfection with CD8 heterodimer expression plasmid 
(puromycin selection) and a final NFAT-sGFP expression plasmid (blasticidin selection) transfection. After each 
transfection, suitable clones were chosen by antibody selection pressure. By cultivating the cell line with a cocktail 
of four antibodies, it was possible to maintain stable transfectants in culture. The vector maps can be found in 
Appendix II. 
 
3.2.1 Expression of TCR 
The four MAIT TCRs and the BV8.1-AV30.1 TCR were successfully expressed in the 58
-/-
 cell 
line. Stable expression of the TCR chain was confirmed by flow cytometry using a murine CD3 
and human TCR β-chain specific antibody (Figure 3-4). Given that α-chain specific antibodies 
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were not commercially available it was feasible to ascertain mRNA level expression by a RT-
PCR (data not shown here). 
 
3.2.2 Expression of human CD8 
The four MAIT TCR expressing cells were now transfected with the construct coding for the 
human CD8 co-receptor. Stable expression of both CD8 chains (α and β) was verified by flow 
cytometry as shown in Figure 3-4. 
 
Fig. 3-4: Stable expression of human TCR and CD8 αβ co-receptor in the 58
-/-
 cell line 
The MAIT TCR expressing cells (denoted as AJ 16, AJ 24.2, AJ 33 and AJ 58 according to the J region of the α-
chain. All four TCRs share the same BV1-BJ2.3 β-chain.) were super-transfected with CD8 expression plasmids. 
Stable surface expression of the human BV1 TCR chain (blue), the inherent murine CD3 (mCD3) (orange) 
molecule, and the two chains of the CD8 molecule (α: maroon, β: magenta) was confirmed by flow cytometry (plot 
of fluorescence intensity vs. cell number). The grey shaded curve delineates the isotype controls for each antibody.  
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Next, the functionality of the expressed MAIT TCR complex was tested. This was done by 
assaying for IL-2 secretion in the cellular supernatant in response to CD3 cross-linking of the 
TCR by a murine CD3 antibody (clone 145-2C11). Clones that demonstrated stable and high 
expression were selected and cultivated further for experiments. These results are presented in 
Figure 3-5. 
 
Fig. 3-5: IL-2 secretion in response to CD3 cross-linking as assayed by an ELISA 
A murine CD3 specific antibody was used to elicit IL-2 secretion as a means to check for correct functioning of the 
transfected TCR for the four MAIT TCR hybridomas (denoted as AJ 16, AJ 24.2, AJ 33 and AJ 58 according to the 
J region of the α-chain. All four TCRs share the same BV1-BJ2.3 β-chain). The best expressing clones of each cell 
line (designated as clone 1 and clone 2) were used for further study. Unstimulated (Unstim.) cells served as negative 
controls while an IL-2 standard served as the positive control. For cell line AJ 16, and AJ 58, the reaction time was 
1.6 minutes, for AJ 33 it was 3 minutes and for AJ 24.2 it was 6 minutes.  
 
3.2.3 Expression of NFAT-GFP 
The final transfection in this series was that of an NFAT-GFP construct which would render the 
cells GFP positive upon antigen recognition and subsequent TCR activation. This effect could be 
simulated in vitro by using a murine CD3 antibody (clone 145-2C11). The resultant GFP 
expression construct could be easily detected by flow cytometry and fluorescence microscopy 
(Figure 3-6). The GFP expression was never observed in 100% of the population, and the 
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individual cells expressed GFP to varied degrees. Similar observations were made for a NFAT 
driven lacZ construct (Sanderson and Shastri, 1994) used to report T cell activation. 
 
 
Fig. 3-6: GFP expression upon TCR activation by CD3 cross-linking in vitro 
Crosslinking of the CD3 chains of the TCR complex leads to the same downstream signaling cascade that 
follows TCR activation. This is translated into an NFAT driven GFP expression in the activated MAIT 
hybridoma cells as detected by (a, b) Fluorescence microscopy images and (c) Flow cytometry histogram. 
Almost 85% of the cells are GFP + in the above example as can be discerned by a direct comparison 
between the bright light (a) and fluorescence channel (b) images. In the flow cytometry image (c), the 
grey curve corresponds to the unstimulated negative control while the green curve depicts the stimulated, 
GFP + cells. This data corresponds to the AJ33 MAIT TCR hybridoma cell line.  
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3.3 MAIT TCR antigen search: Testing of candidate MS antigens 
The classical MAIT (BV1-BJ2.3 and AV7.2-AJ33) TCR was found to be expressed most 
frequently in the lesion infiltrating CD8+ T cells of patient FE. Also, the possibility that the other 
three related TCRs (identical BV1-BJ2.3 β-chain co-expressed with AV7.2-AJ16, AV7.2-AJ24.3 
and AV7.2-AJ58) might recognize a similar antigen, qualified this TCR as an interesting subject 
of further study. All antigen search experiments that follow were directed towards this TCR.  
 
The initial antigen search experiments (Section 3.3.1 to 3.3.4) were carried it out at a stage when 
it was not known that the AV7.2-AJ33 α-chain belonged to the MAIT TCR. These experiments 
were designed to test whether the antigen recognized by the TCR (BV1-BJ2.3/ AV7.2-AJ33) 
was indeed ‘MS specific’. Consequently, molecules put forward as ‘candidate MS antigens’ were 
first tested using patient HLA matched antigen presenting cells (instead of strictly MR1 
expressing APCs). This included co-incubation of the TCR hybridoma with human brain tissue 
(Section 3.3.1), white and grey matter brain extracts (Section 3.3.2), autologous and EBV 
derived antigens (Section 3.3.3) and myelin derived antigens (Section 3.3.4). The experiments in 
Sections 3.3.2 to 3.3.4 were carried out in collaboration with Katherina Siewert (MPI of 
Neurobiology). 
 
 
3.3.1 Human brain tissue 
The objective of this experiment was to ascertain whether the antigenic target of the TCR was a 
‘brain specific’ or even ‘patient specific’ entity. The hybridoma cells were co-incubated with 10 
µm thick tissue sections of brain tissue originating from the patient (FE), and as controls; an 
unrelated MS patient and a meningitis patient. 12-16 hours later, the samples were analyzed 
under a fluorescence microscope and the GFP + activated cells in the vicinity of the tissue were 
counted (cells/mm
2
). The experiment was repeated with the application of a pan-MHC class I 
antibody (clone W6/32) in an attempt to block antigen presentation, as at this stage it was 
assumed that the TCR was restricted by a classical MHC class I molecule. A drop in activation 
would be expected if the antigenic signal was in fact brain or patient specific. The results are 
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depicted in Figure 3-7. In general, a higher activation was observed in response to the patient 
tissue > unrelated MS patient > meningitis patient. This effect could not be eliminated 
completely by blocking with the pan-MHC class I antibody. At face value, this observation may 
be attributed to the expression of an antigen that is specific to the MS patient, but also found in 
other brain samples. This experiment would need to be repeated with an antibody capable of 
blocking MR1 in order to obtain significant results. 
 
 
 
Fig. 3-7: TCR activation in response 
to brain tissue 
The number of GFP+ cells observed per 
mm2 (sq.mm) of the scanned area was 
plotted for each tissue sample tested in 
the presence (black) or absence (grey) 
of the pan-MHC class I blocking 
antibody (clone W6/32). Unstimulated 
cells (Unstim.) were used as a negative 
control. Tissue test samples were 
sourced from the MS patient in whom 
the TCR was detected (Pat. FE); an 
unrelated MS patient (Pat. MS-1) and a 
meningitis patient (Pat. M) 
 
3.3.2 Human brain extracts 
Next the TCR was investigated in the context of brain derived antigens that were present in 
human brain white matter (WM) and grey matter (GM) homogenates. In addition, the 
glycoprotein fractions were also tested. The extracts were added to a (HLA matched) fraction of 
peripheral blood cells that contained dendritic cells and macrophages and were capable of 
endocytosing external protein, processing it and presenting it subsequently via the HLA 
molecules on the surface. The hybridoma cells were incubated with a murine CD3 antibody 
(clone 145-2C11) to mimic TCR activation in the positive control and no antigen was added in 
the negative control. The TCR activation was measured by estimating the IL-2 secreted in the 
supernatant by the hybridoma cells. The outcome of the experiment is presented in Figure 3-8. 
No activation was observed in response to the human brain extracts of the white and grey matter 
fractions. Via the positive control it was ascertained that the TCR was functionally active. 
Absence of activation may be due to low amounts or inadequate processing of the antigen. 
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Fig. 3-8: TCR response to human brain extracts 
The BV1-BJ2.3/AV7.2-AJ33 TCR hybridoma was co-cultured with a (patient FE HLA matched) fraction of 
peripheral blood cells containing dendritic cells and macrophages that presented antigens derived from brain 
homogenates. TCR activation was measured as a function of secreted IL-2. No significant response was elicited 
from the tested fractions. CD3 cross-linked (antibody clone 145-2C11) TCR hybridoma cells served as positive 
control and gave a measurable response. Unstimulated cells (Unstim.) were used as the negative control. WM: white 
matter; GM: grey matter; glyc: glycoprotein fraction. The brain extracts were provided by E. Meinl (MPI of 
Neurobiology) 
 
 
3.3.3 Autologous antigens and EBV derived antigens 
The examination of autologous or ‘self’ antigens is an integral part of studying autoimmune 
conditions.  In addition, antigens of microbial origin that may mimic the autologous antigen or 
be inherently self-reactive have also been implicated in autoimmunity and MS immune 
pathogenesis (Hafler 1999; Van Noort et al. 2000). More specifically, the Epstein-Barr virus 
(EBV) has been linked to MS incidence (Serafini et al. 2007) making it an interesting candidate. 
 
With the intention of testing these two hypotheses, the BV1-BJ2.3/AV7.2-AJ33 TCR hybridoma 
cells were co-cultured along with patient FE derived autologous B cells that had been 
transformed with EBV. These B cells carry all patient specific HLA molecules, and are hence 
capable of presenting EBV antigens of the latent phase in addition to autologous antigens. In a 
parallel experiment, the B cells were transfected with ‘lytic phase inducing’ plasmids BZLF1 and 
BRLF1 (gift of Prof. Miller, Yale University) prior to co-culture, so that they were capable of 
presenting lytic phase antigens as well. CD3 stimulation (antibody clone 145-2C11) of the cells 
was used as a positive control while absence of antigen served as the negative control. IL-2 
secreted in the cellular supernatant was a measure of activation. The results are summarized in 
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the following Figure 3-9. The hybridoma cells were not activated to a level that was clearly 
distinguishable from that of the negative control. Such low levels of IL-2 production cannot 
indicate antigen recognition based TCR activation.  
 
 
 
Fig. 3-9: TCR response to autologous and EBV derived antigens 
The BV1-BJ2.3/AV7.2-AJ33 TCR hybridoma cells were co-cultured with EBV transformed autologous B cells of 
patient FE. (a) No IL-2 could be detected in the supernatant from the co-cultures. CD3 crosslinked cells (antibody 
clone 145-2C11) served as a positive control and showed a measurable response. Unstimulated cells (Unstim.) 
served as negative control. EBV-B lytic: EBV transformed B cells of patient FE that had been induced to enter the 
lytic phase of viral life cycle; EBV-B latent: EBV transformed B cells of patient FE that carried the virus in latency. 
(b) The co-culture of the MAIT TCR hybridoma (white arrows) that are seen as rounded, isolated cells and EBV 
transformed autologous B cells of patient FE (yellow arrows) that are larger in size, and clumped together. The scale 
bar corresponds to 20 µm. 
 
 
3.3.4 Myelin derived MS candidate antigens 
Myelin derived antigens such as myelin oligodendrocyte protein (MOG), myelin basic protein 
(MBP) and neurofascin are believed to be the antigenic targets in MS based on a number of 
studies in animal models of the disease. These candidates were also tested by presentation via a 
(HLA matched) fraction of peripheral blood cells that contained dendritic cells and macrophages 
that were co-cultured with the BV1-BJ2.3/AV7.2-AJ33 TCR bearing hybridoma cells. TCR 
activation was measured based on amounts of secreted IL-2. The outcome of this study is 
depicted in Figure 3-10. No significant IL-2 secretion could be detected in response to myelin 
derived MS candidate antigens. This indicates non-recognition of these antigens by the TCR. 
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Fig. 3-10: MAIT TCR response to myelin derived MS candidate antigens 
BV1-BJ2.3/AV7.2-AJ33 TCR hybridoma cells were co-cultured with a (patient FE HLA matched) fraction of 
peripheral blood cells containing dendritic cells and macrophages that presented the candidate antigens to the TCR. 
TCR activation was measured as a function of secreted IL-2. No significant response was elicited from the tested 
molecules. CD3 crosslinked cells (antibody clone 145-2C11) served as a positive control, validating the 
functionality of the TCR. Unstimulated cells (Unstim.) served as the negative control. MBP: myelin basic protein, 
MOG: myelin oligodendrocyte protein, NF: neurofascin (isoforms 155 and 186) 
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3.4 MAIT antigen unbiased search: screening of PECP libraries 
The failure to detect the antigen of the BV1BJ2.3-AV7.2-AJ33 TCR by screening of 
‘ubiquitously expressed’ and ‘candidate MS’ antigens made it necessary to apply an unbiased 
method of antigen search. At this stage, it became known that the BV1-BJ2.3-AV7.2-AJ33 TCR 
might be a MAIT TCR. The 58
-/-
 cell line expressing the entire TCR complex (MAIT TCR, CD8, 
and NFAT-GFP) is from now on referred to as the MAIT hybridoma. Since not much is known 
about the antigen specificities of this TCR, the need for an unbiased method of antigen search 
was great. Such a method would not only have to allow the screening of all possible peptide 
antigens, but also ensure proper antigen processing and presentation to the TCR. In addition, the 
method would have to be sensitive enough to detect even the lowest levels of activation and have 
a scheme in place that would allow for the isolation of the antigen. Keeping all of the above in 
mind, the combination of plasmid encoded combinatorial peptide (PECP) libraries combined 
with the NFAT-GFP TCR activation readout was applied for antigen search (Siewert et al., in 
press). 
 
3.4.1 Library synthesis (A0101, B0801) 
MHC class I molecules are capable of presenting peptides that are 8-10 amino acids in length. In 
addition, these peptides contain conserved amino acid residues or ‘anchor positions’ that are 
specific to the MHC class I molecule that binds them. For example peptides presented by MHC 
class I molecule A*0101 are anchored at position 3 and 9 by an aspartic acid and tyrosine residue 
(Figure 3-11). Keeping the above in mind, the plasmid encoded combinatorial libraries (PECP) 
were designed to code for nonamers (9 amino acid length) that carried the specific anchor 
molecules for preferential binding to a specific MHC class I molecule. Opposed to a randomized 
library, an anchored library is composed of an increased number of peptides capable of being 
presented by the HLA molecule. This in turn adds greatly to the potential repertoire of antigens 
that a TCR may recognize and hence bind to. The PECP libraries were all designed in a similar 
manner, and several copies were generated. HLA matched PECP libraries take conserved amino 
acid anchors into consideration and code for antigenic peptides that would best bind to a given 
HLA molecule.  
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The patient FE is homozygous for HLA-A*0101, -B*0801 and -Cw*0701 (Skulina et al. 2004). 
PECP libraries were generated for the HLA molecules whose anchor positions are known and 
well defined, that is the HLA-A*0101 and HLA-B*0801. A randomized unbiased PECP library 
called the N library (provided by Katherina Siewert) was used to investigate other HLA 
molecules that are not as well defined such as HLA-Cw*0701 or the MHC class I related protein 
(MR1). At this stage, it was known that the BV1-BJ2.3/ AV7.2-AJ33 TCR might be a MAIT 
TCR that was restricted by MR1. 
 
The nonamer coding region of the library was 27 nucleotides long. It is flanked upstream by a 
Kozak sequence and start codon and downstream by a stop codon to ensure correct initiation and 
termination of the peptides during translation. This region was further flanked by two ‘rare 
cutting’ restriction enzyme recognition sites of 8 nucleotides each (upstream: NotI, downstream: 
AscI). The presence of these sites ensures that the frequency of randomly occurring restriction 
sites remains low (more than 16 fold less than a 6 nucleotide recognition site restriction enzyme), 
hence facilitating accurate cloning of fragments. Randomized nucleotide sequences often code 
for stop codons, and this can inadvertently lead to the generation of truncated and non-functional 
peptides. To lower the incidence of such randomized stop codons, guanine and thymidine 
residues were exclusively introduced at position three of every codon. This ensured that the total 
number of codons was reduced by half while the stop codons were reduced from three to one. 
Hence, for a randomized library, the number of non-functional truncated peptides was decreased 
from 35 % to 25 %. The sequence details of the libraries used in this study are summarized 
below in Figure 3-11. 
 
a. Randomized nonapeptide library/ N library (N27-K) 
 
AscI 
AscI 
NotI 
NotI 
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b. HLA-A *0101 matched nonapeptide library (A1-39-K) 
 
 
c. HLA-B *0801 matched nonapeptide library (B8-359-K) 
 
 
Fig. 3-11: PECP libraries generated for antigen search 
Pictorial representation and electropherograms of the peptide coding region (blue) of the PECP libraries generated 
for antigen search. The nonamer coding amino acid residues are flanked on either side by rare cutter restriction sites 
of AscI and NotI (grey). They begin with a guiding kozak sequence, the start codon (green) and finish in the stop 
codon (red). The remainder sequence of the expression plasmid has not been presented in this figure. For all the 
three libraries, the upper panel depicts a schematic of library design followed by the electropherogram of the actual 
library. In the cDNA sequences depicted in blue, ‘N’ represents the presence of any of the four (adenine, cytosine, 
thymidine and guanine) residues while a ‘K’ residue corresponds to a guanine or thymidine residue. (a) N27-K 
library encoding randomized nonapeptides (provided by Katherina Siewert, MPI of Neurobiology). This library was 
applied in searching for the MAIT antigen as the MR1 anchor residues are unknown. (b) A1-39-K library containing 
nonapeptides anchored at positions 3 and 9 by aspartic acid (D) and tyrosine (Y) residue. (c) B8-359-K library 
containing nonapeptides anchored at positions 3, 5 and 9 by a lysine (K), lysine or arginine (R) and leucine (L) 
residue respectively. The anchor positions are depicted in blue numerals. 
AscI 
NotI 
NotI 
AscI 
AscI 
AscI 
NotI 
NotI 
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3.4.2 TCR Activation by the unbiased PECP (N) library 
The MAIT antigen is unknown to this date. Some studies strongly argue in the favor of it being a 
peptide (Huang et al. 2005; Miley et al. 2003) but there are other reports that support it being a 
lipid (Shimamura et al. 2007). To test whether the antigen was a peptide, the activation of the 
MAIT TCR in response to a plasmid encoded combinatorial library (PECP) was examined. 
MAIT TCR hybridoma cells were co-cultured with antigen presenting cells (COS-7) that had 
been transfected with the expression vectors for the PECP N-library and one HLA molecule. The 
different MHC class I molecules (HLA-A*0101, -B*0801, -Cw*0701) of the patient FE and 
MR1 were tested. Untransfected COS-7 cells were used as negative control.  
 
Activated GFP + hybridoma cells were observed in all experiments, including the control. This 
indicated a ‘background’ level activation of the MAIT TCR hybridoma cells. As a first step, the 
experiment was repeated on a larger scale and activation in response to each HLA molecule was 
quantified (Section 3.5). As MR1 is highly conserved amongst mammals, the same molecule 
from COS-7 (African green monkey cell line) that was used as an antigen presenting cell might 
be capable of presenting antigen to and activating the MAIT TCR. This presumably contributed 
to a ‘background activation’ of the MAIT TCR (Section 3.6 and 3.7) and posed a challenge in 
narrowing down the antigenic signal. In order to figure out the source of the background 
activation, it was necessary to quantify the observed signal and identify its source.  
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3.5 Investigation of HLA restriction of the MAIT TCR 
To confirm that the BV1-BJ2.3/AV7.2-AJ33 TCR isolated from the MS lesion of patient FE was 
indeed a MAIT TCR, it was necessary to study TCR activation in context of all patient MHC 
class I molecules and MR1. The antigen presenting COS-7 cells were transfected with the 
expression vectors for the randomized nonapeptide library (N library) in combination with the 
four different MHC molecules (A, B, C and MR1). As controls, COS-7 cells transfected only 
with MR1 or the library and untransfected cells were analyzed. At 48 and 72 hours after 
transfection, the MAIT hybridoma cells were co-cultured with the APCs. After 16 hours of co-
incubation, the GFP +, activated hybridoma cells were manually counted under the fluorescence 
microscope by two independent observers. 
Activated cells were observed in all samples including the controls, as represented in the 
following Figure 3-12. No exclusive bias for a particular MHC molecule was apparent, and the 
background activation was evident by the presence of GFP + cells in the negative controls 
(transfection of empty expression plasmid, and no transfection). However, the MAIT TCR 
hybridoma activation in response to the N library presented by MR1 was higher than in all other 
samples. This effect was maintained at samples checked at 48 and 72 hours after transfection. 
The activation was diminished post 72 hours in comparison to that at 48 hours. The experiments 
were carried out four times. In the first experiment, despite high background activation, the 
highest number of GFP + activated cells was observed in the samples where MR1 and the N 
library were co-transfected.  
This indicated that MR1 might be involved in antigen restriction to the MAIT TCR, but was not 
conclusive because the second follow up experiment showed a random distribution of activation 
and a high background. In order to reduce this background, the MAIT TCR hybridoma cells 
were extensively re-cloned to select clones with minimum background (Figure 3-13). During the 
third and fourth experiment (Figure 3-12), the MR1-N library sample consistently contained 
more activated cells than the other HLA class I molecules. These observations indicate that MR1 
might indeed be the appropriate antigen presenting partner for the MAIT TCR. However, the 
‘background activation’, that seems to be an inherent property of the MAIT TCR hybridoma, 
must be taken into account during antigen search experiments. Only the activation that was 
above this background level could be deemed as ‘real’ or coming from the real MR1 antigen.  
Results 
 
97 
 
 
 
 
 
Fig. 3-12: MAIT TCR activation by N library presented by different MHC molecules 
(a-f) Activated MAIT TCR hybridoma cells observed in co-culture with COS-7 transfected with (a) N library and 
HLA-A*0101 ,(b) N library and HLB-A*0801, (c) N library and HLA-Cw*0701, (d) N library and MR1, (e) empty 
expression plasmid and (f) untransfected COS-7 cells. (g) Plot of activated (GFP +) MAIT hybridoma cells counted 
per unit area (cm
2
) in response to the N library presented by different MHC molecules. The MAIT TCR hybridoma 
cells were co-cultured for up to 16 hours with COS-7 (APC) cells transfected transiently with the different HLA 
molecules. This experiment was repeated four times and the co-culture was initiated 48 and 72 hours post 
transfection. The GFP +, activated MAIT TCR hybridoma cells per unit area (cm
2
) was recorded for each HLA 
molecule to be tested. The three MHC class I alleles of the patient FE (only three, as the patient is homozygous) and 
the MHC Related molecule-1 (MR1) were tested. As negative controls, the empty pCDNA expression plasmid and 
untransfected COS-7 (APCs) were used. HLA: human leukocyte antigen, A1: A*0101, B8: B*0801, Cw7: Cw*0701 
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3.6 Background activation of the MAIT TCR 
The background activation observed might be due to an endogenous MAIT antigen sourced from 
the COS-7 cells or the cell culture media, the capability of COS-7 MR1 to present the MAIT 
antigen to human TCRs (Section 3.7) or even a clone with a TCR signaling defect. This situation 
might be circumvented by the selection of a more ‘stable’ clone by re-cloning (Section 3.6.1).  
 
3.6.1 Reduction of background activation by re-cloning 
Re-cloning of the MAIT TCR hybridoma cells was done to select a ‘stable’ clone that met two 
criteria. First, the background activation had to be as minimal as possible. In case the clone 
contained GFP + cells in the resting phase that were detectable by fluorescence microscopy, the 
clone was discarded to avoid picking of false positives. Second, in the presence of antigenic 
stimuli, the cells should respond with a high signal, that can be clearly measured by flow 
cytometry or observed with fluorescent microscopy. This could be simulated by TCR activation 
following CD3 cross-linking. It is important to point out that CD3 cross-linking does not furnish 
a 100 % response in 58
-/-
 TCR hybridoma cells. At no stage did the entire population respond 
completely, irrespective of the cell numbers and antibody concentration applied. This seems to 
be an inherent property of the cell line, and has to be accepted. The reduction in unspecific 
background in a resting, unstimulated phase and the increase in activation upon TCR activation 
due to cross-linking are depicted in Figure 3-13. 
 
In the three clones presented in the figure, clone 3 shows the optimal parameters, that is high 
activation upon CD3 cross-linking (up to 87% of the population is activated and GFP +). These 
cells were also clearly visualized via fluorescence microscopy (data not depicted here). Most 
importantly, clone 3 shows a very low background (0.14%), and the cells that are in the lower 
right quadrant (background) are not bright enough to be detected under the fluorescence 
microscope as false positives. This is not true for clone 2, which includes bright GFP+ cells in 
the resting phase, that were detected under the fluorescence microscope, and these could 
contribute to false positives during an experiment. 
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Fig. 3-13: Re-cloning reduces the background due to unspecific activation 
Flow cytometry histograms and scatter plots depicting the activation response (GFP expression) of three different 
MAIT TCR hybridoma clones following CD3 cross-linking (stimulation). This was done to simulate antigen 
recognition, in order to select a clone that responds specifically to antigen stimuli and has low background 
activation. The first column depicts histograms that show the stimulated sample in green and the unstimulated cells 
(negative control) in grey. This is followed by scatter plots divided into 4 quadrants based on the negative control. 
The lower right quadrant contains the fraction of the cell population that was GFP +. The cells were stained with the 
TOPRO 3 dye and only the live cells were gated and further analyzed.  
(a) Clone 1, depicted in the topmost panel, does not respond well to stimulation and contains cells that express GFP 
even in the absence of stimulation (background).             
(b) Clone 2, depicted in the middle panel, does show a strong response upon stimulation (up to 86% of the cells are 
GFP +) but also contains GFP + cells in the unstimulated fraction that were sufficiently bright to be detected as false 
positives under the fluorescence microscope. These are highlighted in the inset in a red box.  
(c) Clone 3, in the lowest panel, is an ideal case which shows low background and high activation only upon 
stimulation. The GFP + cells in the lower right quadrant of the unstimulated fraction (red box) were not visible 
under the fluorescence microscope. Hence, this clone may be used for further experiments. 
GFP 
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3.7 Investigation of cross presentation between monkey MR1 (COS-7) 
and human MAIT TCR 
MR1 is known to be conserved in mammals (Riegert et al. 1998), and hence it is quite likely that 
the African green monkey (COS-7) derived MR1 may be capable of antigen presentation to the 
human MAIT TCR. To examine this hypothesis, the COS-7 MR1 polypeptide sequence 
(provided by Wakiro Sato, MPI of Neurobiology) was compared with that of human MR1. The 
differences within human and African green monkey MR1 are depicted on a crystal structure of a 
MHC class I molecule (HLA-A*0201) in Figure 3-14.  
 
a1. a2. 
  
 
 
Fig. 3-14: Comparison of human and monkey (COS-7) MR1 molecules 
(a) The crystal structure (dark grey) of a MHC class I molecule (HLA-A*0201) (Orth et al. 2003) used as a template 
to compare amino acid exchanges between human and monkey MR1. These exchanges have been highlighted in red. 
The orientation of their side chains is also visible. All amino acid residues are named according to the standard one 
letter code. (a1) A top view of the MHC class I molecule that shows the α1/α2 domains that bind the peptide ligand 
and interact with the T cell receptor. (a2) The molecule viewed after turning it 90°C to the left. This view shows all 
the three (α1, α2, α3) domains of the MHC class I molecule in addition to the β2 microglobulin  (light grey). The 
monkey MR1 molecule differs from the human MR1 molecule at 16 amino acid residues within the α1, α2 and α3 
domain. 8 of these exchanges lie within the ligand binding α1/α2 domains and 8 lie within the α3 domain. These 16 
exchanges do not include any of the amino acid residues that are implicated to be important for interaction with the 
ligand and the T cell receptor (Huang et al. 2005). The structure was downloaded from the protein database 
(DOI:10.2210/pdb1qew/pdb) and molecular graphics images were produced using the UCSF Chimera package from 
the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco 
(supported by NIH P41 RR001081).  
α1 
α2 
α2 
α3 
β2m 
V 34 I 
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There are 16 amino acid exchanges between the human and monkey MR1 molecule, where 8 lie 
within the α1 and α2 ligand binding domains and 8 in the α3 domain. The residues at position 
161, 163 and 173 may lie in close proximity to the interacting TCR while all other residues are 
oriented away from the interaction surface. The exchange at position 161 (I161V) is 
conservative. At position 163, a polar glutamine (Q) residue is exchanged for a charged arginine 
(R) residue. The exchange at position 173 (L173R) is from a large hydrophobic aliphatic amino 
acid to a positively charged one. Further E181K (change from negative to positively charged 
residue) is present on the side of the model, but in the human MR1, it may be at the top of the 
helix. However, none of these exchanges are at positions that are thought to be responsible for 
interaction with the ligand or T cell receptor (Huang et al 2005). This suggests that despite the 
differences, the African green monkey MR1 may bind to its ligand in a manner similar to that of 
human MR1. 
 
The sequence similarity between the African green monkey and human MR1 is as high as 94%, 
and is second only to the relatedness between human and chimpanzee MR1 (99%). Within the 
ligand binding region of MR1, 3 residues are deemed most important (Huang et al. 2005) for 
ligand positioning and discrimination. All these residues are perfectly conserved in the human 
and African green monkey MR1. This indicates that the MR1 from the African green monkey 
might very well be capable of presenting the MAIT antigen to and activating the human MAIT 
TCR. In view of the background activation, MAIT TCR activation arising from an endogenous 
antigen presented by the monkey MR1 cannot be prevented. This background has to be 
accounted for in all experiments, and only activation above this level may be deemed as ‘real’ or 
coming from an actual antigenic stimulus. 
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3.8 TCR activation by antigen pools isolated from single APCs 
Once it was observed that the MAIT TCR activation was higher than the background in the 
presence of the N library and human MR1, the MAIT antigen was searched for using MR1 
presented N library. MR1 expressing COS-7 cells were transfected with the N library and co-
cultured with the MAIT TCR hybridoma. APCs underlying GFP + MAIT hybridoma cells were 
isolated. APCs were only isolated when the hybridoma was well attached to the APC surface to 
avoid picking false positives. Due to the presence of the background, it was necessary to screen a 
large number of cells in order to locate the antigenic signal. Some representative examples of 
APC isolation by microcapillary during antigen search experiments are presented in Figure 3-15. 
 
 
 
Fig. 3-15: Isolation of APCs (COS-7 cells) from co-culture with MAIT TCR hybridoma cells 
Images acquired by fluorescence microscope at 10x magnification. MAIT TCR hybridoma cells were co-cultured 
with COS-7 cells that stably expressed human MR1 and transiently expressed the randomized PECP nonapeptide N 
library. 16 hours after co-culture, activated hybridoma cells were detected under a fluorescence microscope and the 
underlying COS-7 cell was isolated. (a-c) Antigen presenting COS-7 cell in direct contact with an activated (GFP +) 
MAIT TCR hybridoma cell (depicted with yellow arrow) from three different experiments. (d-f) Image after the 
COS-7 cell has been isolated from the cell culture dish by a microcapillary (microcapillary not in image). 
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To this end, 267 single cells were isolated and the library plasmids within them were amplified 
in separate single cell PCRs to create smaller plasmid pools, henceforth called sub-pools, from 
the mother library. These sub-pools were re-cloned into the pcDNA backbone either via 
directional TOPO cloning or conventional restriction digestion followed by ligation. The sub-
pools were then co-transfected with MR1 into the COS-7 antigen presenting cells for a second 
round of screening. To enhance the signal, cells were re-picked and these smaller sub-pools were 
then screened as mentioned above. However, in subsequent rounds of screening, the activation 
signal could not be enhanced or enriched especially because in some cases it was difficult to 
differentiate between ‘background’ and ‘real’ TCR activation. Hence, this method could not be 
applied for identifying the antigen of this particular TCR. 
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3.9 Investigation of the MR1 anchor residues 
3.9.1 Expression of recombinant human MR1 and β2 microglobulin 
The application of an unbiased plasmid encoded peptide library for the identification of the 
MAIT TCR may have been unsuccessful due to the fact that the binding anchors of MR1 are not 
known. A MR1 anchored library would contain only those antigens that would bind MR1, and 
hence increase the chances of the correct mimotope causing activation. To fulfill this need, a 
pragmatic approach was devised that would provide the first insights into MR1 anchor positions. 
This could be achieved by analysis of endogenous MR1 ligands (whose sequences would 
represent the MR1 anchor positions if they did exist). If MR1 follows a pathway similar to that 
of MHC class I molecules, it would only translocate from the endoplasmic reticulum to the 
surface when bound to an endogenous peptide. Recombinant human MR1 (associated with β2 
microglobulin) may be used for screening chemically synthesized peptide libraries. Elution of 
the bound peptides, and subsequent sequencing would shed light on the MR1 anchor positions.  
 
To this end, human MR1 and ß2 microglobulin were cloned into pTT5 vectors (vector maps 
presented in Appendix II) for expression in HEK293E cells. The pTT5 vector was previously 
used in our laboratory for the expression of monovalent Fab fragments (Birgit Obermeier, MPI 
of Neurobiology). The leader sequences of the Fab fragments were combined with the MR1 and 
β2 microglobulin sequence (Heavy chain leader => MR1, light chain leader => β2 
microglobulin) as it was known that these leader sequences facilitated the secretion of the Fab 
fragments into the cell supernatant (personal communication from Klaus Dornmair and Birgit 
Obermeier, MPI of Neurobiology). In the MR1 construct, the MR1 coding region was followed 
by a myc tag and polyhistidine (His(6)) tag to allow for purification and detection of the protein. 
These experiments were done in collaboration with Wakiro Sato (MPI of Neurobiology).  
 
MR1 was secreted in the supernatant in low quantities of approximately 7-10 µg from 3x10
8
 
cells. As reported by others, the majority of the MR1 protein was retained within the cells (Miley 
et al. 2003, Le Bourhis et al. 2011). It is believed that in the absence of a binding partner, the 
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MR1 is unable to leave the endoplasmic reticulum, and is retained there. β2 microglobulin was 
secreted and detected both in the supernatant and cell lysate.  
 
MR1 and ß2 microglobulin were detected in both supernatant and cell lysate by western blot. 
The cellular supernatant and lysate were separated by SDS-PAGE (4-20% gradient gel) and then 
transferred to a PVDF membrane. The MR1 was detected at 38 kDa via the myc tag (antibody 
clone 9E10.3, raised in mouse) followed by a secondary HRP-coupled anti mouse antibody that 
was detected by chemiluminescence. The β2 microglobulin at 12 kDa was detected via a 
polyclonal antibody against human β2 microglobulin followed by the secondary HRP-coupled 
anti mouse antibody that was detected by chemiluminescence. (Figure 3-17). 
 
 
Fig 3-16: Western blot of the recombinantly expressed human MR1 and β2 microglobulin 
20 µl of the undiluted supernatant from 3x 10
8 
cells and 20 µl of cellular lysate from 5x 10
4
 cells were run under 
reducing conditions on a gradient gel (4-20%), separated on the basis of molecular weight and immobilized onto a 
PVDF membrane. (a) MR1 (38 kDa) was detected via the C terminal myc tag followed by a secondary HRP-
coupled anti-mouse antibody. This was detected by chemiluminescence. Exposure time: 15 seconds (b) The β2 
microglobulin (12 kDa) was detected using a polyclonal antibody preparation that recognizes human β2 
microglobulin followed by a secondary HRP-coupled anti-mouse antibody. This was detected by 
chemiluminescence.. Exposure time: 5 seconds 
  
 
 
3.9.2 Analysis of MR1 bound peptides 
In order to learn more about the anchor positions of the human MR1 molecule, a nonamer 
positional scanning synthetic combinatorial peptide library was screened with recombinant MR1. 
The bound peptides were eluted by treatment with 0.2% trifluoroacetic acid and analyzed by 
Edman degradation (Reinhard Mentele, MPI of Biochemistry) and mass spectrometry (Forne 
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Ignasi, LMU). The reverse phase HPLC run of the phenylthiohydantoin-amino acids analyzed by 
Edman degradation sequencing is presented in Appendix IV. There was no discernible signal 
detected above the background. No pattern, that could be suggestive of fixed anchor positions, 
was observed in the elution profile. When analysed by mass spectrometry, 38 nonapeptides were 
sequenced. The nonapeptides analyzed by mass spectrometry do not reveal highly conserved 
residues, albeit a pattern that is presented as a frequency plot in Figure 3-18. MR1 seems to bind 
to peptides that begin and end with a positively charged amino acid with a hydrophobic stretch in 
between. The peptide sequences are listed in Appendix V. 
 
 
 
Fig. 3-17: Frequency plot of nonapeptide sequences 
The nonapeptide sequences obtained from mass spectrometry analysis were analyzed with the WebLogo software 
(Crooks et al. 2004). The amino acids are represented in the standard one letter code. The plot consists of a stack of 
letters, and each position corresponds to one stack. The height of each letter corresponds to the relative frequency of 
each amino acid at that particular position. For the nonapeptides pulled down by MR1, there is no stringent sequence 
conservation of a residue at any one particular position but we may discern an overall pattern starting with a 
positively charged or large aliphatic residue followed by a second large hydrophobic residue at position 2. This is 
followed by a relatively hydrophobic patch extending from positions 4 to 7. Position 8 may comprise of a 
hydrophobic or charged residue and the peptide ends in a positively charged residue like arginine (R).  Color code: 
KRH (positive charge): blue, DE (negative charge): red, NQ (polar): pink and AVLIPWFM (large, hydrophobic): 
black. N: amino terminal, C: carboxyl terminal, #1-9: amino acid positions 
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4 Discussion 
 
Multiple Sclerosis (MS) is an autoimmune condition mediated in part by autoaggressive T cells 
that infiltrate the central nervous system in large numbers, and bring about the hallmark 
inflammatory demyelination that leads to plaque formation. The immunopathogenic components 
of this phenomenon, in particular the mechanism of T cell activation and the identity of target 
antigens is not known. Methods to characterize the specificity of T cell mediated immune 
responses would greatly benefit the understanding of autoimmune disorders in general. To cover 
this gap of knowledge, a two pronged PCR approach that could amplify αβ TCR re-arrangements 
either selectively or in an unbiased manner was applied.  
 
Over thousand single cells were analyzed, and a total of nine T cell receptors (TCRs) were 
identified in twenty eight cells of patient FE (Section 4.1). Of these, four were found in a 
collaborative effort and belong to the mucosal-associated invariant T cell (MAIT) subset 
(Section 4.2). The remaining five are apparently CD8+ effector T cells. The MAIT TCRs and 
one effector TCR were recombinantly expressed in a mouse cell line and the dominant MAIT 
clonal expansion (BV1-BJ2.3/ AV7.2-AJ33) was focused on for antigen characterization. Efforts 
in this direction included the screening of candidate antigens (Section 4.3), investigating the 
antigen restriction of the MAIT TCR (Section 4.4), screening of an unbiased plasmid encoded 
peptide library (Section 4.5) and investigating the anchor positions of the MHC class I related 
molecule MR1 (Section 4.6). 
 
 
4.1 Characterization of TCR chains from MS brain 
This study is first of its kind in applying a multiplex RT PCR approach for the detection of 
matching TCR α- and β- chains from clonally expanded CD8+ T cells in the MS brain (Section 
4.1.1). All of the detected TCR pairs were expanded in the brain of the patient, and are expected 
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to contribute to the course of the disease. Clonal expansion is a hallmark of activated cells that 
have multiplied locally upon antigenic stimulus, meaning that these T cells recognize a local 
antigen. In three instances identical β-chains were found in combination with more than one α-
chain, giving rise to similar but distinct TCR heterodimer molecules (Section 4.1.2). 
Furthermore, some clonal expansions were found in different tissue blocks and were not 
restricted to one anatomical site within the MS brain (Section 4.1.3). The technical aspects of the 
method will be discussed in Sections 4.1.4. 
 
 
4.1.1 Significance of the technique for studying T cells and their targets 
T cells play an important role in protective immune responses against threats like microbial 
infections and tumors as well as pathogenic responses in autoimmune diseases like multiple 
sclerosis. The approach used in this study for the characterization of T cell receptors may be 
applied in any of the above situations to delineate the immune mechanisms of T cell responses. 
Unlike earlier efforts that adopted indirect approaches such as fragment length analyses, random 
cloning and sequencing of TCR cDNA to characterize TCRs (Biddison et al. 1989; Beall et al. 
1989; Wucherpfenning et al. 1992), the current PCR based technique allows for the direct 
characterization of paired αβ TCR chains from single T cells. TCR analysis at the level of the 
single cell would provide a better picture of a complex T-cell population such as oligoclonal 
expansions that are observed in pathogenic, protective and autoimmune responses. Moreover, it 
allows for the study of a small number of cells that may be important because of their activation 
markers, their location in the tissue or the subgroup that they belong to, like MAIT cells (Le 
Bourhis et al. 2011).  
 
The study of the resulting infiltrate, be it pathogen-, tumor- or autoimmunity driven is often 
complicated by the presence of bystander cells (Moebius et al. 1990; Hofbauer et al. 2003; 
Matsumoto et al. 2003). The current technique enables the study of specific T cell clones by the 
application of CD8 co-receptor and/or TCR specific antibodies coupled with single cell isolation 
by laser microdissection. The use of unbiased primer pools for both α- and β-chain 
rearrangements affords further independence from the limited repertoire of commercially 
available TCR antibodies. Ultimately, the cDNA of TCR chains recovered from patient samples 
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may be used to reconstruct the receptor in an experimental system such as a TCR hybridoma cell 
line (Seitz et al. 2006) or animal model (Madsen et al. 1999) to characterize their antigenic 
specificity. In the current study, more than half of the characterized TCRs were reconstructed, 
and one was applied in antigen studies. This would eventually lead to functional and disease 
progression studies in response to particular antigenic stimuli and improve our understanding of 
immune reactions of unknown specificity such as those in MS.  
 
 
4.1.2 Identical TCR β-chains pair with different α-chains 
In three instances, the same β-chain (BV1-BJ2.3, BV6.5-BJ2.2 and BV8.1-BJ1.1) was found to 
be coexpressed with more than one α-chain in patient FE. The BV1-BJ2.3 TCR β-chain persisted 
in the patient for seven years and during this time was detected in blood, cerebrospinal fluid 
(CSF) and brain tissue (Babbe et al. 2000, Skulina et al. 2004). It was coexpressed with four α-
chains that are identical or related to the invariant α-chain of the MAIT sub-population. The 
significance of detecting MAIT cells in the MS brain has been addressed in Section 4.2. All four 
TCR pairs share the identical β-chain and the CDR1, CDR2 regions of the α-chains. The CDR3 
region, that is important for antigen binding and recognition, is very similar and the joining 
regions are not identical. On aligning these sequences, as depicted in Figure 4-1, one notices that 
in three out of four TCRs, the CDR3 region begins with arginine, a positively charged amino 
acid. This is followed by a negative residue (aspartic acid).  
 
In two other cases, the dominant BV6.5-BJ2.2 and BV8.1-BJ1.1 clonal expansions were found to 
be coexpressed with two different functional α-chains (Figure 4-1).  In case of the BV6.5-BJ2.2 
β-chain, the two α-chains share the identical variable region. Such relatedness might point to the 
recognition of identical antigenic epitopes, or even antigen driven TCR development. 
Considering the fact that MS pathogenesis has a T cell mediated component, such oligoclonally 
expanded T cells, especially those isolated from the site of the autoimmune attack, would be of 
high significance in understanding the disease. 
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a. 
 
b. 
 
c. 
 
 
Fig. 4-1: Three instances of TCRs where an identical β-chain pairs with more than one α-chain 
The peptide sequences depict the terminal variable region (β-chain: blue, α-chain: purple), followed by the CDR3 
region (red) that plays a pivotal role in antigen binding and recognition, and the joining region (green). TCRs were 
named in accordance with the Arden nomenclature. The underlined residues represent the ‘FGXG’ consensus 
sequence of the joining region. (a) All four MAIT TCRs share the identical BV1-BJ2.3 β-chain (blue), and are 
homologous. This work was done in collaboration with Klaus Dornmair, Joachim Malotka, David Laplaud and 
Katherina Siewert. (b) The two α-chains that are coexpressed with the BV6.5-AV2.2 chain carry the identical 
variable region and joining regions of comparable length. (c) The BV8.1-BJ1.1 chain is coexpressed with two α-
chains where the CDR3 regions are similar in length unlike the joining regions. 
 
Similar results have been reported in earlier studies. A study in a mouse tumor model reported 
the pairing of several distinct albeit structurally related α-chains with the same expanded β-chain 
in infiltrating T cells (Hamrouni et al. 2003). Further evidence comes from the study during 
which the technique used in this study was developed. In the study of inflammatory muscle 
disease, the authors described a case in which three α-chains paired with the same β-chain (Seitz 
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et al. 2006). Taken together, these data suggest that the same antigen may recruit related or 
‘sister’ αβ TCR heterodimers and influence TCR development. This situation may occur when 
the antigen-driven T cell expansion selects the two different clones with an identical β-chain 
rearrangement, but distinct α-chain rearrangements.  
 
Alternately, the same T cell clone may also express two distinct α-chains simultaneously, but 
inadequate mRNA preservation may allow the detection of only one α-chain from the cell. The 
existence of such ‘dual TCRs’ was shown for α-chains (Padovan et al. 1993; Heath et al. 1995) 
in humans and mice. The expression of one specific TCR is usually guaranteed by the defined 
order of TCRα and TCRβ gene locus rearrangements during T cell development. First, one 
TCRβ chain locus is rearranged followed by the expression of the TCRβ chain in combination 
with the constant pre-TCR α-chain on the cell surface (Saint-Ruf et al. 1994). This triggers cell 
proliferation and halts further β-chain rearrangement. After this, the TCRα locus is rearranged. 
However, T cells expressing more than one TCR can be formed if incomplete allelic exclusion 
takes place. This happens relatively often for the TCR α-chain, and it was proposed that up to 
30% of human T cells can contain two rearranged TCRα gene loci and can express two different 
TCRs (Padovan et al. 1993). It was suggested that these naturally occurring dual TCR cells can 
contribute to the high proportion of alloreactive T cells (Morris and Allen 2009). In view of these 
results it is clear that a ‘dual’ TCR with different specificities could play a relevant role in an 
autoimmune disease like MS. 
 
 
4.1.3 Incidence of identical clonal expansions in different anatomical sites 
Some of the clonally expanded T cells were not limited to one tissue block and may be thought 
of as ‘pervasive’ as they are not restricted to one anatomical site within the brain of patient FE. 
The three tissue blocks are different parts of the same lesion that was surgically removed from 
the patient’s brain. The presence of ‘pervasive clones’ confirmed the observations of an earlier 
study (Junker et al. 2007) where MS brain infiltrating T cells were detected in different 
anatomical regions of the brain. This widespread presence may be due to an antigen that is 
ubiquitously expressed in brain tissue but not equally available due to differential processing of 
local APCs. This in turn would prompt the responsible T cell clone to widen its antigen search 
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and not restrict itself to a particular region. Moreover, CD8+ T cells were observed to infiltrate 
both white matter (WM) and grey matter (GM) in the tissue of patient FE. It would be interesting 
to make a comparative study of the TCR repertoire of CD8+ T cells infiltrating the WM and GM  
as discussed in Section 4.7.1.  
 
4.1.4 Technical challenges of TCR characterization 
The characterization of nine TCRs from the MS brain demonstrates the successful application of 
this approach. However, the TCR yield is restricted due to some technical challenges. The first 
challenge arises due to compromised mRNA quality that is a result of inadequate preservation in 
frozen tissues. Even though degradation of RNA during staining and cell isolation procedures is 
minimized by a short staining protocol facilitated by the use of directly labeled antibodies and 
RNAse inhibitors, the yield of TCR sequences is low. This difference is evident from the better 
RNA integrity from RNA extracted from freshly isolated live cells, and higher yields when the 
same technique is applied (Section 3.1.2.2). Data representing the difference in RNA quality 
between the frozen tissue from patient FE in comparison to that from live peripheral blood 
lymphocytes is represented in Appendix III. This loss of RNA quality might be a result of non-
optimal tissue isolation, wherein the tissue sample was not immediately placed under 
refrigeration. The mRNA quality is further compromised during cryostorage and frequent freeze-
thaw cycles during section preparation. To resolve this problem, one would have to ensure that 
the time between tissue isolation and cryostorage is reduced to the minimum. Ideally, the tissue 
should be placed directly on dry ice post isolation and then moved to 80°C. Moreover, freeze 
thaw cycles should be minimized and fresh cryosections should be used whenever possible. The 
tissue may also be immediately fixed in a RNA preserving fixative (Vincek et al. 2003) that 
preserves histomorphology. 
 
The second challenge is the fact that the tissue is cut into 10 µm sections for optimal isolation by 
laser microdissection. Since T cells have a diameter ranging from 7-20 µm, there is a possibility 
that the cell is cut away or partially damaged during sample preparation. This could allow the 
mRNA to get washed out of the cytoplasm during the staining procedures, lowering the 
efficiency of the PCR. Since increasing the thickness of the tissue section would impair cell 
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isolation, this is not an option. One may consider minimizing the number of intermittent washes 
or crosslinking the RNA to the cell membrane, in order to reduce RNA loss.  
 
Thirdly, this method requires the simultaneous use of multiple primers in one PCR reaction. 
Unspecific interactions between different primer oligonucleotides may make them unavailable 
for template amplification. In order to sufficiently cover the entire T cell receptor repertoire, a 
pool of primers must be applied. One may think of adding a pre-amplification step that amplifies 
the cDNA in a sufficient quantity such that this may be further amplified in nested reactions with 
multiple pools containing fewer primers.  
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4.2 Characterization of MAIT cells in the MS brain 
Four TCRs characterized from patient FE belong to the mucosal-associated invariant T (MAIT) 
cell subset. MAIT cells are a T cell subset that has a limited germ-line encoded TCR repertoire 
(Porcelli et al. 1993; Tilloy et al. 1999) characterized by an invariant TCR α-chain. They are 
named based on their preferential residence in the gut mucosa. MAIT cells are CD4
-
/CD8
-
 or 
CD8
α/α
, constitute up to 4 % of all blood T cells in a healthy individual and are believed to 
function at the interface of the innate and adaptive immune system (Porcelli et al. 1993). Antigen 
presentation is restricted by the MHC related molecule I (MR1). To date, the exact function of 
MAIT cells in diseased and healthy individuals, as well as the identity of the MAIT TCR ligand 
is unclear. 
 
4.2.1 The significance of MAIT sister TCR pairs found in the MS patient 
The four MAIT sister pairs found in MS patient FE are interesting for various reasons. First, all 
TCRs share the identical β-chain. Second, this β-chain is part of a clonal expansion that persisted 
in the patient for seven years, and was detected in both blood and brain tissue. Third, one of the 
α-chains is the classical invariant (AV7.2-AJ33) MAIT chain. This chain was detected seven 
times from MS brain infiltrating CD8+ T cells. Fourth, all four α-chains demonstrate a sequence 
homology within the ‘antigen recognizing’ CDR3 regions (Fig. 4-1). This observation may point 
to the fact that all the 4 MAIT TCRs recognize a common antigenic epitope and that the α-chains 
evolved under its influence. These results also present a first time report of MAIT sister pairing 
with the BV1 β-chain.  
 
4.2.2 Proposed role and significance of MAIT cells in autoimmunity and MS 
Interesting evidence comes from a report (Berer et al. 2011) where the contribution of 
commensal microflora to autoimmune demyelination was demonstrated in an animal model of 
MS. The commensal gut microbiota was shown to be capable of triggering a relapsing-remitting 
course of the disease in the absence of pathogenic agents, and also played a role in B cell 
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recruitment and activation. In light of the fact that MAIT cells preferentially reside in the gut 
mucosa and recognize microbial antigens (Gold et al. 2010; Le Bourhis et al. 2010), their 
detection in the MS brain might indicate their involvement in microbiota mediated 
autoimmunity. Another study (Miyazaki et al. 2011) showed that MAIT cell numbers in 
peripheral blood of MS patients were reduced in comparison to healthy controls. This number 
was influenced by course of disease being lower during active disease and increasing with 
clinical recovery. The MAIT cells also suppressed the IFN-γ production of T cells in vitro 
indicating that they might play a role in regulating pathogenic Th1 cells in MS. 
 
The invariant MAIT α-chains were all found to be coexpressed with a β-chain that persisted in 
the patient in detectable numbers for a prolonged period of time. Up to seven years after the 
disease was first diagnosed, this clone was detected in peripheral blood, as well as in brain 
biopsy tissue. This indicates that the MAIT cells did contribute not only to the early stages of MS 
in this patient, but also played a part in the stages that followed. In the light of these 
observations, it is interesting to note that MAIT cells home to the gut mucosa where they 
naturally come in close contact with the commensal microflora. This interaction could follow on 
the lines of molecular mimicry, and prime effector T cells to recognize a ‘self’ antigen, while 
priming MAIT cells to regulate this autoimmune T cell population. The ability of MR1 to present 
a self-ligand has been shown in the context of rare MAIT cell hybridomas that were activated by 
uninfected, MR1-overexpressing cells (Treiner et al. 2003; Huang et al. 2009).  In the course of 
an autoimmune attack, the MAIT cells would leave the periphery, get enriched at the site of 
autoimmunity, and regulate the pathogenicity of the CD8+ T effector cells.  
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4.3 Testing the recognition of candidate MS antigens by the MAIT TCR 
4.3.1 Human brain tissue 
To evaluate the reactivity of the MAIT TCR to a brain antigen, the TCR expressing hybridomas 
were co-cultured with freshly sectioned tissue. In general, a much higher activation was observed 
in response to the patient tissue in comparison to the unrelated MS patient and the meningitis 
patient. This indicated that the MAIT TCR might recognize an antigen that was more readily 
processed and presented in the brain of patient FE rather than the two control patients. Since the 
second MS patient was not analyzed for MAIT TCR infiltration, it would be difficult to speculate 
whether this was indeed the case. In addition, the TCR activation was reduced but not 
completely eliminated upon application of a pan MHC class I antibody. This observation could 
have two reasons. On one hand, the incomplete blockage of activation may be simply due to 
insufficient amounts of blocking antibody in the milieu. On the other hand, MAIT antigen 
presentation may indeed be independent of the class I MHC molecule and is hence not affected 
by HLA blocking. In such a case one has to assume that the antibody binds an epitope that is (a) 
not shared between MHC class I and MR1 or (b) shared between the two molecules, but not 
important for antigen binding and/ or MAIT TCR activation. 
 
4.3.2 Human brain extracts, myelin antigens, autologous and EBV antigens 
Since the MAIT TCR was detected a clonal expansion within the MS brain, human brain extracts 
of WM and GM as well as myelin antigens, that have been suggested to play a role in MS 
pathogenesis, were presented via a fraction of peripheral blood cells containing dendritic cells 
and macrophages to the MAIT TCR hybridomas. No significant activation of the MAIT TCR 
was observed. It is quite unlikely that the MAIT antigen is not expressed in the CNS, as studies 
by us and others (Illes et al. 2003) have reported clonal expansions of MAIT cells within the MS 
brain. These results may be affected by the antigen processing capabilities of the APCs used in 
this experiment, as the peripheral blood fraction was not treated with growth factors for the 
induction of mature dendritic cells. The crude cell preparation used in the experiment may have 
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been dominated by cells that were not efficient antigen presenters, and compromised the antigen 
presentation to the TCR. The significance of correct antigen processing and accessibility is 
addressed in the following Section 4.3.3. In another experiment, the MAIT TCR hybridomas 
were also co-cultured with the Epstein-Barr virus (EBV) transformed autologous B cells, but no 
significant activation was observed. It is also probable that cellular interaction was impeded 
during co-culture, as the EBV-B cells grow in clumps, and fail to form a uniform layer in culture. 
This may have disrupted efficient antigen presentation to the MAIT TCR. However, this non-
recognition of viral antigens supports the observations of a study that showed that the MAIT 
cells do not recognize cells infected with viruses (Le Bourhis et al. 2010). This may be extended 
to our findings, where the MAIT TCR did not respond to the EBV antigens.  
 
4.3.3 Antigen processing and accessibility as limiting factors 
The experiments in which candidate brain and MS antigens were tested might be hindered by the 
lack of suitable APCs that are efficient in antigen processing and presentation. There are many 
studies supporting the notion that different cell types possess variable protein processing 
capabilities. The source of antigenic peptides might be the well characterized proteasome, or the 
immunoproteasome (Hoppes et al. 2010) that has altered substrate specificity, or even an organ 
specific proteasome such as the one described in the Thymus (Murata et al. 2007). Alternately, 
the peptides may be produced in a proteasome independent fashion by tissue-specific enzymes 
(Parmentier 2010). One cannot accurately predict the mechanisms that govern the generation of a 
TCR antigen (Morel et al. 2000; Chapiro et al. 2006) and hence it becomes increasingly 
important to closely replicate the in vivo environment during antigen search experiments. This 
becomes difficult in a situation when the antigen presenting partner of a TCR of unknown 
specificity is also unknown, and unavailable for in vitro cell culture. Keeping the above evidence 
in mind, we decided to adopt an antigen search strategy that would be unbiased, and overcome 
the challenges of antigen processing by coding for nonamer peptides that would cover virtually 
all antigenic epitopes. The related findings are discussed in Section 4.5.
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4.4 Investigation of HLA restriction of the MAIT TCR 
The MS derived MAIT TCR, carrying the classical invariant MAIT α-chain (AV7.2-AJ33) was 
investigated to determine its HLA restriction. The HLA molecules tested were the patient 
matched MHC class I molecules and the MR1 molecule. Antigen presenting cells that 
coexpressed each MHC molecule of interest, as well as a source of antigenic peptides were co-
cultured with the MAIT TCR hybridoma and subsequently analyzed for MAIT TCR activation. 
Surprisingly, activation was not restricted to any one test molecule, but the highest level of 
activation was seen in the presence of the MR1 molecule. This observation indicates that the 
MR1 molecule is possibly best suited to present antigen to the MS derived MAIT TCR and may 
in fact be responsible for restricting the antigen presentation to this particular TCR.  
 
4.5 Unbiased search for the antigen of the MAIT TCR 
4.5.1 Background activation of the MAIT TCR hybridoma 
‘Background activation’ or activation in the absence of antigenic stimuli was often observed for 
the MAIT hybridoma. The cells were re-cloned extensively to reduce this ‘background’ but it 
could not be completely eliminated. This background may be due to the presence of an 
endogenous antigen (Section 4.1.1.1) that is capable of activating the MAIT TCR. Additionally, 
it can also arise if the African green monkey MR1 molecule (from COS-7 cells) is capable of 
cross-presentation to the human MAIT TCR (Section 4.1.1.2).  
 
 
4.5.1.1    Is the MAIT TCR activated by an endogenous antigen? 
Evidence from literature suggests that MR1 is capable of binding endogenous antigens. It is 
known that MAIT cell ontogeny is independent of B cells, but requires MR1 expression on 
hematopoietic cells in the thymus suggesting that these cells present an endogenous ligand to the 
developing MAIT cells (Chua et al.2011). Furthermore, a recent study (Abos et al. 2011) 
detected MR1 on the surface of specific MR1 expressing cell lines without the addition of 
exogenous antigen(s). It has been suggested that MR1 might need to assume the ‘folded’ or 
Discussion 
 
 
119 
 
ligand bound conformation to reach the cell surface. In order to do this independent of an 
exogenous ligand, the MR1 molecule would have to bind to an endogenous partner or a culture 
medium component. These observations suggest that the MR1 cell surface expression occurs in 
the presence of a ligand. The recognition of an endogenous component could contribute to 
background activation, as was observed for the MS derived MAIT TCR expressed in hybridoma 
cells. This background was observed to fluctuate during cell culture, and could be minimized by 
re-cloning and selecting for ‘low background’ clones. However, if the background activation is 
indeed due to an endogenous antigen, then selecting ‘low background’ clones would result in cell 
lines that are less responsive to the endogenous stimuli. This could explain why an enrichment of 
antigenic signal was not observed even after repeated re-analysis of isolated antigen plasmids 
during the screening of plasmid encoded peptide libraries. 
 
 
4.5.1.2    Does the monkey MR1 cross present antigen to the human MAIT TCR? 
MR1 is known to be very well conserved across mammalian species. Human and murine MR1 
are highly homologous at the level of protein sequence within the α1 (89.7% similarity) and α2 
(89.1% similarity) domains (Treiner et al. 2005). Cross-species activation between human and 
mouse MAIT cells (Le Bourhis et al. 2010), was observed in MR1 over-expressing cell lines. In 
light of the above observations, it is quite likely that the African green monkey MR1 (from the 
COS-7 cell line) can similarly cross activate human MAIT cells. The amino acid residues that 
have been suggested to be potentially important for antigen binding and recognition (Huang et al. 
2005) are identical and conserved between human and monkey MR1. The differences between 
the African green monkey (COS-7) and human MR1 molecule are not included in these 
‘important’ residues. Hence the COS-7 MR1 is likely to bind to its ligand in a manner that is 
similar to that of human MR1. If it is indeed capable of cross-presentation to the human MR1, 
presentation of an endogenous ligand would additionally contribute to the observed background 
activation. This ‘background activation’ of the MAIT hybridoma cannot be eliminated 
completely by recloning as it is an inherent part of the system.  
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4.6 Investigation of the MR1 anchor positions 
The first step in creating a human MR1 matched PECP library would be the characterization of 
its anchor positions. A pragmatic approach was followed that would provide preliminary insights 
into the anchor positions of the MR1 molecule. This would be achieved by analysis of 
endogenous MR1 ligands (whose sequences would represent the MR1 anchor positions if they 
did exist) or to screen chemically synthesized peptide libraries with recombinant human MR1, 
and then study the bound peptides.  
 
To this end, recombinant human MR1 (hMR1) was expressed in association with β2 
microglobulin and used to screen chemically synthesized peptide libraries. hMR1 was secreted in 
the cell supernatant, but a greater part of the hMR1 was detected within the cell. It is possible 
that this ‘non-secreted’ form was sequestered within the endoplasmic reticulum (ER) due to the 
non-availability of a binding partner that would stabilize the folded MR1 conformer. A similar 
observation is made in the case of classical MHC molecules and MR1. In the absence of a 
ligand, MR1 is unable to exit the ER and accumulates there (Miley et al. 2003; Le Bourhis et al. 
2011). To circumvent this, the recombinant hMR1 may be coexpressed with a peptide encoding 
combinatorial plasmid library such as the randomized N library. The PECP library may serve as 
a ligand source, and facilitate MR1’s exit from the ER.  
 
Although the amount of secreted MR1 was low, it was sufficient for screening of chemically 
synthesized nonamers belonging to a combinatorial positional scanning peptide library. The 
peptides that bound to MR1 were eluted and analyzed via Edman degradation and mass 
spectrometry. No signal could be detected for the peptides analyzed by Edman degradation and 
this may be due to low sensitivity of the method. Mass spectrometry proved to be more sensitive, 
and the sequences of the eluted peptides indicate that there is no strict sequence conservation at 
any one position within the nonapeptide, albeit a pattern that begins and ends with a charged 
amino acid residue with a stretch of hydrophobic residues in between. Using this pattern as a 
guide, efforts in this direction may screen related peptides to test MAIT TCR reactivity in the 
future. 
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4.7 Further experiments 
4.7.1 Studying the TCR repertoire of CD8+ T cells that infiltrate WM and GM 
The demyelination in MS has long been thought to be focused in the WM and only recently have 
the demyelinating plaques in the GM come to the fore (Geurts et al. 2009). In this study, CD8+ T 
cells were observed to infiltrate both the white matter (WM) and grey matter (GM) in the brain 
tissue of patient FE. Firstly it would be interesting to quantify this infiltration to see if the 
infiltrates in both regions are comparable in number and density. Secondly, a detailed study of 
the TCR repertoire in both regions may be carried out to understand the antigen specificities of 
these T cells. It would be interesting to see whether an overlap in TCR sequences exists between 
the CD8+ effector populations infiltrating GM and WM, or whether these are mutually 
exclusive. The WM and GM may first be macrodissected and analyzed for oligoclonal 
expansions by spectratyping. The dominant expansions detected by spectratyping may then be 
looked for in single cells isolated by laser microdissection using the clone specific or unbiased 
multiplex PCR approach.  
 
4.7.2 Delineating the role of MAIT cells in MS pathogenesis 
In light of a study linking gut flora to MS pathogenesis (Berer et al. 2011), the contribution of 
MAIT cells in MS seems significant and not just a mere coincidence. To delineate this one may 
examine MAIT cells in MS patients or animal models with different courses of the disease. 
Studies that evaluate the presence of MAIT cells in the blood prior to, during and after a relapse 
may be helpful in revealing patterns. Besides, brain tissue could also be stained for the MAIT 
invariant α-chain to get an overall picture of the numbers and density of infiltrating MAIT cells. 
This may then be compared to the numbers of effector T cells infiltrating the same region to 
know which subpopulation is dominant locally. A ‘humanized’ MAIT TCR animal model would 
be useful in understanding the role and location of MAIT cells at different time points in the 
disease. A spontaneous EAE animal model in mice suggests that the human MAIT TCR may 
play a protective role during the disease (personal communication, Wakiro Sato, MPI of 
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Neurobiology). This is in keeping with studies that suggest that the MAIT subpopulation plays a 
regulatory role in MS (Miyazaki et al., 2011).  
 
4.7.3 Identifying the anchor positions of the MR1 molecule 
The use of plasmid encoded combinatorial peptide libraries for antigen identification could thus 
far not narrow down onto the MAIT antigen, although it did provide evidence supporting the 
peptidic nature and MR1 restriction of the TCR derived from patient FE. This approach involved 
the screening of an unbiased nonamer library, and excluded peptides of other lengths. Some 
studies suggest that the MR1 antigen processing and presentation is distinct from that of classical 
MHC molecules (Huang et al. 2008; Gapin et al. 2009). If this is indeed the case, it is possible 
that the MAIT antigen may not be a nonamer. It is possible that nonapeptides are capable of a 
weak association that allows for activation, but not a strong antigenic signal that can be isolated. 
Hence screening of randomized PECP libraries of varied lengths would be an interesting follow 
up experiment.  
 
Furthermore, the PECP library that was used so far could not be matched to the antigen 
presenting molecule since the MR1 anchor positions are not known. The experiments to identify 
the anchor positions of MR1, using a chemically synthesized positional scanning combinatorial 
peptide library, provide a preliminary pattern of nonapeptides that bind to MR1. This may be 
used as a guide for future experiments. The experiment may first be scaled in order to screen 
more peptides (of variable lengths) in order to increase the signal. A confirmation of the peptide 
pattern should be followed by the generation of plasmid encoded peptides that follow this 
pattern. By testing whether they successfully activate the MAIT TCR detected in patient FE, one 
would be able to delineate the (a) anchor positions of MR1 and (b) show that the MAIT TCR 
indeed recognizes a peptide. 
 
 It would be interesting to see if all the four MAIT T cell receptor pairs from patient FE 
recognize the same or similar peptide(s). This is speculated as the TCR sequences are related and 
indicate antigen driven development. More information on the anchor positions of the MR1 
molecule could be gained by analyzing peptide libraries of varied lengths. Additionally, efforts 
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can also be made in eluting the endogenous ligand of MR1. Although this entity would not be 
expected to have a pathogenic potential, it would conform to the MR1 anchor positions. The 
chemical synthesis of mimotopes and database mining would be helpful in further revealing its 
pathogenic association. To cater to a situation where the MR1 ligand is not a peptide, one may 
for instance analyze MR1 binding to lipid ligands. 
 
4.7.4 Characterizing the antigen of the (non-MAIT) effector T cells 
Of the nine T cell receptors characterized in this study, five apparently belong to the cytotoxic T 
cell subset. Reconstruction in mouse hybridoma cell lines would allow for their application in 
antigen search studies. In order to find the antigens that they recognize and respond to, one 
would also have to determine their HLA restriction as a first step. This knowledge will allow for 
the development and application of HLA anchor specific PECP libraries and antigen presenting 
cell lines that are stably transfected with the responsible HLA molecule, both of which are 
essential for antigen search experiments. The screening of these libraries would provide 
mimotopes that would in turn shed light upon the antigen(s) that these T cells recognize. Besides 
being useful in in vitro studies, these TCRs may be studied in in vivo in ‘humanized’ mouse 
models of the disease.  
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Abbreviations 
Quantities are denoted in accordance to the international SI system of units while the amino 
acids have been named according to the standard code. 
 
A  Adenosine  FCM Flow cytometry 
Amp Ampicillin  FCS Fetal calf serum 
APC Antigen presenting cell 
 
FITC 
Fluoresceinisothiocyanate 
(fluorophore) 
ATP Adenosine triphosphate  FPLC Fast protein liquid chromatography 
β2m Beta 2 microglobulin  G Guanine 
bp Base pairs 
 
HEK293E 
Human embryonic kidney 293 
EBNA-1 
C Constant (region of TCR chains) 
 
HLA Human leukocyte antigen 
C Cytosine 
 
hMR1 Human MR1 
CD Cluster of differentation 
 
HRP Horseradish peroxidase 
cDNA Complementary DNA 
 
IL-2 Interleukin-2 
CDR 
Complementarity determining 
region  
ITAM 
Immunoreceptor tyrosine-based 
activation motif 
CMV Cytomegalovirus 
 
J Joining (region of TCR chains) 
CNS Central nervous system 
 
K 
K-nucleotide, stands for random 
insertion of guanine or thymine 
nucleotides 
C-terminal Carboxy terminal 
 
kb Kilo base pairs/ kilobases 
Cy3 Cytochrome 3 (fluorophore) 
 
LB Luria-Bertani culture medium 
D 
Diversity (region of TCR α- or β-
chains)  
LC Liquid chromatography 
DEPC Diethylpyrocarbonate 
 
mAb Monoclonal Antibody 
DMSO Dimethylsulfoxid 
 
MAIT Mucosal-associated invariant T cells 
DNA Deoxyribonucleic acid 
 
MBP Myelin basic protein 
dNTP Desoxy-nucleoside-triphosphate 
 
MHC Major histocompatibility complex 
E. coli  Escherichia coli  
 
MOG Myelin oligodendrocyte glycoprotein 
EAE 
Experimental Autoimmune 
Encephalomyelitis  
MPI Max Planck Institute 
EBNA Epstein-Barr virus nuclear antigen 
 
MS Multiple sclerosis 
EBV Epstein-Barr virus 
 
MWCO Molecular weight cut-off 
ECL Enhanced chemiluminescence 
 
N 
N- or non-templated nucleotide, 
stands for random insertion of any 
nucleotide 
EDTA Ethylenediamine tetraacetate 
 
n.k Not known 
ELISA 
Enzyme linked immunosorbent 
assay  
OD Optical density 
ER Endoplasmatic reticulum 
 
Ori Origin of replication 
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PAGE 
Polyacrylamide- gel 
electrophoresis  
RT Room temperature 
PBS Phosphate buffered saline 
 
SDS Sodium dodecyl sulfate 
PCR Polymerase chain reaction 
 
sGFP 
Synthetic green fluorescent protein 
(S65T) (Heim et al. 1995) 
PFA Paraformaldehyde 
 
SLE Systemic lupus erythematous 
pMHC Peptide-MHC complex 
 
T Thymine 
PS-SCL 
Positional scanning-synthetic 
combinatorial library  
TAP 
Transporter associated with antigen 
processing 
PVDF Polyvinylidene fluoride 
 
Taq 
Polymerase of Thermophilus 
aquaticus 
NCBI  
National Center for 
Biotechnology Information  
TBE Tris/borate/EDTA (buffer) 
NF Neurofascin 
 
TCR T cell receptor 
NFAT Nuclear factor of activated T cells 
 
Tris Tris (hydroxymethyl)-amino methane 
NK- T cells Natural killer T cells 
 
u Unit 
NTA Nitriloacetate 
 
U Uracil 
N-terminal Amino terminal 
 
UV Ultraviolet light 
RE Restriction enzyme 
 
V Variable (region of TCR chains) 
RNA Ribonucleic acid  v/v volume per volume 
RNAse Ribonuclease  w/v weight per volume 
RPM Rounds per minute  X-Gal  
5-Bromo-4-chloro-3-indoxyl-β-D-
galactopyranoside 
RPMI 
„Roswell Park Memorial 
Institute“ (cell culture medium) 
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I. Primer sequences 
All oligonucleotide primers used in this study are listed below. The primer label and its 
nucleotide sequence are followed by its intended site of hybridization. With regards to primers 
used for nested PCRs, the designation ‘out’ refers to primers used in the first reaction and ‘in’ 
refers to primers used in the following second reaction. The designation ‘for’ indicates that the 
primer would amplify its target in the 5’ to 3’ direction, while ‘rev’ refers to a primer that 
achieves the opposite. Wobble nucleotides that were included in the sequences follow the 
standard IUPAC nomenclature: R (A or G), Y (C or T), K (G or T), S (G or C), W (A or T), B (G 
or T or C). All TCR primers are named according to the Arden nomenclature. 
 
 Reverse Transcription (RT)(Section 2.4.3) 
 
Label Sequence Hybridization site 
hMR1-for 5’-ATGGGGGAACTGATGGCGTT Human MR1 signal peptide 
hMR1-rev 5’-TCATCGATCTGGTGTTGGAAG Human MR1 transmembrane region 
Vα7.2-lead 5’-ACGCGTCGACATGTGGGGAGTTTTCCTTC Leader-Region Vα7.2 (TCR) 
Cα-rev-out 5’-GCAGACAGACTTGTCACTGG C-Region α-chain (TCR) 
 
 Colony PCR (Section 2.4.3.2.1) 
 
Label Sequence Hybridization site 
M13 Forward (-20) 5’-GTAAAACGACGGCGTC pCR®2.1-TOPO-Vector 
M13 Reverse 5’-GAGGAAACAGCTATGAC pCR®2.1-TOPO-Vector 
pTT5-for seq 5’-CTTTCTCTCCACAGGTGTC pTT5-Vector 
pTT5-rev seq 5’-CCTTCCGAGTGAGAGACAC pTT5-Vector 
 
 
 Single cell multiplex PCR for TCR chains (Section 2.4.3.2.2) 
 
Clone specific PCR  
 
 RT PCR 
 
Label Sequence Hybridization site 
C α RT imp 5’-GCCACAGCACTGTTGC C-region α-chain (TCR) 
C β-RT-2 5’-GAAGAAGCCTGTGGCC C-region β-chain (TCR) 
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 PCR 1 
 
Label Sequence Hybridization site 
Vα-1
14
-for-out 5’-AGSAGCCTCACTGGAGTTG Variable region α-chain (TCR) 
Vα-1
235
-for-out 5’-CTGAGGTGCAACTACTCATC Variable region α-chain (TCR) 
Vα-2-for-out 5’-CARTGTTCCAGAGGGAGCC Variable region α-chain (TCR) 
Vα-3,25-for-out 5’-GAARATGYCWCCATGAACTGC Variable region α-chain (TCR) 
Vα-4,20-for-out 5’-WTGCTAAGACCACCCAGCC Variable region α-chain (TCR) 
Vα-5-for-out 5’-AGATAGAACAGAATTCCGAGG Variable region α-chain (TCR) 
Vα-6,14-for-out  5’-RYTGCACATATGACACCAGTG Variable region α-chain (TCR) 
Vα-7-for-out  5’-CACGTACCAGACATCTGGG Variable region α-chain (TCR) 
Vα-8,21-for-out  5’-CCTGAGYGTCCAGGARGG Variable region α-chain (TCR) 
Vα-9-for-out  5’-GTGCAACTATTCCTATTCTGG Variable region α-chain (TCR) 
Vα-10,24-for-out  5’-ASTGGAGCAGAGYCCTCAG Variable region α-chain (TCR) 
Vα-11-for-out  5’-TCTTCAGAGGGAGCTGTGG Variable region α-chain (TCR) 
Vα-12-for-out  5’-GGTGGAGAAGGAGGATGTG Variable region α-chain (TCR) 
Vα-13,19,26-for-out  5’-SAASTGGAGCAGAGTCCTC Variable region α-chain (TCR) 
Vα-15-for-out  5’-CCTGAGTGTCCGAGAGGG Variable region α-chain (TCR) 
Vα-16-for-out  5’-ATGCACCTATTCAGTCTCTGG Variable region α-chain (TCR) 
Vα-17-for-out  5’-TGATAGTCCAGAAAGGAGGG Variable region α-chain (TCR) 
Vα-18-for-out  5’-GTCACTGCATGTTCAGGAGG Variable region α-chain (TCR) 
Vα-22,31-for-out  5’-CCCTWCCCTTTTCTGGTATG Variable region α-chain (TCR) 
Vα-23,30-for-out  5’-GGCARGAYCCTGGGAAAGG Variable region α-chain (TCR) 
Vα-27-for-out  5’-CTGTTCCTGAGCATGCAGG Variable region α-chain (TCR) 
Vα-28-for-out  5’-AGACAAGGTGGTACAAAGCC Variable region α-chain (TCR) 
Vα-29-for-out  5’-CAACCAGTGCAGAGTCCTC Variable region α-chain (TCR) 
Vα-32-for-out  5’-GCATGTACAAGAAGGAGAGG Variable region α-chain (TCR) 
BV-1-for-i-out 5’-TGTACTGGTACCAACAGAGC Vβ 1, β-chain (TCR) 
Fe-BV1-BJ2.3-2 5’-CCTGGGCCAAAATACTGCG Jβ 2.3, β-chain (TCR) 
 
 PCR 2 
 
Label Sequence Hybridization site 
BV-1-for-i-nest 5’-GGAGAAGAGAGAGCAAAAGG Vβ 1, β-chain (TCR) 
Fe-BV1-BJ2.3-1 5’-ATACTGCGTATCCTTCCTCC NDN region, Patient FE specific 
 
 PCR 3 
 
Label Sequence Hybridization site 
BV1-for-inner 5’-ATTCTCCGCACAACAGTTCC Vβ 1, β-chain (TCR) 
Fe-BV1-nDn-in-impr 5’-TCCTTCCTCCCGCTAATGC NDN region, Patient FE specific 
 
 PCR 4 
 
Label Sequence Hybridization site 
Vα-4/1-for-in  5’-ACAGAAGACAGAAAGTCCAGC Variable region α-chain (TCR) 
Vα-4/2-for-in  5’-GTCCAGTACCTTGATCCTGC Variable region α-chain (TCR) 
Vα-6-for-in  5’-GCAAAATGCAACAGAAGGTCG Variable region α-chain (TCR) 
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Vα-8/1-for-in  5’-CAGTGCCTCAAACTACTTCC Variable region α-chain (TCR) 
Vα-8/2-for-in  5’-GCCTCAGACTACTTCATTTGG Variable region α-chain (TCR) 
Vα-14-for-in  5’-ACAGAATGCAACGGAGAATCG Variable region α-chain (TCR) 
Vα-24-for-in  5’-CCTTCAGCAACTTAAGGTGG Variable region α-chain (TCR) 
Vα-28-for-in  5’-TCTCTGGTTGTCCACGAGG Variable region α-chain (TCR) 
Vα-2/1-for-in 5’-TGGAAGGTTTACAGCACAGC Variable region α-chain (TCR) 
Vα-2/2-for-in 5’-TGGAAGGTTTACAGCACAGG Variable region α-chain (TCR) 
Vα-5-for-in  5’-CAGCATACTTACAGTGGTACC Variable region α-chain (TCR) 
Vα-10-for-in  5’-TCACTGTGTACTGCAACTCC Variable region α-chain (TCR) 
Vα-12-for-in  5’-TACAAGCAACCACCAAGTGG Variable region α-chain (TCR) 
Vα-22-for-in  5’-AGGCTGATGACAAGGGAAGC Variable region α-chain (TCR) 
Vα-31-for-in  5’-GTGGAATACCCCAGCAAACC Variable region α-chain (TCR) 
Vα-7-for-in  5’-CTCCAGATGAAAGACTCTGC Variable region α-chain (TCR) 
Vα-13-for-in  5’-TTAAGCGCCACGACTGTCG Variable region α-chain (TCR) 
Vα-17-for-in  5’-CTGTGCTTATGAGAACACTGC Variable region α-chain (TCR) 
Vα-18-for-in  5’-CCTTACACTGGTACAGATGG Variable region α-chain (TCR) 
Vα-21-for-in  5’-TGCTGAAGGTCCTACATTCC Variable region α-chain (TCR) 
Vα-23-for-in  5’-GTGGAAGACTTAATGCCTCG Variable region α-chain (TCR) 
Vα-32-for-in  5’-TCACCACGTACTGCAATTCC Variable region α-chain (TCR) 
Vα-3-for-in  5’-TTCAGGTAGAGGCCTTGTCC Variable region α-chain (TCR) 
Vα-11-for-in  5’-AGGGACGATACAACATGACC Variable region α-chain (TCR) 
Vα-15-for-in  5’-CCTCCACCTACTTATACTGG Variable region α-chain (TCR) 
Vα-19-for-in  5’-CCTGCACATCACAGCCTCC Variable region α-chain (TCR) 
Vα-25-for-in  5’-AGACTGACTGCTCAGTTTGG Variable region α-chain (TCR) 
Vα-26-for-in  5’-CCTGCATATCACAGCCTCC Variable region α-chain (TCR) 
Vα-29-for-in  5’-ACTGCAGTTCCTCCAAGGC Variable region α-chain (TCR) 
Vα-1/235-for-in  5’-AAGGCATCAACGGTTTTGAGG Variable region α-chain (TCR) 
Vα-1/14-for-in  5’-CTGAGGAAACCCTCTGTGC Variable region α-chain (TCR) 
Vα-9-for-in  5’-ATCTTTCCACCTGAAGAAACC Variable region α-chain (TCR) 
Vα-16-for-in  5’-TCCTTCCACCTGAAGAAACC Variable region α-chain (TCR) 
Vα-20-for-in  5’-ACGTGGTACCAACAGTTTCC Variable region α-chain (TCR) 
Vα-27-for-in  5’-ACTTCAGACAGACTGTATTGG Variable region α-chain (TCR) 
Vα-30-for-in  5’-CTCTTCACCCTGTATTCAGC Variable region α-chain (TCR) 
Cα-rev-out 5’-GCAGACAGACTTGTCACTGG Variable region α-chain (TCR) 
 
 
 PCR 5 
 
Label Sequence Hybridization site 
Valpha 7i.2 5’-CACGTACCAGACATCTGGG Vα 7.2, α-chain (TCR) 
Valpha 7 Fe-2   5’-TTCTGGTACCAGCAACATGC Vα 7.2, α-chain (TCR) 
Valpha 7 Fe-3 5’-GATGGTTTGGAGGAGAAAGG Vα 7.2, α-chain (TCR) 
Fe 7.2 J-C rev cl  5’-GTTCTGGATATTAAGATCCACC  Patient FE specific, joining-constant region 
Fe-AV7.2J16-rev-1  5’-GATCCACCTTTAACATGGTYC  Patient FE specific, Jα 16 region 
Fe-AV7.2J16-rev-2  5’-TTTAACATGGTYCCCCTTGC  Patient FE specific, Jα 16 region 
Fe-AV7.2J16-rev-3  5’-TTGCAAAGAGCAGCTCGAGG  Patient FE specific, Jα 16 region 
Cα-in-impr 5’-AGTCTCTCAGCTGGTACACG C-Region α-chain (TCR) 
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Unbiased PCR  
 
 RT PCR 
 
Label Sequence Hybridization site 
Cα out 5’-GCAGACAGACTTGTCACTGG C-region α-chain (TCR) 
Cβ out 5’-TGGTCGGGGAAGAAGCCTGTG C-region β-chain (TCR) 
 
 
 PCR 1 
 
Label Sequence Hybridization site 
VP 1 5’-TSYTTTGTCTCCTGGGAGCA β chain leader 1, 5, 16, 17, 23 
VP 2 5’-CCTGAAGTCGCCCAGACTCC Vβ 22, 25 
VP 3 5’-GTCATSCAGAACCCAAGAYACC Vβ 18, 24 
VP 4 5’-GGWTATCTGTMAGMGTGGAACCTC Vβ 2, 4 
VP 5 5’-ATGTACTGGTATCGACAAGAYC Vβ 3, 11, 12, 13, 14, 15 
VP 6 5’-CACTGTGGAAGGAACATCAAACC Vβ 20 
VP 7 5’-TCTCCACTCTSAAGATCCAGC Vβ 6, 8, 21 
VP 8 5’-CAGRATGTARATYTCAGGTGTGATCC Vβ 6 
VP 9 5’-CCAGACWCCAARAYACCTGGTCA Vβ 7, 9 
 
 
 PCR 2 
 
Label Sequence Hybridization site 
VP 1-UP 5’-ACAGCACGACTTCCAAGACTCACYTTTGTCTCCTGGGAGCA UP anchor-VP 1 
VP 2-UP 5’-ACAGCACGACTTCCAAGACTCACCTGATGTCGCCCAGACTCC UP anchor-VP 2 
VP 3-UP 5’-ACAGCACGACTTCCAAGACTCAGTCATSCAGAACCCAAGAYACC UP anchor-VP 3 
VP 4-UP 5’-ACAGCACGACTTCCAAGACTCAGGWTATCTGTMAGMGTGGAACCTC UP anchor-VP 4 
VP 5-UP 5’-ACAGCACGACTTCCAAGACTCAATGTACTGGTATCGACAAGAYC UP anchor-VP 5 
VP 6-UP 5’-ACAGCACGACTTCCAAGACTCACACTGTGGAAGGAACATCAAACC UP anchor-VP 6 
VP 7-UP 5’-ACAGCACGACTTCCAAGACTCATCTCCACTCTSAAGATCCAGC UP anchor-VP 7 
VP 8-UP 5’-ACAGCACGACTTCCAAGACTCACAGRATGTARATYTCAGGTGTGATCC UP anchor-VP 8 
VP 9-UP 5’-ACAGCACGACTTCCAAGACTCATCAGACWCCAARAYACCTGGTCA UP anchor-VP 9 
 
 
 PCR 3 
 
Label Sequence Hybridization site 
UP 5’-ACAGCACGACTTCCAAGACTCA UP anchor 
Cβ in 5’-TCTGATGGCTCAAACACAGC C-Region β-chain (TCR) 
 
 
 
 PCR 4 
Same as for the clone specific PCR 
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 PCR 5 
 
Label Sequence Hybridization site 
Va 1.5 Lead for 5’-ATGCTCCTGCTGCTCGTCC Vα 1.5 leader, α-chain (TCR) 
AJ 34-out         5’-GACTTGTAATCTGGTCCCAG Jα 34 joining, α-chain (TCR) 
Va 30.1 Lead for 5’-ATGGAGAAAATGTTGGAGTGTG Vα 30.1 leader, α-chain (TCR) 
AJ-18-out         5’-GACAGTCAACTGAGTTCCTC Jα 18 joining, α-chain (TCR) 
AV-20.1-Lead for 5’-CGTCGACATGAGGCAAGTG Vα 20.1 leader, α-chain (TCR) 
Ca-start-1 5’-GCAGGGTCAGGGTTCTGG C-Region α-chain (TCR) 
 
 
 
 Single cell PCR for amplification of library plasmids (Section 2.4.3.2.3) 
 
Label Sequence Hybridization site 
pcDNA-for-1 5’-CACTGCTTACTGGCTTATCG pcDNA6/V5-HisA-lib 
pcDNA-for-2-TOPO 5’-CACCCGACTCACTATAGGGAGACC pcDNA6/V5-HisA-lib 
pcDNA-2
nd
-for  5’-TCCGGCGCGCCACCATG pcDNA6/V5-HisA-lib 
pcDNA-rev-1 5’-ACTAGAAGGCACAGTCGAGG  pcDNA6/V5-HisA-lib 
pcDNA-rev-2 5’-CTGATCAGCGGGTTTAAACTC pcDNA6/V5-HisA-lib 
pcDNA-rev-3 5’-TGGTGATGGTGATGATGACC pcDNA6/V5-HisA-lib 
pcDNA-rev-10 5’-CTAGACTCGAGCGGCCGC pcDNA6/V5-HisA-lib 
 
 
 Linker oligonucleotides for construction the PECP libraries (Section 2.4.3.8) 
The coding sequences are underlined. Nucleotides contributing to restriction sites are boxed. The Kozak 
sequences are highlighted in blue. Nucleotides coding for start and stop signals are shown in red. 
 
Label Sequence 
 AscI-Kozak- Start-Coding sequence-Stop – NotI 
N27-all-lib-ASc-for 5’-CAGGGAAGGCGCGCCACCATGNNKATCNNKNNKNNKGTGNNKNNKCTATGAGCGGCCGCTAAACTAT 
N27-A1-39-lib-Asc-for 5’-CAGGGAAGGCGCGCCACCATGNNKNNKGACNNKNNKNNKNNKNNKTATTGAGCGGCCGCTAAACTAT 
N27-B8-359-lib-Asc-for 5’-CAGGGAAGGCGCGCCACCATGNNKNNKAAANNKARGNNKNNKNNKCTNTGAGCGGCCGCTAAACTAT 
N27-NotI-rev 5’-TAGTTTAGCGGCCGCTCA 
Appendix 
 
 
 
 
II.     Vector maps 
 
 
Fig. II-1: pCR®2.1-TOPO vector 
Plac = lacZ-Gen promoter, lacZα = gene 
coding for β-galactosidase (α-fragment), 
f1 ori = origin of replication of the f1 
phage, kanamycin- and ampicillin- 
resistance gene, pUC ori = bacterial (E. 
coli) origin of replication; Source: 
handbook‘TOPO-TA Cloning®’ 
(Invitrogen) 
 
 
 
 
 
 
 
 
Fig. II-2: pBRdel for subcloning the TCR β-
chain 
The pBRdel vector serves as an intermediate 
subcloning vector prior to cloning the entire TCR 
β-chain into the pRSV5neo vector. The standard 
pBRDel vector (3403 bp) contains an origin of 
replication (ori), ampicillin resistance (Ampr) and 
tetramycin (Tetr) resistance genes. The subcloning 
vector contains a complete TCR β-chain sequence 
lying between the SalI and BamHI recognition 
sites. Since the constant region sequence is the 
same for all β-chains, the upstream V-NDN-J-DNA 
sequence can be exchanged with a different one via 
the flanking SalI and BglII recognition sites. The 
complete TCR sequence may now be cut out via a 
SalI-BamHI restriction digestion and cloned into 
the pRSV5neo vector (Fig. II-4). Plasmid map 
constructed in: ‘ApE- A plasmid editor’ freeware 
program (Version 1.1.7) by M.Wayne Davis. 
Source: Joachim Malotka, MPI of Neurobiology 
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Fig. II-3: pRSV5neo vector for cloning of the TCRα- and β-chains 
(a) The pRSV.5 neo vector with the TCR β-chain (BV8.1-BJ1.1) insert. The vector carries genetic elements such as 
the long terminal repeats of the Rous sarcoma virus (RSV LTR), polyA stretch from simian virus 40 (SV40-polyA), 
neomycin resistance gene (NeoR), origin of replication of the simian virus 40 (SV40-ori) , ampicillin resistance gene 
(AmpR ), origin of replication (ori). The recognition sites of all relevant restriction enzymes are indicated.  
(b) The prSV.5 hygro vector with the TCR α-chain (AV30.1-AJ18) insert. The pRSVhygro vector is a derivative of 
the prSV.5 neo vector wherein the neomycin resistance gene is replaced with a hygromycin resistance gene 
(HygroR) via a SmaI and HindIII restriction site. The pRSV.5neo and prSVhygro vector was provided by Joachim 
Malotka, MPI of Neurobiology. Plasmid map constructed in: ‘ApE- A plasmid editor’ freeware program (Version 
1.1.7) by M.Wayne Davis. 
 
 
 
 
 Fig. II-4: pcDNA6/V5-HisA vector  
PCMV = CMV promoter, T7 = T7 promoter, 6xHis 
= polyhistidine tag, BGH pa = BGH 
polyadenylation sequence, f1ori= origin of 
replication f 1 phage, SV40 ori= SV40 promoter 
and origin or replication, EM7= EM7 promoter, 
resistance genes for blasticidin and ampicillin, 
SV 40= SV40 polyaednylation sequence, pUC 
ori= pUC origin. Source: Invitrogen. 
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Fig. II-5: The antigen peptide coding region in pcDNA6/V5-HisA-PECP library  
Open reading frame of the antigen peptide coding region of the plasmid encoded combinatorial peptide 
(PECP) library, Grey: Flanking sequences of the pcDNA6/V5-His A vector, The recognition sites of 
restriction enzymes BamHI (blue) and NotI (red) are highlighted in boxes. 
 
 
 
 
Fig. II-6: Nucleotide sequence of the s-GFP coding region in pcDNA6/V5-HisA-sGFP 
Open reading frame of the s-GFP gene, Grey: Flanking sequences of the pcDNA6/V5-His A vector, The 
recognition sites of restriction enzymes EcoRI (blue) and XhoI (red) are highlighted in boxes.  
 
 
 
 Fig. II-7: pHSE3’- MR1 
The human MR1 gene was cloned into the pHSE3’ 
vector (Pircher et al. 1989) by Wakiro Sato, MPI of 
Neurobiology. It contains the extracellular membrane 
bound (MR1-mem) region carrying a myc tag and 
His(6) tag for subsequent purification and/or 
detection by western blot. The pHSE3’ vector carries 
genetic elements such as the origin of replication 
(ori), and resistance genes for ampicillin (AmpR) and 
Neomycin (NeoR). The recognition sites of the 
enzymes relevant for cloning of the MR1 gene are 
also depicted. Sequence source: Wakiro Sato. 
Plasmid map constructed in: ‘ApE- A plasmid editor’ 
freeware program (Version 1.1.7) by M.Wayne 
Davis. 
 
pcDNA6/V5-HisA-sGFP (5870bp):GFP-coding region 
 
GTCCAGTGTGGTGGAATTCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGC
TGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTG
AAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCTTCACATATGGCGTGCAGTGCTT
CAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCA
TCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAG
CTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTTCAACAGCCACAACGTATA
CATCATGGCTGACAAGCAGAAGAACGGAATCAAGGCCAACTTCAAGACCCGCCACAACATCGAGGACGGCGGCGTGCAGC
TGGCCGACCACTACCAGCAGAACACCCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTACCTGTCCACACAA
TCTGCCCTTTCGAAAGATCCCAACGAAAAGAGAGACCACATGGTCCTTCTTGAGTTTGTAACAGCTGCTGGGATTACACA
TGGCATGGATGAACTATACAAGGGATCCCATCACCATCACCATCACTAAGCTCTCGAGTCTAGAGGGCCCTT 
pcDNA6/V5-His-A-PECP lib (5145 bp): Antigenic peptide coding region 
 
CTTGGTACCGAGCTCGGATCCGGCGCGCCACCATGNNNNNNNNNNNNNNNNNNNNNNNNNNNTGAGCGGCCGCTCGAGTC
TAGAGGGCCCTTCGAAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGCGTACC 
Appendix 
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Fig. II-8: pTT5-MR1 and pTT5-β2 microglobulin 
Human MR1 and β2 microglobulin were cloned into the pTT5 vector. The pTT5 vector contains an EBV 
specific origin of replication (oriP) as well as a promoter of the cytomegalovirus (CMV) and an ampicillin 
resistance gene (AmpR). All the relevant recognition sites of the restriction enzymes are depicted. (a) 
pTT5-MR1 carries the leader sequence (yellow) of the Fab heavy chain, followed by the MR1 gene 
(MR1), and a myc tag, a polyhistidine tag (His (6)), and a C terminal Bir-A site. (b) pTT5-β2m carries the 
leader sequence of the Fab light chain, followed by the β2 microglobulin coding region. Plasmid source: 
Birgit Obermeier, MPI of Neurobiology. Plasmid map constructed in: ‘ApE- A plasmid editor’ freeware 
program (Version 1.1.7) by M.Wayne Davis. 
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III. Electropherograms depicting RNA integrity  
The electropherograms depict RNA integrity on a plot of fluorescence (FU) Vs., Svedberg 
units (s). A comparison of the RNA integrity of RNA isolated from peripheral blood 
lymphocytes (Fig. III-1) in comparison to that isolated from frozen tissue of patient FE (Fig. 
III-2, III-3 and III-4) shows that the amount of degraded RNA in frozen tissue sections 
exceeds that in live cells. This loss in RNA integrity in the tissue samples is possibly due to 
delayed cryopreservation post isolation and repeated freeze thaw cycles. This low RNA 
quality translates into reduced yields of cDNA during reverse transcription. Data provided by 
Joachim Malotka and Anna Backes, MPI of Neurobiology. 
 
 
Fig. III-1: Electropherogram of 
RNA from peripheral blood 
lymphocytes 
The peaks depict different regions of 
the sample such as the 5S, degraded 
RNA, 18S and 28S subunits.  Even 
though this RNA is sourced from live 
cells, in the absence of RNAse 
inhibitors, some of the RNA is 
degraded during sample processing. 
However, the RNA integrity of this 
sample is sufficient for cDNA 
synthesis.  
 
 
Fig. III-2: Electropherogram of 
RNA isolated from block # 9 
The peaks depict the degraded RNA, 
18S and 28S subunits.  The amount 
of degraded RNA is much higher in 
comparison to the intact 18S and 28S 
subunits. The RNA integrity of this 
sample is compromised and hardly 
sufficient for cDNA synthesis. 
Appendix 
 
 
 
 Fig. III-3: Electropherogram of 
RNA isolated from block # 10 
The peaks depict the degraded RNA, 
18S and 28S subunits.  The amount 
of degraded RNA is much higher in 
comparison to the intact 18S and 28S 
subunits. The RNA integrity of this 
sample is compromised and hardly 
sufficient for cDNA synthesis. 
 
 
 
Fig. III-4: Electropherogram of 
RNA isolated from block # 11 
The peaks depict the degraded RNA, 
18S and 28S subunits.  The amount 
of degraded RNA is much higher in 
comparison to the intact 18S and 28S 
subunits. The RNA integrity of this 
sample is compromised and hardly 
sufficient for cDNA synthesis. 
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IV. Edman degradation data 
Detection of phenylthiohydantoin-amino acids via reverse phase HPLC 
Edman degradation was used to sequence the nonapeptides (from the synthetic combinatorial 
peptide libraries in positional scanning format) that were eluted from recombinant human 
MR1. However, the signal from the eluate was too low to be detected. Even after 13 cycles, 
there was no clear signal from the sample that could be distinguished from the background. 
The amino acid residues are denoted as per the standard one alphabet code. Y axis: 
Absorbance unity, X axis: Retention time. Data provided by Reinhard Mentele, MPI of 
Biochemistry. 
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V. Sequence of peptides examined by mass spectrometry 
Data provided by Dr Forne Ignasi, Ludwig-Maximilians-Universität München 
No. P1 P2 P3 P4 P5 P6 P7 P8 P9 
 
No. P1 P2 P3 P4 P5 P6 P7 P8 P9 
1 A Q Y E D I A N R 
 
20 L L G P R A A F V 
2 A T M Q N L N D R 
 
21 L L P N R V R Q R 
3 C C C D C C C M D 
 
22 L V L P N R C G R 
4 C L G P A T K S A 
 
23 M D C C C D C C C 
5 D C C C C C M D C 
 
24 N F C V A V L V L 
6 D G P P K T C S S 
 
25 P A A L L V V G G 
7 F G E R A K L V L 
 
26 P P K T V A H L K 
8 F G T L L T K K R 
 
27 P R G K V R V G N 
9 G D M K N L N D R 
 
28 Q F A G D D A P R 
10 G Y S R P G A G G 
 
29 S T L V L V L V F 
11 K K A L L P F V F 
 
30 T A M Q N L N D R 
12 K L G K F L G K W 
 
31 T L G A Q E D D K 
13 K L L L V P D G N 
 
32 T L T L V K L V N 
14 K N K T T F L R R 
 
33 V C N Y V S W L K 
15 K P K K R G F T T 
 
34 V F F H G A R R K 
16 K P T R A L V H L 
 
35 V L L H A R E V L 
17 K S K A G N L A R 
 
36 V L L P T A E E R 
18 L K P P A V L R R 
 
37 V V K A V R D V F 
19 L L G L L L G S A 
 
38 Y N V N P V Y L Q 
 
The above table presents the 38 nonapeptide sequences (from the synthetic combinatorial peptide 
libraries in positional scanning format) that were eluted from recombinant human MR1. These 
were sequenced by electrospray mass spectrometry. The first column contains an arbitrary 
reference number, while the following columns denote the 9 positions (P1 to P9) of each peptide. 
Sequence alignment analysis of the peptides did not reveal a stringent position bias, albeit a 
pattern that could be suggestive of fixed anchor positions of the human MR1 molecule. 
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